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"The universe we observe has precisely the properties we should expect if there is, at 
bottom, no design, no purpose, no evil and no good, nothing but blind pitiless 
indifference ..... 
...... DNA neither cares nor knows. DNA just is. And we dance to its music" 
Richard Dawkins, River Out of Eden 
In this quote taken from the recently published book, River out of Eden, Richard Dawkins 
makes it quite plain that although there may be nothing particularly special about DNA, it 
is after all the band master, and ultimate conductor of the destiny of life on this planet. 
Something to be remembered as we seek to understand the song, and even rewrite the 
melody. Various groups have sought to do this by reading each note in the sequence, and 
seeing how it may relate to its neighbours, through analogy with previously delineated 
sequences. Gene targeting technology allows us to see what happens to the melody after 
removing whole sections of the score. There are dangers to this approach, the change may 
be so subtle as not to be heard at all, or so disastrous that the whole performance is ruined. 
The trick is to choose the target carefully, and to remember the fallibility of the approach 
when making conclusions as to its success or otherwise. 
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Abstract. 
Gz is a unique member of a class of heterotrimeric G-proteins which mediate cytosolic 
signalling pathways through a class of seven transmembrane spanning receptors. 
However, the in vivo function of Gz has been difficult to determine because the Ga 
guanine triphosphate binding subunit is resistant to both cholera and pertussis toxins. 
Localised to neuronal tissues, it has been speculated that Gza may a wider play a role in 
mediating the signal generated by factors at the nerve terminal which do not themselves 
undergo retrograde axonal transport. To test this novel hypothesis and also determine 
which receptors couple/activate Gza steps in vivo the decision was made to generate a Gza 
null (or knockout) mouse. To this end a region of the mouse genome encompassing the 
first translated exon of mouse Gza has been isolated, cloned, sequenced and used to stably 
disrupt the expression of Gza in a C57BV6 mouse embryonic stem cell line in vitro which 
in tum have been used to produce animal chimc:eras. At this stage it is not known whether 
any of these mice are germline chimc:eras. Each are currently being interbred in the hope 
that this will in fact lead to the production of heterozygous knockout mice and later 
through the breeding of these heterozygous progeny, mice possessing both disrupted 
alleles of the Gza gene. 
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CHAPTER 1 Does Gza act as a Second Messenger in 
Nerve Cell Signalling? 
1 
[1 
Part 1.1 Introduction. 
The (heterotrimeric) G-protein Gz is predominantly found within neuronal tissues (Hinton 
et al., 1990) and platelets (Lounsbury et al., 1991 ), however, it is insensitive to both 
cholera and pertussis toxins (Matsuoka et al., 1988; 1990), so whatever unique biological 
role it might play within these tissues has been difficult to ascertain. The a-subunit of Gz 
(Gza) undergoes retrograde transport within nerve fibres (Crouch et al., 1994) and has a 
slow rate of guanine triphosphate (GTP) hydrolysis (Casey et al., 1990). It has, therefore, 
been proposed that Gza may act as a stable second messenger, mediating the signal 
generated by factors at the nerve terminal which aren't themselves transported back to the 
nucleus (Crouch et al., 1994; Hendry et al., 1995). Furthermore, there is enough evidence 
to suggest that G-proteins in general play a far wider role than simple effector activation at 
or near the cell's smface (Malarkey et al., 1995). This means that any biological function 
assigned to Gza, through its disruption in vivo (Chapter 3, p55) must be taken in the 
context of the ever widening role that G-proteins play in cell signalling. 
2 
Part 1.2 G-proteins and Cytosolic Signalling. 
Section 1.2.1 Introduction 
Specific associations between cytosolic signalling pathways and ligand specific membrane 
spanning receptors have evolved in nature to process and initiate a logical response to 
extracellular signals. Two widely studied groups include the tyrosine kinase growth factor 
receptors (Fantl et al., 1993), known to activate/phosphorylate members of the mitogen-
activated protein (MAP) kinase cascade (Malarkey et al., 1995), and the G-protein coupled 
seven transmembrane receptors (Birnbaumer, 1990). These relationships are not, however, 
exclusive and the degree to which these pathways interact shows that a clear distinction 
can no longer be drawn between a response such as cell division and the activation of any 
one group of effectors, or second messengers. Signals generated by both tyrosine kinase 
and G-protein coupled receptors form complex relationships in order to initiate different 
biological responses, including growth and development (Otte et al., 1992) , 
neurotransmission (Goh & Pennefather, 1989; Wu et al., 1992), neuronal survival and 
regeneration (Thoenen, 1991; Curtis et al, 1994; Curtis & DiStefano, 1994; Snider, 1994), 
sensory transduction (Hepler & Gilman, 1992); blood clotting (Manning & Brass, 1991), 
cardiac function (Luetje et al., 1988; Birnbaumer, 1990), and hormonal regulation (Linder 
& Gilman, 1992). 
Section 1.2.2 The Role of G-proteins in Signal Transduction. 
a) GTP Binding & Hydrolysing Proteins (GTPases). The GTPases are intimately 
involved in many receptor activated pathways (Bourne, 1988). They form a class or family 
which include: (i) the a subunit of the heterotrimeric G-proteins (Ga; Bourne et al., 1990; 
1991); (ii) various translation factors linked to protein synthesis (e.g. the bacterial 
elongation factor (EF)-Tu; Jurnak, 1985; LaCour et al., 1985); (iii) the 2lkDa products of 
the ras family of proto-oncogenes (p21ras; De Vos et al., 1988; Milburn et al., 1990; Pai 
et al., 1989; 1990); (vi) tubulin; and (v) the "small G's" , 20-35kDa proteins which 
function by regulating cell growth, protein secretion and vesicular transport (e.g. products 
of the rab, rap, rho, rac, smg21, smg25, YPT, SEC4 & ARF genes; Bourne, 1988; Balch, 
3 
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1989; Bourne et al., 1990; 1991; Hall, 1990; Kaziro et al., 1991; von Mallard et al., 1991; 
Barlowe et al., 1993; Zhang et al., 1993). 
b) GTPase Activation/Deactivation: a Common Cycle. When activation occurs the GTP-
binding protein, in association with a guanine nucleotide release/exchange protein 
(GN(R/E)P), replaces bound guanine diphosphate (GDP) for GTP. In this GTP-bound 
conformation the protein is capable of regulating cell function through the activation of 
cytosolic effectors. Deactivation occurs when GTP is hydrolysed to GDP. This can occur 
independently or through the intervention of a class of GTPase-activating proteins 
(GAP's; Bourne et al., 1990; Kaziro et al., 1991). 
c) The G-proteins. G-proteins form a subclass of GTPases which classically mediate the 
signals generated by a group of seven transmembrane G-protein coupled receptors 
(GPCR's) and their specific ligands (GPCRL's; Table 1. 1; Birnbaumer, 1990). The G-
protein complex is a heterotrimer made up of an a, p and y subunit (Lamb & Pugh, 1992; 
Linder & Gilman, 1992). Upon receptor activation the Ga subunit (the GTPase, see 
above) exchanges bound GDP for GTP, leading to the dissociation of the GTP-bound Ga 
the Gpy heterodimer. In this activated state the Ga-GTP acts as a cytosolic second 
messenger and can initiate certain pathways. Several examples include: (i) activation of the 
retinal cyclic guanine monophosphate (cGMP) specific, phosphodiesterase by the Ga 
subunit of transducin, Gat (Wheeler & Bitensky, 1977); (ii) stimulation/inhibition of 
adenylyl cyclase by GsalGia (Rodbell et al., 1971; Bi111baumer, 1973; Bll11baumer et al., 
1974; Yamamura et al., 1977; Londos et al., 1978); and (iii) ion channel activation by 
G ia/G 0 alGsa (Breitwieser & Szabo, 1985; Pfaffinger et al., 1985). GTP 
hydrolysis/inactivation of the a-subunit leads to the re-formation of the Gapy heterotrimer 
and a return to complete what has been termed the "G-protein Cycle" (Figure 1.1). Post 
translational acylation of some Ga's may assist in localising this subunit to the membrane 
and receptor (Mumby et al., 1990; Casey, 1992), although GDP-bound Ga's are not 
recognised by their receptor in vitro unless accompanied by associated Gpy's (Hepler & 
Gilman, 1992). Despite this it is still not entirely certain what the actual biological role of 
the Gpy heterodimer is. It is believed that whilst the Gp subunit facilitates receptor 
coupling (Kleuss et al., 1992), the Gy subunit, which undergoes post translational 
4 
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lipidation (Hepler & Gilman, 1992), acts by anchoring the G~ycomplex to the membrane 
(Yamane et al., 1990; Simon et al., 1991 ). It has also been suggested that the G~y 
heterodimer individually, or in association, with the Ga subunit may play a more general 
role in mediating/modifying the signal generated by various membrane spanning receptors 
and other cytosolic effectors (Hepler & Gilman, 1992; Schmidt et al., 1992; Simon et al., 
1991; Stemweis & Smrcka, 1992; Tang & Gilman, 1992; Malarkey et al. , 1995). 
Ta hie 1.1 Ligands Acting Through G-protein Coupled Receptors. 
(Reference: Birnbaumer, 1990) 
Neurotransmitters 
& autocoids 
Peptide & 
glycoprotein 
Arachidonic acid 
metabolites 
Sensory 
Other 
Catecholamines; Acetylcholine (M type); 
Dopamine; Serotonin; Histamine; GABA; 
Glutamic acid; and Purines. 
ACTH; Opioids (>5ligands); MSH, CRF, 
GRF, TRH, GnRH & SRIF; hormones 
Vasopressin/oxytocin; Glucagon; Glucagon 
19-29; CCK, PTH, AngII, GRP, 
calcitonin, CGRP, NPY, PYY, secretin 
galanin, kyotorphin; VIP ; PHI (PMI); 
Bradykinin; LH, FSH & TSH; 
Neurokinins [substance P (NKl), 
substance K] 
PGEl / 2; PGD, PGI 2 , thromboxane, LtA4 , 
LtB4, LtC4, PGF 2a• 
light, odor; and taste. 
Chemoattractant (Met-Leu-Phe or fMLP), 
C5a & C3a; thrornbine; Phosphatidic acid; 
and PAF. 
d) G-protein Tissue Distribution. A number of Ga subunit second messengers have been 
found to be either tissue or cell type specific, and this may reflect the different functions 
which they perform. These include: (i) the two forms of transducin, Gta (Tc-a) cone and 
Gta (Tr-a) rod in the retina (Leara et al., 1986; Rodrigues et al., 1987; Hepler & Gilman, 
1992); (ii) the homolog of Gsa (G0 u) within the olfactory neurones (Jones & Reed, 
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1989); and (iii) Goa which is found with the brain and the neuroendocrine system (Perry, 
1982; Asano et al., 1988; Chang et al., 1988; Gabrion et al., 1989; Peraldi et al., 1989). 
Each of these observations has lead to the speculation that Gza, which appears to be 
abundant within neuronal tissues (Hinton et al., 1990), has a specific role to play within 
nerve cells (Hendry et al., 1996). 
Section 1.2.3 Do G-proteins Play a Role in Mediating the Signal Generated by 
Tyrosine Kinase Growth Factor Receptors? 
a) Growth Factor Tyrosine Kinase Receptors. As the name suggests the tyrosine kinase 
receptors are a class of predominantly growth factor associated receptors, which possess 
an intrinsic tyrosine kinase catalytic function. Several examples include the platelet derived 
growth factor (PDGF) receptor, the epidermal growth factor (EGF) receptor and the 
fibroblast growth factor (FGF) receptor (Fantl et al., 1993). For these receptors the key 
event following ligand binding is the dimerisation of activated monomeric forms of the 
receptor and the phosphorylation of specific intracellular tyrosines (Fantl et al., 1993; 
Kazlauskas & Cooper, 1989). The signal is then transferred to various secondary 
effectors (e.g. PLCy, c-Src, Ras, GAP etc, see Table 1.2), through a region of 'Src' 
homology, designated the Src homology-2 (SH2) domain (Figure 1.1; Matsuda et al., 
1990; Pawson & Gish, 1992). Those effectors that contain SH2 domains but which do 
not themselves appear to possess an intrinsic function (e.g. GRB2, Nck, etc, see Table 1.2) 
also contain a region of Src homology, the SH3 domain which binds praline-rich 
sequences (Ren et al., 1993). These 'adaptors' are thought to assist in the activation of 
those proteins which do not have an intrinsic SH2 domain, through adaptor/SH3 mediated 
binding to the activated tyrosine kinase receptor (e.g. mammalian Son of sevenless, mSos; 
Duchesne et al., 1993). 
b) Tyrosine Kinase Receptor Activation and the Ras/MAP Kinase Signalling Pathway. 
The GRB2 'adaptor' (Egan et al., 1993) provides a key link between tyrosine kinase 
receptors and the Ras/MAP kinase mitogenic signalling pathway, through the activation of 
the p21ras (see above; Trahey & McCormick, 1987; Hall, 1994) specific GNEP mSos 
(Bonfini et al., 1992; Bowtell et al., 1992). This is followed by the phosphorylation or 
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Table 1.2 Proteins Containing SH2 & SH3 Domains. 
(Reference: Malarkey et al., 1995) 
Protein 
PLCy 
GAP 
Src 
SHPTP-1 
SHPTP-2 
VAV 
ZAP-70 
p72SYk 
SH2 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
GRB2 Yes 
p85 PI 3-kinase Yes 
Nck Yes 
SHC Yes 
Tens in Yes 
p4 7 and p67Phox 
a-Spectrin 
STAT 91 Yes 
SH3 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Function/Targets 
Ptdins(4,5)P2 hydrolysis 
Ras GTPase 
Tyr kinase/signalling in 
haematopoietic cells 
Tyrosine phosphatase 
Tyr phosphatase / GRB2 adaptor 
Nucleotide exchange in 
haematopoietic cells 
Tyrosine kinase (T cells) 
Tyrosine kinase (B cells) 
Adaptor to mSos 
llOkDa PI 3-kinase 
Unknown 
Adaptor to GRB2 
Cytoskeletal protein 
Cytochrome b 558 
Cytoskeletal protein 
ISGF complex/GAF 
activation of a 'cascade' of intermediate cytosolic signalling molecules (Figure 1. 1). GTP-
bound p21ras activates a homolog of the oncogene v-raf, the ubiquitously expressed c-raf-
1 (Dent et al., 1992; de Vries-Smits et al., 1992; Howe et al., 1992; Troppmair et al., 
1992; Williams & Robert, 1994) indirectly, by localising it to the membrane to await 
phosphorylation/activation by some other kinase (Leevers et al., 1994; Stakoe et al., 
1994). Activated c-Raf-1 activates/phosphorylates the MAP kinase kinase (MEK; 
Kyriakis et al., 1992; Yan & Tern pleton, 1994; Zheng & Guan, 1994a) and MEK 
phosphorylates/activates the MAP kinases or extracellular regulated kinases (ERK's; 
Anderson et al., 1990; Gomez & Cohen, 1991; Crews & Erikson, 1992; Nakielny et al., 
1992). The Erk's play a number of important biological functions which include, the 
activation of various transcription factors (e.g. c-jun; Pulverer et al., 1991) and cytosolic 
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effectors (e.g. phospholipase A2, cPLA2; for review see Bienis, 1993). MAP kinase has 
also been shown to phosphorylate MEK, a function which may allow it to negatively 
regulate its own activity (Rossomando et al., 1994). MEK is particularly interesting 
because it links a number of pathways through protein kinase C (PKC) to the MAP 
kinase cascade (Figure 1.1). A number of different forms of MEK have been identified 
(MEKl & MEK2), as well as the splice variant of MEKl, MEKlb (MEK3 ; Seger et al., 
1992; Zheng & Guan, 1993; 1994a). 
c) PKC-dependent GPCRL Activation of the Ras/MAP Kinase Cascade. GPCRL 
stimulation of polyphospholipid hydrolysis, through PLCP and the subsequent activation 
of PKC, has been suggested as one way in which G-protein activation can mediate the 
signal generated by the Ras/Map kinase cascade (Force et al. , 1991; Kahan et al. , 1992; 
McKenzie et al., 1992). Possible sites of action include, MEK (Granot et al., 1993 ; 
Bogoyevitch et al., 1994) and/or c-Raf-1 (Kolch et al., 1993), both of which are 
phosphorylated by PKC. However, it seems reasonable to suggest that PKC may play a 
more general role, mediating different reponses to a wide variety of cytoplasmic signalling 
events (Malarkey et al., 1995; Figure 1.1). 
d) PKC-independent GPCRLActivation of the Ras/MAP Kinase Cascade. In addition to 
the activation of MAP kinase through PKC, several GPCRL's appear to be capable of 
activating the Ras/MAP kinase cascade, through components of the 'G-protein cycle' 
(Kahan et al., 1992; Cook et al., 1993; van Corven et al., 1993; Hordijk et al. , 1994). Both 
throm bin and the mitogenic phospholipid, lysophophatidic acid (LPA) have the potential 
to activate p21 ras in vivo, either: (i) directly through the pertussis toxin sensitive Ga, Gai, 
(Gupta et al., 1992; Albias et al., 1993; Gardner et al., 1993; Winitz et al. , 1993); or (ii) 
indirectly through the Gi~y subunit complex (Faure et al., 1994), which is thought to 
facilitate the membrane localisation of various Ras regulatory proteins, possessing a 
region of pleckstrin homology (the PH domain; Koch et al., 1993; Birney, 1994; Crespo 
et al., 1994). It is important to note, however, that many of these studies use either 
constitutively active Gia, or over expressed Gi~y, to obtain p21rasfMAP kinase activation, 
so the actual role of these proteins may be to enhance an existing signal rather than to 
initiate one, by assisting in the activation of p21 ras (Malarkey et al., 1995). 
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e) GPCRL Activation of MAP kinase through the MEK Kinase? The MEK kinase, a 
74kDa protein originally identified through its homology to two known MEK kinases in 
yeasts (STEll & Byr2; Lange-Carter et al., 1993; 1994a;1994b; Lange-Carter & 
Johnson, 1994; Zheng et al., 1994; Zheng & Guan, 1994b; Figure 1.1), has been 
proposed as an alternative downstream regulator of the Ras cascade, which is not 
dependent upon either PKC or Ras/Raf (Gupta et al., 1992; Burgering et al., 1993; 
Kizaka-Kondoh & Okayama, 1993). The evidence linking GPCRL's to MEK kinase is 
largely circumstantial and is based upon the assumption that PKC activation of MEK is 
not the only avenue for Raf/Ras independent activation of the Ras/MAP cascade 
(Malarkey et al., 1995). Notably, the over-expression of MEK kinase also results in the 
specific activation of the stress activated protein/ERK kinase-I (SEK-1), which is part of 
another pathway, the 'stress activated' protein (or SAP) cascade (Yan et al., 1994). 
Section 1.2.4 Other Tyrosine Kinase Associated Signalling Pathways. 
a) The Focal Adhesion Kinase (FAK). FAK is a cytosolic tyrosine kinase, that has been 
localised to cellular focal adhesion sites, and which, although it does not possess either an 
SH2 or SH3 domain (Schaller et al., 1992), does interact with a number of secondary 
effectors including GRB2, PLCy and p85 (Clark & Brugge, 1993; Schlaepfer et al., 1994; 
Malarkey et al., 1995). More specifically FAK may act by translocating c-Src to specific 
membrane locations, for its inactivation by the c-Src regulatory kinase (Csk; Moszcynska 
& Opas, 1994; Sabe et al., 1994). Two suggested biological roles for FAK include the 
phosphorylation of various cytoskeletal proteins (Aderem, 1992; Kornberg et al., 1992) 
and the removal of adherence to the extracellular matrix prior to mitogenesis (Kanner et 
al., 1990; Guan & Shalloway, 1992). Whatever it's true biological function FAK's close 
association with integrin GpIIb-IIIa (Lipfert et al., 1992; Fox et al., 1993; Haimovich et 
al., 1993) makes it a possible link between cytoplasmic signalling pathways and the 
extracellular matrix (Hanks et al., 1992). It is also interesting to note that the PKC 
independent phosphorylation of FAK by the GPCRL's, bombesin and endothelin-1 
(Zachary et al., 1992; Sinnett-Smith et al., 1993; Saville et al., 1994) has also been linked 
to the mobilisation of Gy subunits to focal adhesion sites within the cell (Hansen et al., 
1994; Schorb et al., 1994), although the role of G-proteins in FAK activity is unknown. 
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b) The Tyrosine Kinase2/Janus Kinases. The Tyk2/JAK kinases form a family of 
cytoplasmic tyrosine kinases (Argetsinger et al., 1993; Darnell et al., 1994) which, like 
PAK, do not possess either an SH2 or SH3 domain (Firmbach-Kraft et al., 1990; Wilks 
et al., 1991; Velazquez et al., 1992). Instead they require a set of signal transducers and 
activators of transcription (STAT's: p84, p91 & p113; Fu etal., 1992) which do, to bind 
and mediate the signal generated by a class of non-tyrosine kinase receptors. These 
include the a and y interferon (a & y IFN; Schindler et al., 1992; Shuai et al., 1992), 
interleukin-3 (IL-3; Silvennoinen et al., 1993a), erythropoietin (Witthuhn et al. , 1993) and 
certain growth factor receptors (Argetsinger et al., 1993). The role of JAK/STAT's as 
activators of transcription, however, may be more widespread as the p91 STAT has also 
been implicated in the EGF and PDGF stimulated, Ras independent, formation of DNA 
binding complexes (Fu & Zhang, 1993), two growth factors normally associated with 
receptor tyrosine kinase activation of the Ras/MAP kinase cascade (Shuai et al. , 1992; 
Ruff-Jamison et al., 1993; Silvennoinen et al., 1993b). 
1.2.5 A MAP kinase Independent G-protein Coupled Mitogenic Pathway? 
Despite the fact that many of the putative mitogenic pathways detailed above, act 
principally through cytosolic tyrosine kinases (Y arden & Ulrich, 1988), there may be a G-
protein associated mitogenic pathway which is not dependent upon an association with, or 
the activation of a tyrosine kinase cascade (Crouch & Simpson, 1996). This is 
controversial because it conflicts with the perceived action of GPCRL's which, if they 
effect transcription at all, do so through the Ras/MAP kinase pathway via the hydrolysis 
of phospholipids and the activation of PKC (Brown et al., 1984; Vincentini & Villereal, 
1984; Paris & Pouyssegur, 1986; Zachary et al., 1986), and not directly through the 
components of the G-protein cycle, previously thought to fulfil well defined roles close to 
the membrane (Birnbaumer, 1990). The idea is worth further examination, however, 
because it brings together many of the observations which have pointed to a wider role for 
G-proteins than simple effector activation at or near the cells surface. For instance, Gia 
has been implicated in the stimulation of mitogenesis by EGF, insulin and post receptor 
activated PKC by phorbol ester. This places Gia downstream of PKC and is supported by 
the finding which shows phosphorylation/activation of Gia and the movement of Gia 
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subunits from the membrane to perinuclear sites within the cell prior to EGF stimulated 
cell division (Crouch et al., 1990; 1991 ). It has been recently proposed that the nuclear 
translocation of Gia may be to initiate mitosis, however like many second messengers the 
full extent of its role in mediating biological function is unknown (Crouch & Simpson, 
1996). 
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Figure 1.1 Tyrosine Kinase Signalling Pathways and G-proteins . 
Characteristic of the tyrosine kinase associated family of receptors (Fantl et al., 1993) is 
the presence of an extracellular binding domain, a membrane spanning portion and a 
region of intracellular tyrosine kinase activity, which binds various second messengers 
including: phospholipaseCy (PLCy; Meisenhelder et al., 1989; Ronnstrand et al., 1992); 
the GTPase-activating protein (GAP; Kazlauskas et al., 1990); the growth factor-receptor 
binding protein 2 (GRB2; Lowenstein et al., 1992; Bar-Sagi et al., 1993; Arvidsson et al. , 
1994); the 85kDa subunit of the PI-3 kinase (phosphatidy !inositol 3' kinase, p85; 
Kazlauskas & Cooper, 1989); the phosphotyrosine phosphatase (SHPTP-2; Lachleider et 
al., 1993); and members of the non-receptor Src family of tyrosine kinases (Mori et al., 
1993; Kypta et al., 1990). The 'growth factor associated' tyrosine kinase receptors, 
possess an intrinsic tyrosine kinase catalytic activity, and can bind these effectors directly. 
However, other tyrosine kinase-associated membrane spanning receptors do not and 
require the binding and activation of certain cytosolic tyrosine kinases. These include the 
focal adhesion kinase (FAK, Schaller et al., 1992) and the Janus kinases (JAKs; 
Firmbach-kraft et al., 1990; Wilks et al., 1992; Velazquez et al., 1992). Also shown in the 
figure is the 'G-protein cycle' (Lamb & Pugh, 1992; Linder & Gilman, 1992), activation of 
PKC and the Ras/MAP kinase cascade. Arrows indication possible points of interaction 
between each of these cytosolic signalling pathways (Malarkey et al., 1995). 
12 
Tyrosine Kinase Receptors 
I 
i 
I 
I 
; 
The Ras/Map 
Cascade 
~1-3 K;n.,,)I~ 
• - arPLCy) I \ 
SHPTP-2 1 • • 
I Kinase insert domain I I 
; • Phos photyr osine res idu es 
I Kinase domain I 
I 
~\~J<~f~e) 3 ,< .. 
G~~~3 
~ .. 
i ~ 
J---
1 
I 
I 
,;i~;~~)~ 
=,, .... :_"'i'._ ...... ._ _ .. _:: ·".. .--· .. :: 
t;;i:~t;ti 
I 
I 
m 
Seven Transmembrane 
Spanning G-protein 
Coupled Receptors 
® 
+ 
!.~ 2.+ ·1-ca 
GTP 
~ 
The 'G -Protein Cycle' 
_/ 
GDP 
Part 1.3 Nerve Cell Signalling & Role of Second Messengers. 
Section 3.1 Introduction. 
When forming stable connections with the periphery and over the remainder of their life 
many nerve cells depend upon a constant supply of target tissue derived growth factors, or 
neurotrophic factors (neurotrophins) which are retrogradely transported back to the main 
part of the cell, the cell body (Hendry, 1992) and activate short lived or labile signalling 
messengers (Figure 1.2; Hendry et al., 1995; Oppenheim, 1996). Signalling which 
depends upon the need to transport ligand or ligand bound receptor, does not however 
fully account for the survival affect that either the extracellular matrix (Carbonetto & 
David, 1993; David et al., 1995), or some growth factors which are not retrogradely 
transported have on neuronal cell survival (Hendry & Belford, 1991; Hendry et al., 1992). 
It has been proposed that in these instances the cells response may depend upon the 
activation and retrograde transport of stable second messengers at, or near, the nerve 
terminal (Hendry et al., 1995; Figure 1.2). In fact members of several cytosolic signalling 
pathways are known to undergo retrograde axonal transport (Johanson et al., 1995), 
although the evidence implicating G-proteins in general or Oza in this form of signalling 
remains largely circumstantial (Hinton et al., 1990; Hendry & Crouch, 1991; Crouch et 
al., 1994; Hendry et al., 1995). 
Section 1.3.2 The Neurotrophic Response. 
a) The Neurotrophic Theory/Hypothesis. In 1949 Hamburger and Levi-Montalcini, 
demonstrated that not only do peripheral targets regulate the survival of sensory ganglion 
neurones in chickens, but that there is also a natural and naturally occurring death of a 
proportion of these cells. They concluded therefore that during development the ganglion 
produces more cells and sends out more axons than their peripheral targets could support, 
and that there was an exchange of metabolic information between the target and the nerve 
cell (Levi-Montalcini, 1987; Oppenheim, 1996). Implicit in this statement although not 
fully understood at the time was the basis for the neurotrophic theory, which is that 
developing neurones compete for limited amounts of target tissue derived 'trophic' factors 
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that are taken up in the periphery by nerve terminals and conveyed to the cell body where 
they regulate survival. Subsequent studies in limb removal and tissue transplantation 
would lead to the eventual discovery of the nerve growth factor (NGF; Hamburger, 1993; 
Oppenheim, 1996), as well as many other 'neurotrophic' factors (Table 1.3; for review see 
Curtis & DiStefano, 1994). 
Table 1.3 Nerve Growth/Neurotrophic Factors. 
Trophic Agent Abbreviation References 
Nerve Growth Factor 
Glial Cell-Derived 
Neurotrophic Factor 
Fibroblast Growth Factor 
Insulin-like Growth Factor 
Brain-Derived 
Neurotrophic Factor 
Neurotrophin-3 
Neurotrophin-4/5 
Ciliary Neurotrophic Factor 
Leukemia Inhibitory Factor 
NGF 
GDNF 
FGF 
IGF 
BDNF 
NT-3 
NT-4/5 
CNTF 
LIF 
( see below) 
Yan et al., 1995 
Ferguson & Johnson, 1991 
Ferguson et al., 1991 
Distefano et al., 1992 
Koliastsos et al ., 1993 
II II 
II II 
Curtis et al., 1993 
Curtis et al., 1994 
b) NGF: a Tumour-derived Agent with Unique Physiological Properties. NGF was first 
isolated from certain tumours known to encourage both sympathetic and sensory nerve 
fibre innervation, following their transplantation into the coelomic cavity of chick embryos 
(Bueker, 1948). This response was similar in many ways to that seen following earlier 
limb transplantation studies, however, there were some marked differences and as the 
salivary gland appeared to be the sole endogenous source within mice , the delivery of 
NGF to nerve centres (ganglia) was thought to occur either systemically or through 
diffusion (Levi-Montalcini & Hamburger, 1953; Hamburger, 1993; Oppenheim, 1996). 
For these reasons acceptance of the retrograde axonal transport of target tissue derived 
NGF although central to understanding the biological role of neurotrophic factors as a 
whole, would have to wait another twenty years and the development of sensitive detection 
methods not previously available (Oppenheim, 1996). 
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c) The Retrograde Axonal Transport of Target Tissue Derived NGF. The demonstration 
that subcutaneously injected radiolabelled NGF accumulated within the sympathetic 
ganglia of new born mice and that this observation was nerve terminal dependent, would 
be the first clue to the retrograde axonal transport of this neurotrophic agent (Angeletti et 
al., 1972). A finding suppo11ed by the later observations which showed that (i) NGF is 
supplied by pe1ipheral targets, which removed the necessity for any single endogenous 
source (Hendry & Iversen, 1973) and (ii) that NGF directly injected into the anterior 
chamber of the eye of adult mice accumulates selectively within the cell bodies of its 
innervating superior cervical ganglion neurones, demonstrating that NGF undergoes 
retrograde axonal transported (Hendry et al., 1974). 
d) NGF: The First Neurotrophin. At the time that the retrograde axonal transport of NGF 
was considered, the link between NGF and its putative role as a neurotrophic factor, would 
also be made. In 1973 Hendry and Iversen would suggest that the increased number of 
neurones observed following NGF administration to young animals was due to the 
artificial rescue of many of the cells which would normally fail to make contact and die 
(Hamburger & Levi-Montalcini, 1949; Hendry & Iversen, 1973). This not only helped to 
link NGF with the trophic signal required for nerve cell survival during development, but 
also provide a possible source for the 'metabolic' communication between peripheral target 
and innervating neurone, suggested by Hamburger and Levi-Montalcini 24 years earlier. 
Subsequent studies have since shown that the role and retrograde transport of NGF within 
neurones is widespread (Ebbott & Hendry, 1978; Max et al., 1978; Brunso-Bechtold & 
Hamburger, 1979; Clark, 1982; Seiler & Thoen, 1984; Yan et al., 1988; Wayne & Heaton, 
1990) and have confirmed that the peripheral target is the origin of NGF protein and 
messenger RNA (mRNA; Heumann et al., 1984; Shelton & Reichardt, 1984; Korsching 
& Thoenen, 1988; Carmignoto et al., 1991). 
Section 1.3.3 The Neurotrophic Factors. 
a) Introduction. There are two broad groups of neurotrophic factors (Curtis & DiStefano, 
1994). The neurotrophins (e.g. NGF, BDNF, NT-3 & NT-4/5; see Table 1.3), are widely 
expressed in peripheral tissues and mediate nerve cell survival and nerve fibre innervation 
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during development, and the cytokine-like neurotrophic factors (or neuroactive cytokines, 
e.g. LIF & CNTF; Table 1.3; Thoenen, 1991; Curtis et al., 1994), which are released by 
non-neuronal cells in response to neural trauma and may therefore act to promote nerve 
regeneration and survival following injury. In either case specific receptors mediate the 
retrograde transport and internalisation of the neurotrophic signal at the nerve terminal 
(Curtis & DiStefano, 1994; Hendry et al., 1995). 
Table 1.4 The Neurotrophin/Trk Receptors. 
(for reviews see Meakin & Shooter, 1992; Bothwell, 1995) 
Receptor High Affinity Ligand Other Interactions 
TrkA NGF NT-3, NT4/5(Barbacid, 1994; 
Berkemeier et al., 1991) 
TrkB BDNF & NT-4/5 NT-3 (Barbacid, 1994) 
TrkC NT-3 
b) The Neurotrophins. Neurotrophins bind a group of high affinity receptors (the Trk's; 
TrkA, TrkB, and TrkC; Table 1.4; Meakin & Shooter, 1992; Curtis & DiStefano, 1994; 
Bothwell, 1995), which possess intrinsic tyrosine kinase catalytic domains and regulate 
gene transcription through the phosphorylation of cytosolic transcription factors such as 
CREB (see above; Ghosh et al., 1994; Ginty et al., 1994). Each neurotrophin is also 
known to bind the low affinity neurotrophin receptor (LNTR, p75) which, does not 
possess an internal tyrosine kinase catalytic domain (Meakin & Shooter, 1992; Curtis & 
DiStefano, 1994; Bothwell, 1995). It has been suggested that the LNTR may play a 
selective role in the retrograde transport of neurotrophins from certain peripheral tissues, 
although its function remains unclear (Von Bartheld et al., 1994; Curtis et al., 1995; 
Bothwell, 1995). 
c) The Neurotrophin Knockouts. To investigate further the biological role of 
neurotrophins, mice possessing null gene or null receptor gene mutations, have been 
created (for review see Snider, 1994). Unsurprisingly, many of these 'gene knockouts' fail 
to develop properly and die within a month of birth. Nonetheless those that have survived 
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suggest a degree of ligand redundancy [e.g. BDNF(-/-) & NT-4/5(-/-); Ernfors et al., 
1994; Jones et al., 1994; Cohen-Cory & Fraser, 1995; Liu et al, 1995] and the severe 
developmental abnormalities exhibited by the Trk receptor knockouts (Table 1.5) have 
reinforced the importance of the receptor in mediating the neurotrophic response. 
Table 1.5 The Trk Knockouts. 
Knockout Observed Phenotypic Changes 
TrkA 
(-/-) 
TrkB 
( - / - ) 
TrkC 
(-/-) 
Survival of certain NGF-dependent neurones (Dreyfus, 
1989; Hefti, 1986). Mice are insensitive to heat & 
pain (Smeyne et al., 1994) 
Severe motor neurone deficiencies significant loss of 
trigeminal neurons (Klein et al., 1993) 
Death soon after birth, & abnormal motor behaviour 
(Klein et al., 1994) 
d) The Neuroactive Cytokines. The cytokine-like neurotrophic factors (Thoenen, 1991; 
Curtis et al., 1994) activate a class of receptors which do not possess intrinsic tyrosine 
kinase catalytic domain (e.g. LifP & gp130; Stahl & Yancopoulos, 1992). In this instance 
whilst agonist stimulation results in the formation of a heterodimer and activation of the 
MAP kinase cascade, these class of receptors also stimulate the phosphorylation of 
JAK/STAT's family of cytoplasmic second messengers (Bonni et al., 1993; Boulton et al., 
1994; Darnell et al., 1994). 
e) The Non-Transported 'Trophic' Factors. Several factors which are not retrogradely 
transported within neurones but which can still be said to have a neurotrophic effect on the 
cell include the extracellular matrix (e.g. Laminin which binds the integrin receptor and 
may through FAK activate a number of cytosolic secondary signalling molecules; see 
above; Carbonetto & David, 1993; Fox et al., 1993; Schlaepfer et al., 1994; David et al., 
1995) and several neurotrophic factors, whose retrograde transport appears to be either 
entirely absent or cell-type specific. For example, even though FGF is required for the 
survival of neurons in culture, the regeneration of injured axons (Dreyer et al., 1989; 
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Grothe et al., 1989) and development of the parasympathetic nervous system (Hendry et 
al., 1988), it does not appear to undergo retrograde axonal transport (Hendry & Belford, 
1991 ). Furthermore whilst the neuroactive cytokine LIF promotes the survival of sensory 
neurons (Murphy et al., 1991) and the differentiation of sympathetic neurons from the 
adrenergic to the cholinergic phenotype, it only appears to be transported within the 
sensory neurones (Hendry et al., 1992). 
f) Summary. Recently several neurotrophins have been implicated in aspects of nerve cell 
growth and maintenance which go beyond the simple survival role they might play during 
development, including nerve regeneration (Hagg et al., 1990; Raivich & Kreutzberg, 
1993), maturation (Knusel et al., 1995; Wang et al., 1995) and proliferation (Gaese et al. , 
1994 ). What these observations suggest is that the distinctions made between 
neurotrophins and the cytokine like neurotrophic factors, although convenient, are not 
based upon large functional differences. Furthermore, because each growth factor receptor 
has the potential to activate many shared cytoplasmic signalling pathways (see above), it is 
not unreasonable to suggest that a cell's response to ligand activation is due to the 
combined effect of a large number of different, often competing signals and not 
necessarily the arrival of any single messenger. This provides a new avenue for 
understanding the role of neurotrophins, for whilst receptor knockouts may prove fatal 
and ligand knockouts redundant, subtle phenotypes generated through the disruption of 
putative second messengers may prove more useful in the longer term to understanding 
the function of neurotrophic factors in living systems (for possible 'gene targeting' 
outcomes see Chapter 5, pl09). 
Section 1.3.4 Models For Second Messenger Activation. 
a) Introduction. Neurones face a special problem in conveying signals generated at the 
nerve terminal because of the distance between the site of ligand binding (the nerve 
terminal) and the nucleus. This has lead to the development of models seeking to describe 
systems of active transport in which the growth factor, or second messenger is 
retrogradely transported to the cell body for processing (for reviews Curtis & DiStefano, 
1994; Hendry et al., 1995; Oppenheim, 1996). 
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b) The Labile Second Messenger Model. In most instances neurotrophic factors are 
retrogradely transported within cytosolic vesicles and presumably along microtubules 
back to the cell body, where they mediate the activation of various cytosolic signalling 
pathways (Curtis & Distefano, 1994; Snider, 1994). Whilst ligand binding is important 
for receptor activation it is the activated receptor which directly mediates both vesicle 
formation and subsequent effector activation through its intracellular tyrosine kinase 
catalytic domain (Heumann et al., 1981; Johnson et al., 1989; Distefano et al., 1992; 
Curtis et al., 1994). This has been termed the labile second messenger (LSM; Figure 1.2) 
model because it accounts for the activation and action of short lived cytosolic effectors 
close to the nucleus (Hendry et al., 1995). The value of this model is that it may also 
describe the retrograde transport of cytosolic proteins that use other means of attachment 
to the vesicle membrane, such as fatty acylation or hydrophobic interactions (Curtis & 
DiStefano et al., 1994). 
c) The Stable Second Messenger Model. There may, however, be another means of signal 
generation, which does not depend upon the internalisation and transport of the of the 
ligand. Neurotrophic factors and components of the extracellular matrix that are not 
themselves retrogradely transported (see above), may still convey a signal to the cell body 
through the generation of stable messengers. This has been termed the stable second 
messenger model (SSM; Figure 1.2; Hendry et al., 1995) and although the identity of 
these second messenger is unknown, some possibilities have recently been canvassed 
(Hendry & Crouch, 1991; Crouch et al., 1994; Johanson et al., 1995) 
d) Putative Stable Second Messengers. Several cytosolic proteins which have been 
implicated in a number of signalling pathways undergo retrograde axonal transport 
(Johanson et al., 1995). These include: (i) members of the Ras/MAP kinase signalling 
cascade, ERK, MEK (Traverse et al., 1992) and MEK kinase (see above); (ii) the Growth 
Associated Protein-43 (GAP-43) which has been implicated in nerve fibre regeneration 
(Tetzlaff et al., 1989); and (iii) the PI-3 kinase (Soltoff et al., 1992), thought to be either 
directly involved in vesicle formation (Joly et al., 1994; Wennstrom et al., 1994), or as a 
regulator of membrane trafficking (DeCamilli et al., 1996), through its products, the 
polyphosphatidylinositides (Whitman et al., 1988; Auger et al., 1989). PI-3 kinase also 
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binds p21ras (Roche et al., 1994), and it's activity may be enhanced through association 
with free Gpy's (Stephens et al., 1993; Stephens et al., 1994). It is likely that both PI-3 
kinase and GAP-43 play a role in the formation of signalling complexes at the nerve 
terminal (Figure 1.3), however, just because something is retrogradely transported does 
not necessarily mean that it is involved in mediating a stable signal. 
e) Do G-proteins act as Stable Second Messengers for Neurotrophic Factors that do not 
undergo Retrograde Axonal Transport? The survival effect which FGF has on ciliary 
neurons in culture and the development of sensory and sympathetic neurons in vivo, is in 
both cases at least partly inhibited by pertussis toxin (Hendry & Crouch, 1991). Whilst 
these observations may not mean that neurotrophic factors act through a pertussis toxin 
sensitive G-protein such as Gia or any other Ga, such a conclusion can be supported by 
the demonstration that both Gia and the nerve cell specific Gza both undergo retrograde 
axonal transport within nerve fibres (Hendry & Crouch, 1991; Crouch et al., 1994). 
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Figure 1.2 Second Messenger Models. 
Two models for second messenger activation within nerve cells. 
(A) The labile second messenger (LSM) model, which describes the activation of labile or 
short lived second messengers close to the nucleus. 
(B) The stable second messenger (SSM) model, which may be utilised by those 
neurotrophic factors which do not undergo retrograde axonal transport themselves (Figure 
taken from Hendry et al., 1995). 
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Figure 1.3 Second Messenger Signalling Within Nerve Cells. 
Diagrammatic representation of second messenger signalling within nerve cells, and the 
proposed role that receptor mediated vesicle formation may play in the transport of both 
the ligand bound receptor and secondary effectors. Those shown include members of 
tyrosine kinase associated pathways, PI-3 kinase, GAP and G-proteins (Johanson et al., 
1995; Hendry et al., 1995). 
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Part 1.4 The Neurone Specific G-protein: Gzcx• 
Section 1.4.1 Gza: a Ga with Unique Structural & Biochemical Properties. 
a) Introduction. The Gza gene was originally identified and cloned from human retinal 
(Fong et al., 1988) and rat brain (Matsuoka et al., 1988) cDNA libraries, following low 
stringency hybridisation with bovine Gna and a rat Gi2a probe respectively. This was 
possible because the highly conserved nature of certain regions such as the OTP-binding 
and hydrolysis domain (Figure 1.4). There are however, some important structural 
differences between Gza and other Ga subunits. Gza, unlike Gia, G0 a, or Gta does not 
have a functional ADP-ribosylation site (West et al., 1985; Kaziro et al., 1991), and is 
therefore insensitive to the antagonistic effects of pertussis toxin. Furthermore, although 
Gza has a cholera toxin modification site (Arg-179), the protein itself appears to be 
resistant, possibly due to a change in the adjacent amino acid from valine which is present 
in the cholera toxin sensitive Gta, to aspartic acid (Asp-180) in Gza (Figure 1 .4; Fong et 
al., 1988). 
b) Gza: a Gawith a Slow Rate of GTP-Hydrolysis & Exchange. Following mutation of a 
conserved region (A-G-E to T-S-N; Table 1.4) within the Gsa subunit a fifty fold 
reduction in OTP-hydrolysis was observed. Presumably this means that Gza, which 
possesses this same motif (T-S-N; Figure 1.4), also has a greatly reduced GTP hydrolysis 
rate in comparison to other Ga subunits (Casey et al., 1990). Furthermore, the guanine 
nucleotide exchange rate of Gza which is already slow is, in contrast with other Ga 
subunits (Gilman, 1987), inhibited further by magnesium. The Mg2+ ions are thought to 
stabilise the GDP-bound form of the protein, however the speed of dissociation is likely to 
be faster in vivo, when catalysed by the receptor which is though to act as a GNEP 
(Section 1.2.2, p3; Ross, 1989; Parker et al., 1991). 
c) Gza: Tissue Distribution. Through the use of immunohistochemistry Gza has been 
found within the brain (Fong et al., 1988; Matsuoka et al., 1988; Garibay et al., 1991), the 
ganglion cells of the retina (Fong et al., 1988; Jiang et al., 1991), the adrenal gland (Fong 
et al., 1988; Garibay et al., 1991) and platelets (Gagnon et al., 1991). Within the brain it is 
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Figure 1.4 Comparison of Gza amino acid sequence with other Ga's. 
(A) The region implicated in GTP-hydrolysis, showing the amino acid change A-G-E to 
T-S-N, which is though to influence the slow rate of GTP-hydrolysis exhibited by 
recombinant Gza• (B) The cysteine residue four amino acids from the left is the proposed 
site of ADP-ribosylation. Like Gs1a and Gs2a, Gza lacks this residue. (C) The arginine at 
position 179, present in all the Ga sequences shown, is thought to be the site of cholera 
toxin modification, however, only Gta and Gsa are sensitive. Note the aspartic acid at 
position 180 within the Gza sequence, which is thought to hinder modification by cholera 
toxin. The figure below is adapted from Kaziro et al., 1991; Matsuoka et al., 1988. The 
amino acids are represented by the standard one-letter IUPAC codes. 
A Region of GTP binding and hydrolysis. 
Gza 35-50 K L L L L G T s N s G K s T I V 
Gi1a 35-50 K L L L L G A G E s G K s T I V 
Gi 2a 35-50 K L L L L G A G E s G K s T I V 
Gi 3a 35-50 K L L L L G A G E s G K s T I V 
Go1a 35-50 K L L L L G A G E s G K s T I V 
Gt 1a 31-46 K L L L L G A G E s G K s T I V 
Gt2a 35-50 K L L L L G A G E s G K s T I V 
Gs1a 42-57 R L L L L G A G E s G K s T I V 
Gs2a 44-59 R L L L L G A G E s G K s T I V 
B Putative site of ADP-ribosylation. C Putative Cholera Modification Site. 
Gza 346-355 N L K Y I G L C 178-180 S R D 
Gi 1a 345-354 N L K D C G L F 177-179 TR V 
Gi 2a 346-355 N L K D C G L F 178-180 TR V 
Gi 3a 345-354 N L K E C G L Y 177-179 TR V 
Gola 345-354 N L R G C G L Y 178-180 TR V 
Go2a 345-354 N L R G C G L Y 
Gt1a 341-350 N L K D C G L F 173-175 S R V 
Gt2a 385-394 N L K D C G L F 178-180 S R V 
Gs1a 385-394 H L R Q Y E L L 200-202 CR V 
Gs2a 372-381 H L K Q Y E L L 187-189 CR V 
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particularly abundant within pituitary cells (Paulssen et al., 1991), neurons of the basal 
ganglia, purkinje cells of the cerebellum, granule and pyramidal cells of the hippocampus, 
the large neurons of layers ill and Vin the neocortex (Hinton et al., 1990), some neurones 
within the hippocampus and the cerebral cortex. Gza has also been found within the sciatic 
nerve (Hendry, 1992; Crouch et al., 1994), sympathetic ganglia (Hinton et al., 1990), the 
adrenal medulla (Casey et al., 1990), the anterior horns of the spinal cord (Hinton et al., 
1990) and in vitro within several tumourogenic cell lines. These include: the 
pheochromocytoma cell line PC12 (Matsuoka et al., 1988, Garibay et al., 1991); several 
neuroblastoma cell lines (SK-N-SH & SH-EP; Garibay et al., 1991); a neuroblastoma-
glioma hybrid (NG108-15; Garibay et al., 1991); a hepatoma cell line (Hep G6; Garibay 
et al., 1991); and various pituitary cell lines (GH3, GH4Cl & GH12Cl; Matsuoka et al., 
1988; Garibay et al., 1991; Paulssen et al., 1991). 
d) Other Regions of Gza Localisation. There are a number of non-neuronal tissues and 
organs which may also express Gza, including the heart, kidney and erythrocytes (Fong et 
al., 1988; Spicher et al., 1988; Premont et al., 1989; Garibay et al., 1991; Paulssen et al., 
1991), however, this has been disputed by a number of groups (Fong et al., 1988; 
Matsuoka et al., 1988; Casey et al., 1990; Hinton et al., 1990; Garibay et al., 1991) and its 
apparent localisation to these tissues may be due to the identification of an as yet 
undefined Gza homolog, or contamination of the tissue sample by innervating neurones 
and/or blood platelets (see above). 
e) The Retrograde Axonal Transport of Gza· Not only is Gza retrogradely transported 
within nerve fibres (Crouch et al., 1994), but there is some evidence to suggest that this 
transport also occurs in association with, or is mediated by the cytoskeleton and any 
internalised vesicles. A theory supported by: (i) the localisation of Gza to microtubules 
and 'granular' structures within both purkinje cells and sciatic nerve fibres (Hinton et al., 
1990; Crouch et al., 1994); and (ii) the copurification of Gza protein, from bovine brain, 
with a small GTPase implicated in vesicle transport (Section 1.2.2, p3; Casey et al., 1990; 
Trimble et al., 1991; von Mallard et al., 1991; Barlowe et al., 1993). Gza also undergoes 
myristolation in vitro (Mumby et al., 1990), which may allow it to attach to the membrane 
of internalised vesicles and interact with other membrane bound effectors (Buss et al., 
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1987). It must be noted, however, that although this appears to be the most likely means 
by which Gza is retrogradely transported, evidence for the vesicle mediated retrograde 
axonal transport of Gza is still largely circumstantial. 
Section 1.4.2 A Biological Function for Gza? 
a) Does Gza act as a Stable Second Messenger? According to the SSM, outlined earlier 
(Section 1.3.4, p18) for Gza-GTP to act as a stable second messenger within neurotrophic 
signalling it must not only undergo active, specific and retrograde axonal transport within 
nerve fibres (see above), but it must also be stable enough to reach the cell body while 
activated. Gza does have a very slow intrinsic rate of OTP-hydrolysis (Casey et al., 1990) 
which suggests that it can activate effectors far from the site of receptor activation, 
although it is unknown whether or not this means that Gza can mediate a signal the large 
distance from the nerve terminal to the cell body. Additionally, the GAP (Section 1.2.2, 
p3) activity of some G-protein effectors (Bourne & Stryer, 1992), when combined with its 
slow rate of guanine nucleotide exchange, may also confer a degree of sensitivity to 
whatever signalling system Gza is involved in. 
b) The Role of P KC Phosphorylation in Gza Signalling? Another property of Gza is that 
it is an effective substrate for phosphorylation by PKC (see also Section 1.2.3, p6; 
Carlson et al., 1989; Lounsbury et al., 1991). This has been demonstrated both in vitro 
and in intact platelets, treated with thrombin and other PKC activating agents. However, it 
is not known what affect phosphorylation by PKC has on the activity Gza• It may be that 
PKC phosphorylation of Gza may act to generate a novel signal, however, it is more likely 
that, because the putative PKC phosphorylation site (Ser-27; Lounsbury et al., 1993) lies 
within a region known to facilitate binding to the G~'Y heterodimer (Conklin & Bourne, 
1993), that PKC phosphorylation of GDP-Gza acts to prevent reassembly of the G-
protein Gza~'Y heterotrimer, rapidly attenuating any signal generated through this Gza 
pathway following effector activation. Furthermore, because activation of Gza may directly 
or indirectly lead to the activation of PKC (Figure 1. 1 ), PKC phosphorylation of Gza-
GDP may act as a method of regulating its own activity (Caron & Lefkowitz, 1993; Fields 
& Casey, 1995). 
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c) PKC: Clues to a Possible Biological Function for Gza• In platelets PKC activation 
leads to a number of responses which include: (i) the attenuation of adrenaline and 
thrombin induced inhibition of cyclic AMP accumulation (Jakobs et al., 1985; Watanabe 
et al., 1985; Carlson et al., 1989); (ii) the inhibition of platelet activating factor mediated 
increases in cytosolic calcium (MacIntyre et al., 1985); and (iii) the loss of thromboxane 
A2 activated PLC accumulation (Carlson et al., 1989). Gza is not, however, one of those 
G-proteins which is thought to couple with either the a-2 adrenergic receptor (Simonds et 
al., 1989) or the thromboxane A2 receptor (Shenker et al., 1991). Other functions for Gza 
in platelets may be to control platelet formation and/or megakaryocyte maturation 
(Manning & Brass, 1991). Within the hippocampus PKC has been implicated in long 
term potentiation (LTP; Bliss & Collingridge, 1993) and a pertussis toxin insensitive G-
protein has also been associated with short term potentiation (STP; the first phase of LTP; 
Goh & Pennefather, 1989). Unfortunately no direct link between Gza, PKC, and a definite 
biological function has been established within either of these systems. 
Section 1.4.3 Summary. 
Despite many in vitro experiments (Casey et al., 1990; Wong et al., 1992; Shum et al., 
1995) it is still not clear which receptors activate Gza in vivo, because of its insensitivity to 
both cholera or pertussis toxin. The unique biochemical properties of Gza, however, make 
it an ideal candidate for stable second messenger activation within nerve cells, something 
which is enhanced by its tissue distribution (Hinton et al., 1990), retrograde axonal 
transport (Crouch et al., 1994) and its selective accumulation within the nuclei of sensory 
neurons (Hendry et al., 1995; Hendry et al., 1996). Like Gia, Gza also posses a site for 
phosphorylation by PKC, and it is interesting to speculate upon whether or not this 
interaction may be the point at which apparently distinct signalling mechanisms, the seven 
transmembrane and tyrosine kinase receptor associated signalling pathways, converge. 
However, there is as yet no direct evidence linking Gza with a typical tyrosine kinase 
signalling pathway associated response such as nerve cell survival or axon regeneration. 
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Part 1.5 Project Goals. 
Section 1.5.1 General Aims. 
In the past, several methods have been used to identify the function of 0-proteins in vivo. 
Toxins provide the clearest and simplest way to disrupt function, whilst antisense mRNA 
targeted oligonucleotides have been used to stop translation of functional protein in tissue 
culture and transgenic animals (e.g. Oza; Moxham et al., 1993). Unfortunately, two of the 
0-protein 'specific' toxins (e.g. pertussis and cholera toxin; Matsuoka et al. , 1988; 1990) 
appear to have no affect on the intrinsic function of Oza, whilst the use of antisense 
oligonucleotides to target Oza mRNA has lead to inconclusive results (Sven Johanson, 
personal communication). A gene targeting approach was, therefore, chosen to stably and 
specifically disrupt expression of the Oza gene (see Part 3.1, p56). 
Section 1.5.2 Specific Aims. 
The specific goals of the project include: 
(i) To design a strategy that can be used to target the expression of the Oza gene in vivo. 
(ii) To clone and completely characterise a portion of the mouse genome encompassing 
the Oza gene (Part 3.2, p65). 
(iii) To create a mouse Oza-specific control construct, that can be used as the control for 
screening homologous recombinants in vivo using the polymerase chain reaction (PCR; 
Section 3.1.3, p58). 
(iv) To create a mouse Oza-specific targeting construct, that can be used to disrupt 
expression of the Oza gene in C57BL/6 mouse embryonic stem (ES) cells (Part 3.3, p86). 
(v) To complete the characterisation of the mouse Oza gene including its genomic 
organisation, with the eventual aim of obtaining a full length cDNA copy of the mRNA 
(Chapter 4, p98). 
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CHAPTER 2 Materials and Methods. 
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Part 2.1 Reagents and Media. 
Section 2.1.1 Bacterial Strains. 
Escherichia coli DH5a [endAJ hsdR17 (rK-mK+)supE44 thi-1 recAJ gyrA (Nair)relAl 
LJ(lacZYA-argF) Ul69 deoR (~80 dlaciJ(lacZ) Ml 5) (NEB, Woodcock et al. , 1989)] 
E. coli JMl 10 [F' traD36lacNLJ(lacZ)Ml 5 proA + B+ /rpsL (Strr) thr leu thi lacY galK 
galT arajhuA dam dcm supE44LJ(lac-proAB); NEB, Yanish-Perron et al., 1985] 
E.coli XLl-Blue [F'::Tnl0 proA+B+lac/q LJ(lacZ) Ml5/recAJ endAJ gyrA96 (Nalr) thi 
hsdR17 (rK-mK+) supE4 relAl lac, NEB] 
Section 2.1.2 Enzymes. 
a) Modification Enzymes. DNA Polymerase I, Large (Klenow) Fragment; Thermus 
aquaticus (TAQ) DNA Polymerase; T4 DNA Ligase; T7 Sequenase; Calf Intestinal 
Phosphatase (CIP); and T4 Polynucleotide Kinase (Sambrook et al., 1989, NEB) 
b) Restriction Enzymes. Restriction endonucleases used in each instance are indicated in 
the text and were purchased from either Promega or NEB. 
Section 2.1.3 Cloning Vectors and Genomic Subclones. 
pBluescript II (pB) SK/KS(+/-) phagemid (Appendix 2.1), cloning vectors 
provided by kindly Dr Klaus Matthaei. 
pBSK( + )G2aP(696bp, 4BF/3R), the partial MG2a cDNA clone constructed by 
Leck, 1993 and kindly provided by Dr Klaus Matthaei. 
pBSK( + )G2aP(mimic) a derivative of the partial MGza cDNA clone (see above) 
constructed by Leck, 1993 and also provided by Dr Klaus Matthaei. 
pBSK( + )HG2a the HG2a cDNA clone (Matsuoka et al., 1990), also provided by 
Dr Klaus Matthaei. 
A(DASH®II; Appendix 2.2)MGza, phage genomic clones obtained using the 
partial mouse cDNA fragment (see above; Leck, 1993). 
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pBSK( + )pgkNeopla (Appendix 2.3), a plasmid containing the pgkNeopla 
selectable marker, conferring resistance to neomycin, and constructed by Xiao-Wen 
Wang and provided by Dr Klaus Matthaei. 
pBSK( + )pgkThymidine Kinase(TK)pla (Appendix 2.4), a construct containing the 
pgkTKpla selectable marker, conferring sensitivity to gancyclovir, constructed by 
Xiao Wen Wang and provided by Dr Klaus Matthaei. 
Section 2.1.4 Molecular Weight Standards. 
20µg of A phage DNA ( 48.5kb; NEB) was cut with either Ace I or HindIII in a 400µ1 
volume to obtain the molecular weight DNA standards, AIAccI (13.070kb, 11.828kb, 
6.957kb, 5.581kb, 3.574kb, 2.720kb, 2.180kb, 1.444kb, 0.639kb & 0.499kb) and 
AIHindITI (23.130kb, 9.419kb, 6.557kb, 4.371kb, 2.322kb, 2.028kb, 0.564kb & 0.125kb) 
respectively. Once completely digested 200µ1 of 5x Loading Buffer (50mM Tris-HCl pH 
8.0, l00mM EDTA, 1 % Sarcosyl, 7.5% Ficoll 400, 0.05% Bromophenol Blue & 0.05% 
Xylene Cyanol) was added to give a final concentration of 0.5µg/ 15 µl. Before 
electrophoresis each sample was heated (65°C, 15min). 
2.1.5 Media and Solutions. 
a) Culture Media. Unless otherwise indicated Luria-Bertani (LB) broth and LB agar were 
used to grow bacterial strains on solid media (1.5% agar) and in suspension (Sambrook et 
al., 1989). Bacto-yeast extract, tryptone and agar were obtained from Difeo Laboratories, 
whilst ampicillin (Sigma; 50µg/ml in solid media & 1 00µg/ml in liquid media) was used 
to select and maintain recombinant bacterial strains. 
b) Reagents. The reagents used were of analytical grade and were obtained from: Ajax; 
Boehringer Mannheim; Bio-Rad; Sigma; Hopkins & Williams; Rhone-Poulenc; 
Pharmacia; Bethesda Research; and Progen Industries. 
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Part 2.2 Experimental Protocols. 
Section 2.2.1 Preparation of Bacterial Plasmid DNA. 
a) Large Scale Alkali Lysis. Large scale preparations of plasmid DNA were performed 
following the three step alkali lysis method of Garger et al., 1983. The cells from a 11 
overnight culture were harvested (6 000xg; 15min at 4°C), resuspended in 24ml of 
Solution I (50mM Glucose, l0mM EDTA & 25mM Tris-HCl pH8), lysed by adding 
55ml of Solution II [0.2M NaOH & 1 % Sodium Dodecyl Sulphate (SDS)] and 
precipitated by adding 28ml of Solution ill [5M Potassium Acetate (KOAc) pH4.8]. High 
molecular weight RNA, chromosomal DNA and protein were then pelleted by 
centrifugation (20 000xg; 20min at 4°C, Beckman) and the DNA extracted with an equal 
volume of TE [l0mM Tris-HCl pH8.0 & lmM Ethylenediaminetetraacetic acid (EDTA)]-
saturated phenol:chloroform :isoamyl alcohol (25:24: 1). The DNA was rescued from the 
aqueous phase with 0.6 (v/v) 100% propan-2-ol, collected by centrifugation (10 000rpm; 
IEC Centra M2; 35min, 4°C), washed with 70% ethanol (EtOH), dried and resuspended in 
28ml TE. To remove any small molecular weight RNA and contaminating protein, the 
DNA was purified on a Caesium Chloride (CsCl)/Ethidium Bromide (EtBr) gradient (80 
000rpm; 8-12hrs, 22°C) and recovered through a side puncture. The EtBr was then 
extracted using isoamyl alcohol and the CsCl removed by overnight dialysis against TE. 
b) Small Scale Alkali Lysis. A small scale DNA preparation based on the above protocol 
(Ausubel et al., 1989) was used to obtain plasmid DNA for the rapid analysis of cloned 
products. Overnight bacterial cultures (1.5ml) were transferred to microfuge tubes, 
pelleted by centrifugation (45sec), resuspended in 200µ1 of Solution I, lysed by adding 
200µ1 of freshly prepared Solution II and precipitated with 150µ1 of Solution III. Each 
mix was then spun in a bench top microfuge (12 000rpm; 5min), the supernatant removed 
and the DNA extracted with an equal volume of TE-saturated phenol:chloroform 
:isoamylalcohol (25:24:1). The DNA was then precipitated with two volumes of 100% 
EtOH, pelleted, washed with 70% EtOH, dried in a vacuum desiccator and resuspended in 
50µ1 of TE (pH8.0) containing DNase free RNase A (l0µg/ml). 
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c) Large Scale Column Purification. The Qiagen Plasmid Medi® protocol was used to 
obtain large quantities of highly pure plasmid DNA. The procedure itself is based upon 
the alkali lysis method (Garger et al., 1983), however, in this instance the DNA is 
recovered by binding to the 'Qiagen' anion-exchange resin. 25ml of an overnight culture 
was harvested (6000xg; 15min at 4°C), resuspended in 4ml Buffer Pl (50mM Tris-HCI 
pH8.0, l0mM EDTA & l00µg/ml RNase A), lysed through the addition of 4ml Buffer 
P2 (2M NaOH & 1 % SDS) and incubated at room temperature for 5min. 4ml of Buffer 
P3 (3.0M KOAc pH5.5) was then added and this was followed by a further incubation 
(15min, ice). To remove precipitate the solution was mixed again, spun (20 000xg; 15min, 
4°C) and the supernatant taken to a fresh tube. Any suspended material, which could 
cause problems during column purification was removed carefully and each column 
equilibrated by applying 4ml Buffer QBT [750mM NaCl, 50mM MOPS pH7.0, 3-(N-
morpholino)propanesulfonic acid pKa7.2), 15% EtOH & 0.15% Triton X-100] . The 
supernatant was then loaded onto each column and allowed to drain under gravity through 
the Qiagen tip. To remove residual buffers the columns were washed twice with 10ml 
Buffer QC (1.0M NaCl, 50mM MOPS pH7.0 & 15% EtOH), the DNA recovered using 
5ml Buffer QF (1.25M NaCl, 50mM Tris-HCI pH 8.5 & 15% EtOH), precipitated with 
0. 7 ( v/v) isopropanol and collected by centrifugation ( 15 000xg; 30min, 4°C). The 
resulting pellet was washed with 70% EtOH and resuspended in TE. 
d) S,nall Scale Column Purification. The Wizard® Minipreps Purification System 
(Promega) is adapted from many of the standard miniprep bacterial plasmid DNA 
protocols that have been used previously (Garger et al., 1983), but differs in that it uses a 
silica based resin to harvest plasmid DNA following cell lysis and KOAc precipitation. 
The decision to use this protocol was based upon the need to obtain small quantities of 
highly pure DNA for use in sequencing and subcloning. Another advantage of using this 
method is that many DNA preparations can be conducted simultaneously and with a 
consistent yield, through the use of Promega's Vac-Man® laboratory vacuum manifold. 
For each preparation 3ml of an overnight bacterial culture was pelleted by centrifugation 
for l-2min in a bench top microfuge and resuspended in 200µ1 of the 'Cell Resuspension 
Solution' (50mM Tris-HCI pH7.5, l0mM EDTA, l00µg/ml RNaseA). The cells were 
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then lysed by adding 200µ1 of the 'Cell Lysis Solution' (0.2M NaOH, 1 % SDS) and the 
protein precipitation by adding 200µ1 of the 'Neutralisation Solution' ( 1.32M KO Ac 
pH4.8). After spinning the tubes at top speed in a microfuge for 5min the 
supernatant/'Wizard' DNA purification resin (1ml) mix was passed through the 'Wizard 
mini-column', and the solution discarded. The DNA-bound mini column was then washed 
with 2ml of the 'Column Wash Solution' (200mM NaCl, 20mM Tris-HCI pH7.5, 5mM 
EDT A, dilute 1: 1 with 95% EtOH), removed from the syringe, spun at top speed for 20 
seconds and the DNA eluted from the column with 50µ1 of TE. 
Section 2.2.2 Preparation of A Phage DNA. 
The stored lysate from each of the A phage mouse genomic clones (Part 3.2, p65), diluted 
to 10-8 plaque forming units (pfu) per 1 0µl was used to infect 200µ1 of an overnight 
culture of E. coli XLl-Blue containing 25µ1 l0mM CaC12 and 25µ1 l0mM MgC12. This 
was left to incubate for 20min at 37°C, mixed with 3ml of Top Agarose (0.7% agarose, 
prewarmed to 55°C) and poured onto an LB agarose plate. Following overnight 
incubation at 37°C, a single phage plaque was picked and added to 100µ1 of phage buffer 
(20mM Tris-HCI pH7.4; l00mM NaCl; l0mM MgSO4 adjust to pH7.4). The previous 
day a single colony of E. coli XLl-Blue, was used to inoculate 3ml of LB containing 30µ1 
IM MgSO4 and 3µ1 20% Maltose. 500µ1 of this culture was added to the 100µ1 of 
diluted phage and the mix incubated for 20min at 37°C. For each preparation of phage 
DNA the prepared phage culture was used to inoculate 100ml LB, 1ml lM MgSO4, 
prewarmed to 37°C in a 250ml flask. This liquid culture was then incubated (37°C, 3-
6hrs) and the OD monitored every 30min or until complete lysis had occurred. After 
which 0.5ml of chloroform was added with mixing. The culture was then centrifugated (8 
500rpm; l0min, 6°C), the supernatant transferred to a clean flask and RNaseA and DNase 
added to a final concentration of l00µg/ml (30min, 37°C). To precipitate the phage one 
volume of phage precipitation solution (20% PEG 8 000 & 2M NaCl) made up in SM 
Buffer (11: 8g NaCl, 2.8g MgSO4, 6. lg Tris pH7.5; & 0. lg gelatin) was added, the 
solution incubated (1hr, ice), centrifugated (12 000rpm; l0min, 4°C) and the resulting 
pellet resuspended in 6ml of L3 buffer (l00mM Tris-HCI, l00mM NaCl, & 25mM 
EDTA pH7.5), 2ml of 10% SDS. This was followed by a further incubation period (70°C, 
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20min), the A phage DNA extracted with an equal volume of TE-saturated 
phenol:chloroform:isoamyalcohol (25:24: 1) and the solution spun (4 000rpm). This was 
repeated twice, the DNA precipitated with I/10th (v/v) 3M NaOAc pH7.0, equal volume 
isopropyl alcohol, at room temperature for 20min, the pellet washed with 70% EtOH and 
dissolved in 500µ1 TE. 
Section 2.2.3 Preparation of Mouse Cerebellum mRNA. 
a) Extraction of Total RNA from Mouse Cerebellum. The method used is adapted from 
the RNA isolation protocol of Chomczynski and Sacchi, 1987. Adult mice (BALB/c, 20-
30g) of either sex were killed with an overdose of ether. The skin around the head of the 
animal was removed and the skull cut open through the temporal ridges. To remove the 
brain, cuts were made at the orbitals, optic nerves and spinal cord. The cerebellum was 
then cut out, weighed and placed in a homogeniser containing 1ml of Trisolv® (Biotecx) 
per 50-100mg of tissue, homogenised and allowed to sit at room temperature for 5min to 
allow dissociation of nucleoprotein complexes. The tissue was then transferred to a new 
tube, 0.2ml of chloroform added and vortexed for 15secs. After a further 2-3min the 
homogenate was centrifugated (12 000xg, 15min, 4°C) and the aqueous layer removed. 
Note that the same method was used to prepare RNA from the mouse liver, kidneys, lung, 
spleen, whole brain, lungs and other tissues. 
b) RNA Precipitation. the aqueous layer from the above RNA extraction step was 
transferred to a fresh tube, mixed with isopropanol (0.5ml/1ml of Trisolv®) and stored at 
room tern perature for 5-1 Om in at 4°C. The RN A was then pelleted by centrifugation ( 12 
000xg, l0min, 4°C), and washed twice with 75% EtOH. At the end of the procedure the 
RNA was then left as a pellet or resuspended in 20-50µ1 of diethylpyrocarbonate (DEPC) 
treated-RNase free doubly distilled (dd) H20 and the yield calculated. 
c) Column Purification of mRNA. Whole mouse cerebellum RNA was obtained following 
the procedure described above and run through oligonucleotide dT cellulose columns 
(Pharmacia) to specifically isolate the mRNA. Each column was first inverted several 
times to resuspend the oligonucleotide dT-cellulose, washed with storage buffer and then 
with 1 ml of High Salt Buffer which was allowed to drain through the column under 
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gravity. The RNA was prepared by res us pending approximately 1.25mg in 1ml of Elution 
Buffer (TE, in 0.1 % DEPC treated ddH2O), which was then heated at 65°C for 5min, 
transferred to ice and mixed with 0.2ml of Sample Buffer. The elution buffer was then 
prewarmed to 65°C, applied to the top of the column bed and allowed to soak under 
gravity. The column was then spun (350xg; 2min), 0.25ml of High Salt buffer added and 
spun again (350xg for 2min). This wash step was repeated once more using 0.25ml High 
Salt Buffer and another three times with 0.25ml of Low Salt Buffer. The RNA was then 
eluted from the column using 0.25ml aliquots of prewarmed (65°C) Elution Buffer 
(350xg, 2min). After each spin the eluate was added to 100µ1 of Sample Buffer, 10µ1 of 
Glycogen Solution and 2.5ml of EtOH mix. This solution was then chilled at -20°C for 
2hrs and spun (4°C, 12 000rpm) to recover the mRNA which was stored at -70°C until 
needed. The yield was then calculated using spectrophotometric analysis (Section 2.2.5, 
p37). 
Section 2.2.4 Preparation of Oligonucleotides. 
a) Introduction. The desired oligonucleotide (Table 2.1) was prepared by the 
Biomolecular Resource Facility at the John Curtin School of Medical Research, Australian 
National University (ANU). The primer would arrive either as lyophilised powder or in 
ammonium hydroxide. In either case the following protocols were used to further purify 
each sample. 
b) n-Butanol Precipitation from Ammonium Hydroxide. In this procedure 1ml of n-
butanol was added to 100µ1 of the ammonium hydroxide solution. This was vortexed for 
15 to 20 seconds and spun at high speed for several minutes. The pelleted oligonucleotide 
was washed with 70% EtOH, dried and resuspended in 100µ1 ddH2O. 
c) Diethyl Ether Precipitation from Acetic Acid. About 200nmoles of the lypholised 
oligonucleotide was first redissolved in 1 0µl of ddH2O, mixed and 40µ1 of glacial acetic 
acid added in a step wise manner until the oligonucleotide was completely dissolved. 1ml 
of diethyl ether was then added and the solution was left to stand (30min) . The 
oligonucleotide was then pelleted, washed with diethyl ether and dissolved in ddH2O. 
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Table 2.1 Oligonucleotides Utilised. 
*TH (Hybridisation Temperature)=TM(Melting Temperature)-5°C 
TM=2x(nA+nT)+4x(nG+nC) and n=number of A's, number of C's etc. 
5' Oligon ucleotide 3' 
lBF GCCTGCAAGGAGTACAAGCCC 
4BF CCCGAGCTGCTGGGTGTCATG 
3R GCCAATGTACTTGAGATTGTTCTG 
anti-lBF GGGCTTGTACTCCTTGCAG 
anti-4BF CATGACACCCAGCAGCTCG 
4CF CCTGAGCTGCTGGGTGTCATG 
anti-4CF CATGAGACCCAGCAGCTCA 
Al-1 CATCCGCAACCCTACTCAGAGATT 
Al-2 TTTGCTATAAACGGAGGCTCTAGG 
NeoP5 GCCTGAAGAACGAGATCAGCAGCC 
NeoP6 GCCAAGTTCTAATTCCATCAGAAGC 
Universal TGACCGGCAGCAAAATG 
Reverse GGAAACAGCTATGACCATG 
proml CGTGCTACTTCCATTTGTCACGTC 
prom2 GGTGGATGTGGAATGTGTGCGA 
mG 2 GF ATGGGATGTCGGCAAAGCTCAGA 
mG 2 GF (Not I) GCGGCCGCATGGGATGTCGGCAAAGCTCAGA 
mG 2 GR TACTCCTTGCAGGCGTCCAGGTT 
NOTIPA CAATTCGCGGCCGCTTTTTTTTTTTTTTT 
NOTPCR CTCAATTCGCGGCCGCTTTT 
. 
Section 2.2.5 Spectrophotometric Analysis . 
*TH 
63 °C 
65°C 
63 °C 
ss 0 c 
57°c 
65°C 
s2 °c 
67 °C 
65°c 
71°c 
67 °C 
47 °c 
49 °c 
67 °C 
63 °C 
65°C 
65°C 
67 °C 
NA 
62 °C 
Following the preparation of RNA, single stranded (ss)DNA double stranded (ds) DNA, 
or oligonucleotide, 5µ1 of each sample was diluted in 1000µ1 of ddH2O and the optical 
density at 260nm (OD260) used to obtain the concentration (C; Sambrook et al., 1989). 
OD26o=Absorbance at 260nm (A26o)x1000/5. 
OD2601=50µg/ml therefore C(dsDNA)=50xOD26oµg/ml 
=33µg/ml therefo!e C(ssDN A)=33xOD26oµg/ml 
=40µg/ml therefore C(RNA)=40xOD26oµg/ml for 
The following formula was used to calculate the concentration of each oligonucleotide: 
C=(A260 x 100 x dilution)/[(1.54xnA)+(0.75xnC)+(l.17xnG)+(0.92xnT)] 
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Part 2.3 Recombinant DNA Techniques. 
Section 2.3.1 Restriction Endonuclease Digests. 
Each restriction digest was carried out in the appropriate lxNEB buffer for that enzyme. 
These include: NEBuffer 1 (l0mM Tris Propane-HCl, l0mM MgC12 & lmM 
dithiothreitol (DTT) pH7.0); NEBuffer 2 (l0mM Tris-HCl, l0mM MgC12, 50mM NaCl 
& lmM DTT pH7.9); NEBuffer 3 (50mM Tris-HCl, l0mM MgC12, l00mM NaCl & 
lmM DTT pH7.9); NEBuffer 4 (20mM Tris-acetate, l0mM MgAc, 50mM KOAc & 
lmM DTT pH7.9); EcoRI Buffer (50mM NaCl, l00mM Tris-HCl, l0mM MgC12, 
0.025% Triton X-100 pH7.5); and BamHI Buffer (150mM NaCl, l0mM Tris-HCl, 
l0mM MgC12, lmM DTT pH 7.9). For most digests a mix containing 20µ1 (lµg; 
0.05µg/ml) of plasmid DNA, 2µ1 of l0x NEBuffer, 2µ1 of l0x acetylated-Bovine Serum 
Albumin (BSA) and 2U of enzyme was prepared and incubated at 37°C for 60min. 
Section 2.3.2 Analytical and Preparative Separation of DNA Fragments. 
In order to determine the success of a restriction digest, polymerase chain reaction (PCR) 
or to estimate DNA concentration and quality, electrophoresis was carried out at room 
temperature on horizontal 1 % agarose gels. The gels were prepared by dissolving agarose 
in T AE ( 40mM Tris-acetate & 2mM EDT A pH8.0). Ethidium bromide (EtBr) was then 
added to both the gel and buffer (T AE) to a final concentration of 0.5µg/ml. The gels were 
submerged in either a Pharmacia or Biorad Mini-Submarine® electrophoresis tank and 
electrophoresis was conducted at 80V for 1-2hrs. Following separation by electrophoresis 
the DNA was visualised under ultraviolet (UV) light and photographed. 
Section 2.3.3 Gel Purification of Restricted DNA Fragments. 
a) Glass Milk Extraction. This protocol was adapted from the Gene Clean® system (Bio 
101, Bresatec) which utilises Glass Milk to bind DNA. Following electrophoretic 
separation the desired band was cut from the agarose using a scalpel blade, submerged in 
3xNaI and incubated (5min, 55°C). Once the agarose had completely melted 5µ1 of glass 
milk was added. This was followed by a further incubation period on ice (5min), the 
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solution spun at top speed (12 000rpm, 5sec) and the supernatant removed. The glass 
I 
milk/bound DNA was then washed in 300µ1 of the 'New Wash solution and repelleted 
(12 000xg, 5sec). This was repeated twice more and after the final wash the pellet was 
resuspended in 6µ1 of TE, incubated for 2min at 55°C, spun at top speed (12 000xg, 
30sec) and the supernatant removed. This step was repeated and the yield calculated. 
b) Squeeze/Freeze Method. In each instance the DNA band cut from the gel was wrapped 
in wax paper and stored at -20°C for 1-2hrs. The frozen block of agarose was then 
'squeezed/thawed' between two pieces of parafilm and the buffer collected in a tube. The 
DNA was then precipitated (2xl00% EtOH, I/10th volume 3M NH4OAc pH 5.3), 
pelleted (12 000xg, 30min), washed with 70% EtOH and resuspended in 20-30µ1 TE. 
Section 2.3.4 Blunt Ending DNA fragments. 
The Klenow fragment of T4 DNA polymerase is a DNA dependent DNA polymerase 
which, although it retains its 3' to 5' exonuclease has lost the 5' to 3' exonuclease activity 
(Sambrook et al., 1989). This means that the enzyme can be used to catalyse the 'filling in' 
of 5' overhangs left following enzyme restriction. Each reaction was carried out in 
lxKlenow Buffer (l0mM Tris-HCl pH7.5, 5mM MgC12 & 7.5mM DTT; NEB) 
supplemented with 33µM of each deoxynucleotide triphosphate (dNTP) for l0min at 
37°C and the enzyme deactivated (70°C, 5-1 0min). 
Section 2.3.5 Dephosphorylation of Linearised Vectors. 
The dephosphorylation reaction removes 5' phosphate groups from the ends of linearised 
plasmid and phage vector DNA, thus preventing vector self ligation (Sambrook et al., 
1989). Each reaction was conducted in either one of the four NEB restriction buffers 
(Section 2.3.1, p38) and catalysed by 2U of the Calf Intestinal Phosphatase (CIP). 
Following a 30min incubation at 37°C, the mix was transferred to a 50°C water bath and 
left for another 30min. This 50°C step is especially important when 'phosphatasing' blunt 
ends. The enzyme was then deactivated by phenol:chloroform extraction, the plasmid 
DNA precipitated by the addition of two volumes 100% EtOH, 1/10th volume 3M 
NH4OAc pH5.3, centrifugated and the pellet resuspended in 20µ1 ddH2O. 
39 
I 
Section 2.3.6 Ligation of DNA Fragments. 
Ligations were conducted to stably clone restricted DNA fragments. In each instance the 
ligation mix consisted of DNA/vector in a 2: 1 ratio, lxT4 DNA Ligase Buffer (50mM 
Tris-HCI pH 7.8, l0mM MgCh, l0mM DTT, lmM dATP, 25mg/ml of Bovine Serum 
Albumin), IOU of T4 DNA Ligase (NEB) and ddH2O in a 20µ1 reaction volume. The 
ligation was then incubated in a water bath (Blunt End Cloning, overnight 16°C; Sticky or 
Sticky/Blunt Cloning, 2-3hrs room temperature). The controls used in each case include: 
(i) vector and T4 DNA ligase but no insert, to indicate the degree of vector religation; and 
(ii) vector alone to indicate the degree of digestion. 
Section 2.3.7 Transformation and Selection of Bacterial Clones. 
a) Preparation of Chemically Competent Cells. Chemically competent E. coli strains were 
prepared by diluting (1: 100) an overnight culture of the desired strain in LB broth and 
grown to an OD6oo=0.6 in a 11 conical flask. This culture was then harvested in two 50mL 
polypropylene tubes, chilled on ice for 10-15min and spun (1 000xg; 12-ISmin, 4°C). The 
resultant pellet was then resuspended in cold 16.7ml RPI solution (l00mM RbCl, 50mM 
MnC!i.4H2O, 30mM IM KOAc pH7.5, l0mM CaC!i.2H2O & IS% Glycerol. Adjusted 
to pH5.8 with 0.2M Acetic Acid. Filter sterilise), repelleted (1 000xg; I2- I5min, 4°C) and 
resuspended in 4ml RF2 solution (l0mM RbCl, 75mM CaC!i.2H2O, l0mM 0.5M 
MOPS pH6.8 & Glycerol 15%. Adjust to pH6.8 with NaOH. Filter sterilise). After this 
wash the cells were kept on ice for 15min and stored (-70°C). 
b) Transfonnation. For each transformation 20µ1 of ligation mix was added to a single 
200µL aliquot of chemically competent bacterial cells, thawed on ice. After 30min on ice 
this transformation mix was then heat shocked (42°C, 90sec), allowed to recover in 1ml of 
LB (37°C, 60min), plated onto LB agar containing appropriate antibiotic selection media 
(e.g. ampicillin 50µg/ml) and incubated at 37°C, overnight (Brown et al., 1979). 
c) Preparation of Electrocompetent Cells. A bacterial culture of the desired E. coli strain 
was grown overnight (37°C) in 10ml of SOB media ( 4% Tryptone, 1 % Yeast Extract, 
0.02M NaCl & 0.005M KCI, autoclave then add MgSO4 to final concentration 0.04M). 
This starting culture was then diluted in 11 of LB broth and grown with vigorous shaking 
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at 37°C to OD6000.5-1. When this density was reached the cells were harvested by 
centrifugation ( 4000xg; 15min, 4°C) and resuspended in an equal volume of cold 10% 
glycerol. This washing step was repeated several times with 500ml, 20ml and 3ml of the 
10% glycerol solution. Following this final wash the cells were aliquoted, snap frozen in 
liquid nitrogen and stored at -70°C. 
d) Electroporation. Prior to electroporation electro competent cells were allowed to thawed 
on ice. A 40µL aliquot was then combined with 1µ1 of the ligation mix and transferred to 
an ice cold micro-cuvette (Biorad®) and electroporated (25µF, 2.5kV and 200 ohms) with 
the Biorad® Gene Pulser. 1ml of SOC broth (SOB+0.02M Glucose) was then added and 
the cells allowed to recover at 37°C for 60min. Several dilutions of this mini-culture were 
then plated onto LB agar bacterial plates, containing the appropriate antibiotic and 
incubated overnight at 37°C. 
Section 2.3.8 Screening Cloned Inserts. 
a) Blue/White Selection System. 25µ1 X-gal [5-bromo-4-chloro-3-indolyl-~-D galactose; 
2% dimethylfluoride (DMF)] and 15µ1 IPTG (l00mM) was spread out evenly and 
allowed to dry on each LB agar plate prior to spreading the transformation mix (see 
above). Present on certain cloning vectors the lacZ gene codes for the expression of 
enzyme ~-galactosidase which is induced by IPTG and uses X-gal as a substrate to 
produce a blue colouration in those cells which contain the vector. If the expression of the 
gene is interrupted by a cloned insert the fusion protein which is produced will be 
incapable of utilising X-gal. Those cells containing vectors with cloned inserts will , 
therefore, appear white (Sambrook et al., 1989). This form of screening, however, gives no 
indication of the size of the insert and false positives are common due to random deletions 
which inactivate the lacZ gene. 
b) Colony Cracking. In most instances and whether or not blue/white selection was used 
all t.ransfo1mants were subjected to analysis by colony 'cracking'. A well isolated colony 
was picked with a sterile toothpick, replicated onto a fresh agar plate and resuspended into 
25µ1 of the 'cracking solution' (0.01 % Bromocresol green, 0.005M EDT A, 0.05M NaOH, 
0.5% SDS & 10% Glycerol). This was repeated as many times as necessary and the 
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replica plate placed in a 37°C incubator, so that the transferred cells could be used once 
positive clones were identified. All of the samples were then incubated at 65°C for 30min, 
allowed to cool to room temperature, and subjected to agarose (1 % ) gel electrophoresis. 
Positive clones were easily identified by their increased size when compared with uncut 
vector and due to the addition of the cloned insert. 
Section 2.3.9 The Reverse Transcriptase (RT) Reaction. 
a) Oligonucleotide dT Primers. For separate non-specific first strand synthesis of mRNA, 
an 18mer oligonucleotide dT primer was used prior to PCR amplification of a specific 
cDNA product. The RT mix was made up with 5x AMV RT Buffer, 500µM dNTP mix, 
l0mM DTT and 0.5µg primer/µg total RNA. The reaction was conducted in a sterile 
0.5mL eppendorf tube, incubated (42°C, 1hr) and the enzyme heat killed (65°C, 15min). 
b) The Promega Riboclone® System. The Riboclone® System was used for first strand 
synthesis of mRNA and was used in an attempt to clone a full length MGza cDNA clone. 
0.5µg of the NOTIPA (Table 2.1) was added for every lµg of purified mRNA in a total 
volume of 15µ1 with ddH2O. This mix was then heated to 70°C for 5min and allowed to 
cool to room temperature. To the annealed primer and template was added 5µ1 first strand 
5x AMV Buffer (Promega), 25U rRNasin® ribonuclease inhibitor, 2.5µ140mM sodium 
pyrophosphate, 15U/µg RNA AMV RT and ddH2O to a volume of 25µ1. Each of these 
components (except the enzyme which was added last) were preheated to 42°C for 5min 
to prevent the sodium pyrophosphate from precipitating. The reaction was then incubated 
(42°C, 1hr) and 50mM EDTA added. This RT mix was stored at -20°C, until needed. 
Section 2.3.10 The Polymerase Chain Reaction (PCR). 
Each 20µ1 PCR reaction was made up in lxPCR buffer (GeneAmp® PCR Reagent Kit; 
l0mM Tris-HCI pH 8.3, 50mM KCl, 1.5mM MgC}i, 0.001 % gelatin), 200µM of each 
dNTP, 1 U Supertaq® DNA polymerase and 5pmol of each primer. The PCR reaction 
mixtures were pippetted into positive displacement pipette tips, using a Cycle Prep® 
automatic pippetor. The PCR reaction was then carried out in a Corbett Research fast 
capillary thermal sequencer. The cycling conditions for each reaction are shown in each of 
the following chapters. The PCR cycling conditions used to amplify the MGzaP cDNA 
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fragment were as follows: DNA denaturation (95°C, 5min), annealing temperature (TA; 
63°C, 4BF/3R), annealing time (AT; 5sec ), primer extension temperature (TE; 72°C) and 
primer extension time (ET; 30sec). This cycle was repeated 35 times (35x) and followed 
by a final primer extension (72°C) period of 3min. In each instance 2µL of 5x Loading 
Buffer (Part 2.1, p30) was added and each sample heated for 15min at 65°C, prior to 
agarose gel electrophoresis. 
Section 2.3.11 The One-step RT-PCR Reaction. 
The RT-PCR protocol developed by Sellner et al. , 1992 was used to isolate the partial 
MG2a cDNA clone (Leck, 1993), and in subsequent attempts to obtain a full length cDNA 
MG2a clone. Each 20µ1 reaction contained mouse cerebellum total RNA (or mimic RNA 
control; Chapter 4, p98), 200µM of each dNTP, lx PCR (GeneAmp®) or RT-PCR 
Buffer (Leck, 1993; 67mM Tris pH 8.3, 0.5mM DTT, 50mM KCl, 0.1 % Triton X-1 00, 
6µM EDTA & 2mM MgC12), 0.5U of AMV RT, 5pmol of forward primer (4BF) and 
5pmol of reverse primer (3R) to primer the RT reaction. The reactions were conducted in 
positive displacement pipette tips (see above), using the following cycling conditions for 
this example. The RT reaction (42°C, 59min), RT inactivation (95°C, 5min). PCR 
amplification: DNA denaturation (95°C, 5sec) primer annealing (TA, 63°C; AT, 5sec), 
primer extension (TE, 72°C; ET, 2min). This was repeated 35 times and a second step of 
primer extension added (72°C, 7min). The enzyme was then inactivated (99°C, 1 0min) 
and the solution stored at 4°C. Note that prior to agarose (1 % ) gel electrophoresis each 
sample was heated (65°C, 15min). 
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Part 2.4 Hybridisation Protocols. 
Section 2.4.1 Preparation of Radiolabelled Probes. 
a) End Labelling. All oligonucleotide probes were radioactively endlabelled (Sambrook et 
al., 1989). The concentration of each primer was first carefully determined by 
spectrophotometric analysis and diluted to 5pmol/µl. 0.4pmol (0.8µ1) of the 
oligonucleotide was then diluted in 19.2µ1 ddH2O, to which was added 3µ1 l0xKinase 
Buffer (70mM Tris-HCl pH7.6, l0mM MgC12& 5mM DTT; NEB), 3µ1 acetylated-BSA 
(I0µg/ml, NEB), 1µ1 0. IM DTT; 1µ1 Spermidine, 1µ1 y32P-ATP (1 000Ci/mmol) and 1µ1 
T4 Kinase (NEB). The solution was then mixed, 1µ1 removed as a control and incubated 
(15min, 37°C). At the end of this time 3µ1 of l0xStop buffer (0.125M EDTA & 5% 
SDS) was added and 1µ1 of the labelled probe removed for chromatographic analysis. 
b) Random Priming. Larger fragments of DNA were radiolabelled by random priming 
(Amersham). To 2.5µ1 of DNA (50ng) was added 5µ1 of Primer Solution and 12.5µ1 of 
ddH2O. The solution was then heated (95°C, 5min) to denature the dsDNA and the 
primers allowed to bind at room temperature. The labelling reaction was at 37°C for 
30min in a 50µ1 volume which contained 5µ1 of !Ox Labelling Buffer, 4µ1 each of cold 
nucleotides (dTTP, dGTP & dCTP), 2µ1 of a 32P-dATP (I0µCi/µl), 5µ1 BSA, 9µ1 ddH2O 
and 1 U Klenow. Labelled probe was then precipitated by adding 5.5µL 3M NaOAc 
pH5.3, 120µ1 100% EtOH and 5µ1 (I00µg/ml) of ssDNA. The mix was then spun (12 
000rpm; 20min) and the pellet resuspended in 100µ1 ddH2O. 
Section 2.4.2 Analysis of Radiolabelled Probes. 
a) Thin Layer Chromatography (TLC). After preparing the probe 1µ1 of the control and 
lµl of the reaction ·were spotted onto PEI (polyethylene imine) paper (Merck) and lowered 
into PEI buffer (0.75M NaH2PO4 & 0.75M H3PO4 pH3.5) for 20min. The paper was 
placed under X-ray film (Xerox/Fuji; room temperature, 20min). The degree of 
incorporation was determined by visually comparing the signal of the unincorporated 
radiolabelled dNTPs with the amount released by the labelled probe (Figure 3.6). 
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b) Scintillation Counting. To obtain a more definitive measure of radioactivity scintillation 
counting was used. lµL of labelled purified probe was placed in an eppendorf tube and 
the counts/min/µg measured using a Rack Beta Liquid Scintillation Counter 1217. 
Section 2.4.3 DNA Transfer and Hybridisation. 
a) Southern Transfer. The blotting protocol used was adapted from an alkaline transfer 
method that utilises the capillary action generated by layers of folded paper (Reed & 
Mann, 1985). Two large pieces of 3MM Whatman paper were soaked in 0.4M NaOH 
and placed on a tray above a dish containing transfer solution (0.0lM NaOH). The 
depurinated (0.25M HCl, l0min) agarose gel was then placed in water to remove excess 
HCl and allowed to soak briefly in 0.4M NaOH before being layered on top of the 
Whatman paper. The positively charged nylon membrane (PCNM; Hybond N+) which 
was also washed in 0.4M NaOH, carefully placed on top of the gel and the position of the 
wells marked. It was not necessary to introduce a separate denaturing step prior to blotting 
as this process would occur during transfer. Several layers (5-10) of 3MM Whatman 
paper were then layered above the PCNM membrane, and were placed many folded sheets 
of paper (15cm) surmounted by a weight, to keep it all in place. To increase the efficiency 
of transfer wet sheets were replaced with dry ones after 2hrs. The transfer was allowed to 
continue for up to another 2hrs before the membrane was removed. 
b) Alkaline DNA Dot/Slot Blotting. Vacuum blotting was used to quickly transfer A phage 
DNA to positively charged membranes (Hybond N+ ), for hybridisation with radiolabelled 
3R. This procedure used to strip coat protein from the phage plaques, could also be 
applied to: (i) purified or crude DNA ( <5µg); (ii) whole soft tissue (e.g. liver, <0.5mg) ; 
(iii) whole blood ( <l 0µl); cultured cells; or (iv) sperm (Reed & Matthaei, 1990). The 
dot/blot apparatus was assembled with a sheet of PCNM. Each of the samples, prepared 
by heating (95°C; 0.4M NaOH), were added to the wells in batches of eight (0.5ml). The 
vacuum was then applied to transfer the prepared material to the membrane. Immediately 
following this the membrane was washed (2x PE & 0.1 % SDS), dried and stored at 4°C, 
until used. 
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c) DNA Probes. Prior to hybridisation with ramdomly primed radiolabelled DNA 
fragments the membranes were incubated for 1hr at 65°C in 10ml of prehybridisation 
solution containing 0.5% SDS, 6x SSC (17% NaCl; 8.82% Sodium citrate pH7.0) , 
0.01M EDTA, 5x Denhardts (0.5% Ficoll, 0.1 % Polyvinylpyrrolidone, 0.1 % fraction V 
BSA) and l00µg/ml denatured (95°C, 5min) salmon sperm DNA (Sambrook et al., 
1989). The radiolabelled probe (about 2x105 cpm/µl) was then denatured (95°C, 5min) 
added to the prehybridisation solution and the membrane left to incubate (4-5hrs, 65°C) in 
a Hybaid® oven. At the end of this time the filters were washed twice with shaking at 
room temperature (20min; 2xSSC & 0.1 % SDS). This was followed by further high 
stringency washes ( 65°C; 0.lxSSC & 0.1 % SDS). The membrane was then exposed to 
X-ray film for up to a week at -70°C. 
d) Oligonucleotide Probes. When using an oligonucleotide probe the membranes were 
incubated for 1-2hrs in 20mL of the prehybridisation solution [5x PE (0.133M Sodium 
Phosphate pH6.9 & 0.001M EDTA), 7% SDS & 1 % BSA] at the TH. At the end of this 
time 10ml of the solution was removed, end-labelled probe added and the membrane left to 
incubate for 4-5hrs at the TH, A set of washing steps were then conducted to remove any 
unbound or non-specifically attached probe. The membrane was first washed in 5x SSC 
(14.17% NaCl & 7.35% Sodium Citrate), 0.1 % SDS at room temperature for 15min. This 
was followed by a temperature wash at the TH in 5x SSC, 1 % SDS for a further 15min 
and a final washing step at room temperature in 2x SSC and 0.1 % SDS for l0min. The 
membrane was then exposed to X-ray film for up to a week at -70°C. 
e) Stripping the Radiolabelled Probes. In a number of instances the same membrane was 
hybridised with different probes. Before each procedure the previous probe was removed, 
either through boiling the membrane in 0.1 % SDS, and allowing it to cool to room 
temperature (Sambrook et al., 1989) or through the use of a gentle stipping solution 
containing 110ml Formamide, 20ml 20xSSPE, 10ml 20% SDS, made up to 200ml with 
ddH2O. Gentle stripping was conducted within a Hybaid® oven at 65°C for 15 to 30min, 
or until the label was removed. Note that in either case the stripped membrane was 
exposed to X-ray film overnight, to confirm that no bound label remained. 
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Section 2.4.4 RNA Transfer and Hybridisation. 
a) Preparation and Electrophoretic Separation of RNA. Prior to use RNA samples stored 
under ethanol were centrifuged, rinsed, dried and resuspended in a small volume of TE 
plus 2mM DTT and 1 U/µl RNasin RNase inhibitor (Promega). Samples were prepared 
for electrophoresis by mixing l0µg of RNA with 2µ1 of l0xMOPS buffer (0.2M MOPS, 
0.05M NaOAc pH7.0, 0.01M disodium EDTA & 0.1 % DEPC), 3.3µ137% formaldehyde 
and ddH2O to 20µ1. This mix was heated at 55°C for 15min and 2µ1 of l0xRNA sample 
buffer (Loading buffer made up in DEPC treated ddH2O) added. Electrophoresis of RNA 
was carried up in a denaturing gel consisting of 0.188g of iodoacetamide, 0.3ml of EtOH, 
1 % agarose, I 0ml 1 Ox MOPS buffer, 2ml 37% formaldehyde solution, 5ml EtBr 
(1 mg/ml) and 86ml ddH2O. The gel was run at 80V for approximately 60min using 
lxMOPS buffer as the running buffer. 
b) Northern Transfer. Northern transfer of RNA was conducted in a similar manner to 
Southern DNA blotting, however, in this instance lxMOPS buffer was used as the RNA 
transfer buffer, whilst the denaturing and depurinating steps were excluded. The RNA was 
fixed to the membrane using UV illumination. 
c) Hybridisation of RNA Filters. Each RNA-bound membrane was incubated (42°C, 
overnight) in Hybaid® bottles with 10ml of prehybridisation solution (5xSSC, 
5xDenhardts, 0.5% SDS & 50% Formamide). To this was added 100µ1 I0mg/ml sheared 
salmon sperm DNA, boiled for 1 0min prior to incubation. Following this period the 
desired probe (see above) was boiled and added directly to the solution. This second 
hybridisation step was left for 8hrs and the membrane washed: (i) 5-1 0min, 2xSSC, 0.1 % 
SDS, room temperature; (ii) 15min, 2xSSC, 0.1 % SDS, 55°C; (iii) 15min, lxSSC, 0.1 % 
SDS, 55°C; and (iv) 15min, 0.5xSSC, 0.1 % SDS, 55°C, if required. The membrane was 
then placed under X-ray film (overnight to one week; -70°C). 
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Part 2.5 The Generation of Deletion Clones. 
Section 2.5.1 Introduction. 
The Erase a base® sequencing protocol is a rapid and relatively efficient means of 
generating overlapping sequences, from a single large DNA fragment (Promega). The 
procedure itself involves the use of the DNase ExoIII which cuts dsDNA from 
unprotected 5' ends (not 3' or a-phosphorothioate protected DNA ends) at a defined rate, 
creating a number of deletion fragments which can be separately recircularised, cloned and 
sequenced (Figure 2. lA). 
Section 2.5.2 Protection of 5' Protruding Ends. 
Approximately 5µg of the designated clone was digested with the enzyme chosen to 
generate the 'primer protecting' site (e.g. Natl; Table 2.2). If Klenow was active in this 
restriction buffer, the 'fill in reaction' (of the 5' overhangs with a-phosphorothioate 
nucleotide's) was performed directly. However in the cases that it was not, the DNA was 
first extracted. The volume of the digestion mix was brought to 100µ1 with ddH20 and 
added to an equal volume of TE-saturated phenol:chloroform:isoamylalcohol (25:24: 1). 
The mixture was then vortexed and the two phases separated by centrifugation (12 000xg, 
5 min). The aqueous layer was then transferred to a fresh tube, to which was added I/10th 
volume of 2M NaCl and 2x 100% EtOH. This mix was then left at -20°C for l0min, 
centrifugated (12 000xg, 5min) and the DNA pellet washed with 70% EtOH, dried and 
resuspended in 50-100µ1 of lxKlenow Buffer (Promega). 
Section 2.5.3 Exolll Deletion, Ligation and Transformation Procedures. 
The following example given is based upon using 5µg of the 4kb Kpnl clone 8K (Section 
3.2.6, p76). The protected linearised clone was cut with EcoRI to expose one end, 
precipitated and resuspended in 50µ1 of lxExoIII buffer (50mM Tris-HCl pH8.0, 5mM 
MgCl2 & 1 0mM 2-mercaptoethanol). Meanwhile 7 .5µ1 of S 1 nuclease mix [25 time 
points: 172µ1 ddH20, 27µL S17.4xbuffer (0.3M KOAc, 2.5M NaCl, l0mM ZnS04 & 
50% Glycerol) & 60U ExoIII] was aliquoted into twenty small tubes and left on ice. The 
48 
:11: 
1,, 
Table 2.2 Restriction Enzyme Recognition Sites. 
(Taken from the Promega Catalogue) 
Restriction Enzymes That Generate 
Exom Resistant 3' Overhangs 
Enzyme Recognition Sequence 
V 
AatIT 5' ... GACGTC ... 3' 
3' ... CTGCAG ... 5' 
I\ V 
BanII 5' ... GPuGCPyC ... 3' 
3' ... CPyCGPuG ... 5' 
I\ 
V 
Bgll 5' ... GCCNNNNNGGC ... 3' 
3' ... CGGNNNNNCCG ... 5' 
I\ V 
BstXl_ 5' ... CCANNNNNNTGG ... 3' 
3' ... GGTNNNNNNACC ... 5' 
A V 
Haell 5' ... PuGCGCPy ... 3' 
3' ... PyCGCGPu ... 5' 
/\ V 
Hhal 5' ... GCGC ... 3' 
3' ... CGCG ... 5' 
I\ V 
Kpnl 5' ... GGTACC ... 3' 
3' ... CCATGG ... 5' 
I\ V 
Nsil 5' ... ATGCAT ... 3' 
3' ... TACGTA ... 5' 
/\ V 
Pvul 5' ... CGATCG ... 3' 
3' ... GCTAGC ... 5' 
/\ V 
Sacl 5' ... GAGCTC ... 3' 
3' ... CTCGAG ... 5' 
I\ V 
Sphl 5' ... GCATGC ... 3' 
3' ... CGTACG ... 5' 
I\ 
Restriction Enzymes That Generate 5' 
Overhangs or Blunt Ends 
Enzyme Recognition Sequence 
V 
BamHI 5' ... GGATCC ... 3' 
3' ... CCTAGG ... 5' 
V A 
Clal 5' ... ATCGAT ... 3' 
3' ... TAGCTA ... 5' 
V /\ 
Csp45I 5' ... TTCGAA ... 3' 
3' ... AAGCTT ... 5' 
V /\ 
EcoRI 5' ... GAATTC ... 3' 
3 ' ... CTI AAG ... 5' 
V /\ 
EcoRV 5' ... GATATC ... 3' 
3' ... CTATAG ... 5' 
V /\ 
Hindlll 5' ... AAGCTT ... 3' 
3' ... TTCGAA ... 5' 
V I\ 
Ncol 5' ... CCATGG ... 3' 
3' ... GGTACC ... 5' 
V A 
Ndel 5' ... CATATG ... 3' 
3' ... GTATAC ... 5' 
V /\ 
Notl 5' ... GCGGCCGC ... 3' 
3' ... CGCCGGCG ... 5' 
V I\ 
Sall 5' ... GTCGAC ... 3' 
3' ... CAGCTG ... 5' 
V /\ 
Smal 5' ... CCCGGG ... 3' 
3' ... GGGCCC ... 5' 
V /\ 
Spel 5' ... ACT AGT ... 3' 
3' ... TGATCA ... 5' 
V I\ 
Xbal 5' ... TCTAGA ... 3' 
3' ... GAGCTC ... 5' 
V I\ 
Xhol 5' ... CTCGAG ... 3' 
3' ... GAGCTC ... 5' 
I\ 
(*) Although Apal, Pstl and Sacll generate 3' overhangs, these ends are not protected 
from Exam (see below) 
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DNA mix was then warmed to 37°C (225bp/sec at 37°C; Figure 2.IB) and 382U of 
Exolll (Promega) added. After a lag time of 20-30secs a series of 20 aliquot's were 
removed (2.5µ1) at 30sec intervals. These were added to the S 1 nuclease mix and pipetted 
up and down briefly to deactivate the Exolll. After all the samples were taken the tubes 
were then placed at room temperature and Sl stop buffer (0.3M Tris base & 0.05M 
EDT A) added after 30min. To determine the extent of digestion and the success of the 
procedure 2µ1 from each time point was removed and run on a 1 % agarose gel. 
Meanwhile lµl of Klenow mix (30µ1 Klenow buffer & 3-5U Klenow) was added to the 
remainder of each sample, incubated (37°C, 3min) and 1µ1 of dNTP mix (0.125mM each 
of dATP, dCTP, dGTP & dTTP) added. Each tube was then left for a further 5min at 
37°C, 40µ1 of Ligation mix (25 time points: 790µ1 ddH20, 100µ1 1 0xLigase buffer, 
I00µL 50% PEG, 10µ1 I00mM DTT & SU T4 DNA Ligase) added and each tube left at 
room temperature for 60min. 10µ1 of each sample was transformed into chemically 
competent E. coli DH5a cells, whilst the remainder of the overnight ligation mix was 
stored at 4°C. 
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Figure 2.1 The Promega Erase a base® Protocol. 
(A) Shown is a diagrammatic representation of the protocol used to generate timed 
deletion clones for sequencing. Initially the plasmid is cut with a specific endonuclease 
which linearises it and provides the site for primer protection. If the enzyme is a 3' cutter 
and therefore produces naturally endonuclease resistant ends, then a second enzyme is 
used to deprotect one end. However, if the enzyme produces 5' ends then both ends are 
first protected, before the second enzyme digest. In either case a series of timed deletions 
are taken using ExoIII from the deprotected end and S 1 nuclease used to 'chew back' the 
ssDNA overhang. The ends are then blunt ended, the fragments religated, transfo1med into 
chemically competent E. coli and prepared for sequencing. 
(B) A graph showing the activity (digestion rate) of the ExoIII exonuclease against 
temperature (Promega Catalogue). 
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Part 2.6 DNA Sequencing 
Section 2.6.1 Cycle Sequencing. 
a) Introduction. Templates for cycle sequencing were prepared using the Wizard® 
Miniprep System and concentrated to 250ng/µL The sequencing reactions were performed 
in positive displacement pippette tips, using a Corbett Research fast capillary thermal 
sequencer, following the Applied Biosystems technical manual. 
b) Dye Pri,ner Cycle Sequencing. For each sample 0.5µ1 (8U/µl) of enzyme (AmpliTaq® 
DNA Polymerase) was diluted in 1.0µ1 5xCycle Sequencing Buffer (400mM Tris-HCl 
pH8.9, l00mM Ammonium Sulphate & 25mM MgC12), 5.5µ1 ddH2O and the 
sequencing mix prepared (Table 2.3). The cycling conditions were as follows: (i) DNA 
denaturation (95°C, 30sec ), annealing temperature (TA; 55°C, 30sec ), and primer 
extension (70°C, lmin). This cycle was repeated 15 times; then (ii) DNA denaturation 
(95°C, 30sec) and primer extension (70°C, lmin). This second cycle was repeated 15 
times and the products prepared for electrophoresis. Each mix was combined in a tube 
with 80µ195% EtOH, 1.5µ1 of 3M NaOAc, placed on ice for 10-15min and then spun (12 
000rpm; 15-30min). The pellet was then washed with 70% EtOH and dried. 
Table 2.3 Dye Primer Cycle Sequencing Reaction Mixes. 
Reagent A C G T 
d/ddNTP Mix* 1µ1 lµl 2µ1 2µ1 
Primer (0.4pmol/µL) lµl 1µ1 2µ1 2µ1 
5xSeq. B offer lµl 1µ1 2µ1 2µ1 
DNA template 1µ1 lµl 2µ1 2µ1 
Diluted Taq 1µ1 1µ1 2µ1 2µ1 
*d/ddA mix (1.5mM ddATP, 62.5µM dATP, 250µM dCTP, 375µM c7dGTP, 250µM 
dTTP); d/ddC mix (0.75mM ddCTP, 250µM dATP, 62.5µM dCTP, 375µM c7dGTP, 
250µM dTTP); d/ddG mix (0.125mM ddGTP, 250µM dATP, 250µM dCTP, 94µM 
c7dGTP, 250µM dTTP); and d/ddT mix (1.25mM ddTTP, 250µM dATP, 250µM dCTP, 
375µM c7dGTP, 62.5µM dTTP). 
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c) Dye Terminator Cycle Sequencing. 5.0µ1 of ssDNA (0.5µg) or dsDNA (l.0µg) was 
added to 9.5µ1 of the terminator mix (Applied Biosystems). The primer was then added 
(0.8pmol for ssDNA or 3.2pmol for dsDNA) and the volume made up to 20µ1 with 
ddH2O. The cycling conditions were as follows: DNA denaturation (95°C, 30sec), 
annealing temperature (TA; 50°C, 15sec), and primer extension (60°C, 4min). This cycle 
was repeated 25 times and the products prepared for electrophoresis. The dye terminators 
were extracted with 100µ1 phenol:H2O:chloroform (68:18:14). The lower phase was 
discarded and the DNA precipitated with 15µ1 of 2M NaOAc pH4.5, 300µ1 of 100% 
EtOH and centrifugated. The pellet was then washed with 70% EtOH and dried. 
Special Acknowledgments. The prepared sequencing products of TAQ dye primer and 
dye terminator cycle sequencing were given to the Biomolecular Resource Facility, ANU 
which ran the automated sequencer. 
Section 2.6.2 Preparation of Single Stranded Template DNA. 
Cultures of recombinant M13 phage were grown (6-8 hrs, 37°C) and precipitated from the 
solution with the addition of 4% PEG 6000/SM NaCl. After 5min centrifugation, DNA 
from the phage pellet was purified with TE-saturated:phenol:chloroform, precipitated and 
resuspended in 15µ1 TE (Sambrook et al., 1989). 
Section 2.6.3 Manual Sequencing. 
a) ssDNA Sequencing. Sequencing reactions were carried out using the dideoxy chain 
termination procedure of Sanger et al., 1977, but was modified to incorporate the use of 
T7 Polymerase (Pharmacia) instead of Klenow (Tabor & Richardson, 1987). To 5µ1 of 
template DNA was added lµL of Universal primer and 1µ1 of l0x Annealing Buffer 
(30mM MgCh, lM Tris pH 7.5 & SM NaCl). This solution was then boiled and left to 
cool to room temperature. 1.5µ1 of the labelling mix, diluted 1/5, 0.5µ1 of a33P-dATP (1 
000Ci/mmol) and 1µ1 of T7 polymerase (3U/µl) was added to the annealing solution and 
incubated (5min, room temperature). 2.25µ1 was then aliquoted into prewarmed 1.25µ1 of 
the appropriate termination mix. After incubation (5min, 37°C) stop buffer was added. 
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b) dsDNA Sequencing. The dsDNA (2-4µg/µl) was first diluted in 18µ1 of ddH2O and 
denatured by adding 2µ1 of 2M NaOH. The sample was then incubated for 5min at room 
temperature and 8µ1 of SM NH4OAc pH7.5, 100µ1 of 100% EtOH was added to recover 
the ssDNA. The supernatant was then removed, the pellet washed with 70% EtOH, dried 
in vacuo and dissolved in 7µ1 ddH2O. 2µ1 of sequencing buffer (Pharmacia) and 1µ1 of 
primer (0.5pmol) was added and the solution heated (37°C, 20min). The following 
labelling and termination reactions were run exactly as described for ssDNA. 
c) Denaturing Polyacrylamide Gel Electrophoresis (DNA Sequencing). The products 
from DNA sequencing reactions were separated on 6% denaturing polyacrylamide gels 
( 400x200x0.4mm). Prior to loading the samples were heated (90°C, 3min), in order to 
prevent the occurrence of secondary structures which will disrupt the electrophoretic 
mobility of the DNA fragments. A solution containing 6% acrylamide (Acrylamide: 
Bisacrylamide 19:1, Sequagel, National Diagnostics), 8.3M urea, 90mM Tris-HCl pH8.2, 
90mM Borate and lmM EDTA was polymerised by adding 0.06% ammonium 
persulphate (APS; from a 10% stock solution) and 0.03% TEMED (N,N,N' ,N'-
tetramethylethyldiamine) and poured between two prepared glass plates. If a limited 
amount of sequence data was required then the gel was run until the bromophenol blue 
dye present in the stop buffer reached the bottom of the gel. For longer stretches of 
information, or to provide a broad range of sequencing data, another run of the sample was 
loaded and the first run left until the xylene cyanol left the gel. The gel was fixed by 
applying a mixture of 20% EtOH, 10% acetic acid for 15min, transferred to 3MM 
Whatman paper, covered and dried at 80°C for 1hr, before being exposed to X-ray film. 
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CHAPTER 3 Targeting Gza Expression In Vivo. 
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Part 3.1 Introduction. 
Section 3.1.1 Gene Targeting. 
Since the discovery that mammalian somatic cells possess the enzymatic machinery, and 
therefore the ability to mediate the introduction of non-replicating DNA molecules into the 
genome (Folger et al., 1982; Lin et al., 1984; Wake et al., 1985), the study of such 
processes has lead to specific inactivation of a wide variety of genes in vivo (Gene 
Targeting; Appendix 3.1; Thomas et al., 1986; Capecchi, 1989; Askew et al., 1993; 
Barinaga, 1994; Shastry, 1994). Targeting gene expression has lead to both the creation of 
animal models for human genetic disorders [e.g. Gauchers's disease models (Tybulewicz 
et al., 1992), Lesch-Nyhan syndrome (Kuehn et al., 1987), and Cystic Fibrosis, (Dorin & 
Porteous, 1991)] and to a greater understanding of the role that some proteins play in vivo 
(Smithies et al., 1985; Thomas et al., 1986; Thomas & Capecchi, 1986;1987). Many gene 
targeting approaches begin with the inactivation of a single allele of the targeted gene in 
embryonic stem (ES) cells through the introduction of exogenous DNA (a linearised 
plasmid or retroviral vector) containing a copy of the same gene, interrupted by a marker 
or foreign genetic element (Robertson et al., 1986; Thomas & Capecchi, 1987). Once this 
'targeting construct' enters the genome of the ES cells in vitro, the non-functional copy of 
the gene which it carries recombines, and replaces the functional gene region (Riele et al., 
1992). Adaptations of this theme include: the hit-and-run approach or in-out technique 
(Hasty et al., 1991; Shastry, 1994); the tag and exchange strategy (Askew et al., 1993) and 
the Cre-lox system (Barinaga, 1994). ES cells are pluripotent in vivo and in vitro (Evans 
& Kaufman, 1981; Martin, 1981), a property which allows the researcher to inactivate the 
gene in vitro, and reintroduce the modified ES cells into mouse blastocysts (Robertson, 
1991; Wood et al., 1993a; 1993b), which grow within pseudopregnant female foster 
mothers and contribute to the formation of chim&ric animals (mice possessing cells from 
both the native and foreign ES cell populations; Figure 3.1). Thus any modification made 
to the genome of the ES cells which is carried by the 'germline' chim&ra (Gassler et al., 
1986; Robertson et al., 1986) will be passed on to subsequent murine generations 
(Bradley et al., 1984 ). 
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Figure 3.1 Gene Targeting. 
Shown is a diagrammatic representation of a general approach taken used to disrupt the 
expression of genes in vivo (Courtesy of Dr Klaus Matthaei; Capecchi, 1989). A 
linearised targeting construct is introduced by electroporation into ES cells and allowed to 
recombine with the genome. Clones which possessing a stably and specifically deleted 
copy of the gene ( +/-) are then isolated using selection media and confirmed with PCR. 
To produce a chimceric mouse, the C57BL/6 (black) ES cells are injected into the 
blastocyst from a white mouse strain (e.g. BALB/c). This combined (chimceric) blastocyst 
is then implanted into the uterus of a pseudopregnant female foster mother, where it is 
allowed to develop. The resultant progeny will contain cells which have originated from 
both the introduced C57BL/6 ES cells and the BALB/c ES cells native to the recipient 
blastocyst. The aim of producing a chimceric mouse is to obtain cells which are both 
heterozygous for the gene targeted and destined to contribute to the germline, so that the 
desired mutation can be passed on to succeeding generations. Whether or not this occurs 
is largely dependent upon the quality of the introduced ES cells and the technical expertise 
of the researcher. The only sure method of confirming the presence of germline chimceric 
animals is to breed them back into either the initial mouse strain, from which the 
introduced ES cells were obtained (e.g. C57BL/6) or another and to then screen these for 
the presence of progeny which are heterozygous ( +/-) for the null mutation. These 
heterozygous mice can then be interbred to obtain: homozygous positive ( +/+, 25% ), 
heterozygous negative (-/+, 50%) and homozygous negative (-/-, 25%) progeny. If the 
mutation results in a lethal phenotype, then the resultant progeny will be either 
heterozygous negative ( +/-, 33%) or homozygous positive ( +/+, 66%; Thomas et al., 
1986; Capecchi, 1989; Robertson, 1991; Wood et al., 1993a). 
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Section 3.1.2 ES Cell Selection. 
To screen for the presence of the targeting construct in vitro, the disrupting portion of 
DNA usually contains a selectable marker. The most common markers used confer 
resistance to the antibiotic neomycin (Near; Gassler et al., 1986; Robertson et al., 1986). 
DNA introduced into ES cells has, however, a greater propensity for random integration 
rather than homologous or specific recombination (Figure 3.2; Roth & Wilson, 1985; 
Roth et al., 1985). During homologous recombination the targeting construct enters the 
genome of the ES cell specifically and stably, in a process that coincides with the loss of 
any flanking regions, and the replacement of the native or functional gene with the 
modified/non-functional copy (Figure 3.2A; Capecchi, 1989). If, however, the targeting 
construct enters the genome randomly, and does not disrupt the targeted gene, then the 
flanking regions will have remained. To eliminate those clones which contain randomly 
inserted exogenous copies of the inactivated gene, a copy of the thymidine kinase (TK) 
gene (pgkTK or HSV-TK), is placed at the periphery of the targeting construct (Figure 
3.2B). This confers sensitivity to gancyclovir (GANC), thus any cells containing a 
randomly inserted copy of the targeting construct will die when grown in media containing 
gancyclovir. Furthermore, because the TK gene will be lost following homologous 
recombination, those ES cells which contain a specifically integrated non-functional copy 
of the targeted gene should remain resistant to gancyclovir. Similarly since they also 
contain the pgkNeo gene, resistant to neomycin (0418; Folger et al., 1984; Lin et al., 
1984; Smith & Berg, 1984; Smithies, 1984). This is, however, not always true (see below). 
Section 3.1.3 PCR: a Sensitive Method of Eliminating False Positives. 
The use of antibiotic selection greatly enriches the number of clones which possess copies 
of the disrupted gene, however, a large number of these surviving ES cells still possess 
randomly incorporated copies of the targeting construct. They survive extinction because 
the TK gene has been inactivated through random mutation, or damage, during entry into 
the genome. A PCR (Mullis & Faloona, 1987) protocol which uses strategically placed 
priming sites close to the target and within the selectable marker, can provide a rapid and 
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Figure 3.2 Homologous Recombination vs Random Integration. 
(A) During the process of homologous recombination a modified copy of the gene 
(targeting construct) enters the genome specifically carrying with it a selectable marker or 
disrupting element (e.g. pgkNeo). When this occurs the non-homologous ends are lost as 
a.re any markers placed at the periphery (e.g. pgkTK). Recombinant cells which possess a 
specifically integrated targeting construct can be easily isolated because of their resistance 
to both neomycin and ga.ncyclovir (G418r, GANCr). Furthermore, both the foreign primer 
binding sites carried by the targeting construct, and those endogenous to the gene region 
targeted, can also be used to screen for specific integration. 
(B) When random integration occurs the entire targeting construct (including the 
'flanking' ends) enters the genome stably but non-specifically. So although these 'non-
targeted' clones will be resistant to neomycin (G418r) they will die in the presence of 
ga.ncyclovir (GANC8). If however, the pgkTK gene is damaged during entry these ES cell 
clones will be resistant to both gancyclovir and neomycin (GANCr, G418r), whilst the 
endogenous priming sites used to screen for homologous recombination (see above) will 
be absent (Thomas & Capecchi, 1986; 1987; Capecchi, 1989). 
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efficient means of identifying and eliminating these false positives (Nitschke et al., 1993). 
If the targeting construct has entered the genome specifically each primer binding site will 
lie in close proximity with respect to the other, and can be used to produce a DNA band 
on an agarose gel corresponding to the distance between them (Figure 3.2A). 
Section 3.1.4 The Frequency of Homologous Recombination. 
The introduction of exogenous DNA into the nucleus of ES cells in vitro, has been 
achieved through: (i) precipitation with calcium phosphate (Gassler et al., 1986); (ii) 
retroviral infection (Robertson et al., 1986; Kuehn et al., 1987); and/or (iii) electroporation 
(Thompson et al., 1989). What these methods have revealed is that neither the plasmid 
copy number, the position of the target within the genome (Thomas et al., 1986), the 
number of targets, or the number of successful transformants affect the targeting 
frequency or the number of homologous recombinants (Capecchi, 1989). This is 
surprising because the 'in coming' DNA has to search 3x109bp of genomic DNA to find 
the target gene, however, it does mean that these experiments can be done with very few 
molecules per cell (Capecchi, 1989). The rate/frequency of homologous recombination is 
in fact dependent upon: (i) the degree of sequence identity between the target and the ends 
of the targeting construct which mediate the reaction (Kucherlapati et al., 1984); and (ii) 
the position of the cell in the cell cycle, peaking in early S phase (Wong & Capecchi, 
1987). It has been reported that homologous recombination can take place with as little as 
25bp of identity between the targeting construct and the target (Ayares et al., 1986). The 
frequency does, however, increase with the degree of identity so that with 5kb of shared 
sequence nearly all constructs which enter the nucleus take part in at least one 
homologous recombinational event (Folger et al., 1982). Taking this argument further the 
greatest possible frequency of recombination will occur if both the targeted ES cell and 
exogenous DNA are derived from the same source/strain (e.g. C57BL/6; Figure 3.1). It is 
preferable, therefore, that the targeting construct contain, in addition to the gene itself, part 
of the gene region to be targeted (e.g. an exon and part of the surrounding genome, Part 
3.2, p65). 
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Figure 3.3 Replacement vs Insertion Targeting. 
Both 'replacement' and 'insertion' targeting events are largely dependent upon and describe 
the construction of the 'targeting' construct. 
(A) During 'replacement' targeting the selection marker replaces an excised portion of the 
cloned gene. This allows the homologous regions of the introduced construct to come 
alongside and line up with the corresponding genomic sequence. 
(B) During 'insertion' targeting, often a single restriction site is chosen and used to 
introduce the selection marker. This means that during homologous recombination the 
marker needs to loop away from the site of recombination in order to allow the 
homologous ends of the targeting construct to pair with the targeted gene region 
(Capecchi, 1989). 
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Section 3.1.5 Sequence Insertion vs Sequence Replacement Targeting. 
Both sequence insertion targeting and deletion or replacement targeting describe the 
recombinational event which follows transformation of the exogenous DNA. Each are a 
form of targeting which depend upon the construction of the targeting consttuct itself, and 
the placement of the selectable marker or disrupting element: " .... . sequence replacement 
vectors replace endogenous DNA with exogenous sequences, while sequence insertion 
vectors insert the exogenous sequence into the endogenous locus" (Capecchi, 1989). At 
first glance (see Figure 3.3), it would appear that replacement targeting should result in a 
greater targeting frequency, however, it has been shown that both methods are equally 
efficient at mediating homologous recombinational events and appear to respond equally 
well to changes in identity between the exogenous DNA and the target (e.g. a two fold 
increase in (%) identity results in a 20-fold increase in the targeting frequency; Thomas & 
Capecchi, 1987; Capecchi, 1989). Because of this, the choice of targeting vector is largely 
determined by the restriction sites available (Thomas & Capecchi, 1987; Abeliovich et al. , 
1993). 
Section 3.1.6 Microinjection vs Aggregation. 
Crucial to the success of any gene targeting experiment is the production ES cell 'embryo' 
chimreras. Currently two methods exist, through microinjection and aggregation or 
coculture (Figure 3.4). The most successful method is the direct injection of 15-20 ES 
cells into the blastocoel cavity followed by transfer into pseudopregnant foster mothers 
(Gassler et al., 1986). In practice this approach can be a costly, time consuming and 
difficult procedure, that requires dexterity and the manipulation of elaborate and 
specialised equipment. Several simplified methods have, however, been developed (Wood 
et al., 1993a). Both coculture aggregation and 'darning needle' aggregation are based on 
the principle that ES cells, like embryonic carcinoma cells (Fujii & Martin, 1980; 1983), 
readily aggregate with morulae and, therefore, all that is required is to bring the two cell 
populations close together. The resultant chimreras are then cultured overnight to the 
blastocyst stage before they are implanted into pseudopregnant female recipients. A 
comparison of the two methods (aggregation vs injection) shows that there is, however, no 
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real difference in the number of germline chimc:eras produced (Table 3.1; Wood et al., 
1993a). This means that the method of choice is largely dependent upon the availability of 
money, equipment and technical expertise. 
Table 3.1 Germline Chimrera Production by 'Darning NeedJe' Aggregation of 
MoruJae vs Blastocyst Injection. 
(Table taken from: Wood et al., 1993a) 
Embryos Germline 
Technique transferred Newborns Chirna:ras Transmitters 
Morulae Males Females 
aggregation 321 89(28%) 31(9.6%) 1(0.3%) 11(3.4%) 
Blastocyst 631 250(40%) 72(11.4%) 23(3.6%) 24(3.8%) 
injection 
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Figure 3.4 CocuJture vs Direct Injection. 
Shown in the figure is a diagrammatic representation of both coculture and direct injection 
techniques used to obtain chimceric animals from ES cells in culture (Wood et al., 1993a). 
(A) In the case of direct injection, the cells are forced into the blastocoel cavity through a 
specially made, drawn out glass pipette. This is technically difficult and problems often 
arise if the cavity is not properly penetrated, or if ES cells lyse increasing the viscosity of 
the media and causing material to 'stick' to the outside of the glass pipette. The 'chimceric' 
blastocyst is then allowed to incubate for 1-2hrs before being implanted into a 
pseudopregnant female foster mother. 
(B) In the case of those techniques involving aggregation, morulae are stripped of their 
outer layer (zona pellucida), and allowed to coculture or aggregate with a lawn of the 
targeted ES cells, prepared earlier. The closer the contact, the greater the chance that the 
morulae will take up the free ES cells (e.g. 'Darning Needle' Aggregation). The cells are 
then cultured and the 'chimceric' morulae reimplanted into pseudopregnant female foster 
mothers (Wood et al., 1993b). 
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Part 3.2 The Cloning & Characterisation of Mouse Gza (MGza). 
Section 3.2.1 Introduction. 
Whilst the genetic organisation of the coding and non-coding regions of the MGza gene 
is unknown, certain assumptions can be made, based upon what is known about the 
orthologous human (HGza) and rat (RGza) genes. MGza differs from other Ga genes, as 
it is divided into only three exons, a 5' untranslated region (exonl) and two exons which 
contain translated sequence (exon2 & exon3, Figure 3.5A). As this unique pattern appears 
to be relatively well conserved between species, the decision was made to 'knockout' 
expression of MGza at a point close to start of translation (ATG), by disrupting the first 
translated exon, exon2. The following sections detail the steps taken to completely clone 
and characterise that portion of the mouse genome surrounding exon2, so that it could be 
used to construct a MGza, C57BL/6 specific targeting construct. 
Section 3.2.2 The Isolation of MGza Genomic Clones. 
Despite the fact that neither the complete sequence nor the organisation of the MGza gene 
was available, a partial complementary DNA (cDNA) of the MGza mRNA (MGzaP), 
spanning parts of both the second and third exons had been isolated and sequenced 
previously by this laboratory. This partial cDN A clone, designated 
pBSK(+)MGzaP(696bp,4BF/3R) (Figure 4.1; Leck, 1993) was used to screen a 
C57BL/6 mouse A DASH®II phage genomic library (AM; Stratagene; Appendix 2.2). To 
confirm the identity of the A phage mouse genomic clones (AMGza) obtained in this way 
and to independently isolate the exon2 specific AMGza clones, a second round of low 
stringency screening (55°C) was employed, using the consensus oligonucleotide IBP 
(Table 2.1). Note that the binding site for IBP lies outside the region spanned by the 
MGzaP 'probe' (Figure 3.5B; Leck, 1993). 
Section 3.2.3 Restriction Mapping the Isolated AMGza Clones. 
a) Mapping the Site of 1 BF Hybridisation. To identify the position of MGza exon2 the 
DNA from each of the AMGza clones, AMGzal, AMGza2, AMGza4 and AMGzal 1 was 
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Figure 3.5 The Organisation of the Gza Gene. 
(A) Shown in this figure are the known coding regions of some of the Ga genes. 
According to rat and human studies the Gza gene possesses two coding exons (exon2 & 
exon3), and one 5' non-coding exon (exonl). This contrasts with many other Ga 's 
including Gi2a, which although it shares a high degree of sequence similarity with Gza, is 
made up of seven coding and one 3' non-coding exon (Itoh et al., 1988; Kozasa et al. , 
1988; Fong et al., 1988; Matsuoka et al., 1990; Raport et al., 1989). Pertussis and cholera 
toxin ADP-ribosylation sites are also indicated (*), as are the highly conserved regions P, 
G', G and R. The G and P regions are thought to involved in GTP binding and hydrolysis, 
respectively, whilst the region marked R is believed to be involved in receptor coupling 
(Matsuoka et al., 1990). 
(B) Both the RGza and HGza coding and non-coding exons are separated by large 
regions of the genome (>20kb, Fong et al., 1988; Matsuoka et al., 1990). The translated 
( or protein coding) regions of each exon are shaded. Also shown are the start sites of 
translation and transcription (arrows) as well as the approximate positions of each of the 
consensus oligonucleotides (IBF, 4BF & 3R). Both 4BF (exon2) and 3R (exon3) form 
the 5' and 3' boundaries of the partial MGza cDNA probe (Leck, 1993), whilst IBF was 
used to identify the exon2 specific AMGza clones, AMGzal, AMGza2, AMGza4 & 
AMGzal l. 
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Figure 3.6 Mapping the lBF Positive AMGza Clones 
(A) Restriction Map of IBF specific genomic clone, AMGzal and (B) Restriction Map 
of IBF specific genomic clone, AMGza4. In each instance both the agarose gel and 
corresponding autoradiograph are shown. Lane 1, AMGza DNA cut with H indlll 
(AMGzalHindllI); Lane 2, AMGza DNA doubly cut with Hindlll and E co RI 
(AMGzalHindlll/EcoRl); Lane 3, AMGzalEcoRl; Lane 4, AMGzalEcoRI/BamHl; Lane 5, 
AMGzalBamHl; and Lane 6, AMGzalBamHI/Hindlll. A 7kb Hindlll/EcoRI fragment, 
present in both clones AMGzal and AMGza4, is clearly shown to bind radiolabelled IBF 
(Lane 2 of both gels). This band, designated MGza2(7 .OH/E), was later found to 
encompass the whole of MGza exon2. Also shown is the 2kb BamHI fragment, present in 
both clones, which although difficult to see following separation by agarose gel 
electrophoresis, is visible following hybridisation with IBF. The larger bands (> 15kb ), are 
the arms of the A phage cloning vector. The size marker used, Af Hindlll, is reproduced on 
the left. 
(C) Autoradiograph of radiolabelled oligonucleotide IBF, separated from unincorporated 
label using TLC, and conducted to ascertain the success of the labelling reaction. Lane 1, 
is the control lane, containing unincorporated nucleotide, taken prior to labelling; and Lane 
2, contains lµL of kinase reaction mix, following incubation with the T4 polynucleotide 
kinase. 
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first prepared from a large scale liquid culture (Section 2.2.2, p34), and digested (lµg ; 
Section 2.3.1, p38) with the specific endonucleases HindIIT, EcoRI, and BamHI* (Section 
2.1.2, p30), chosen because they do not cut either the RGza or HGza coding sequences. 
Thus any lBF positive restriction fragment, which may later be isolated should contain 
most, if not all, of MGza exon2. The restriction fragments were then separated by agarose 
(I%) gel electrophoresis (Section 2.2.3, p35), photographed under UV illumination, 
transferred to positively charged nylon membrane (PCNM) using the alkaline transfer 
method, and subjected to high stringency hybridisation (63°C; Section 2.4.3, p45) with 
endlabelled lBF (Section 2.4.1, p44). In this way a number of lBF binding DNA bands 
were identified, including a 2kb BamHI fragment, which is itself encompassed by a larger, 
7kb region of the genome flanked by HindIII and EcoRI (7kbH/E) restriction sites 
(Figure 3.6; 3.10). 
b) Confirmation of the exon2 Specific AMGza Clones. Following high stringency 
hybridisation with radiolabelled lBF the membranes were stripped (Section 2.4.3 , p45), 
and reprobed (63°C) with endlabelled exon3 specific primer 3R (Figure 3.5B; Table 2.1). 
As expected, from the high degree of sequence and organisational conservation between 
the MGza, RGza and HGza genes, none of the exon2 specific AMGza clones were found 
to also contained exon3, which they may have done if exon3 lay in close proximity to 
exon2. The decision was, therefore, made to clone and characterise the IBP positive, 
putative exon2 containing 7kbH/E genomic fragment, designated MGza2(7.0H/E), 
because it is both large enough to entirely contain a genomic copy of MGza exon2 ( ~ 1kb) 
and small enough to be easily prepared and sequenced. 
Section 3.2.4 The Cloning & Characterisation of a 7kb MGza Subclone. 
a) Isolation of the MGza2(7.0HIE) Genomic Fragment. The IBP positive, putative exon2 
containing genomic clone AMGzal, was digested with HindIIT and Eco RI. The resulting 
DNA fragments were then cloned into HindIII/EcoRI cut phagemid vector, pBSK( +) 
(Appendix 2.1) and transformed (Section 2.3.7, p40) into electrocompetent E. coli DH5a 
(Section 2.1.1, p30). Clones possessing a fragment of the correct size, were then identified 
through colony cracking (Section 2.3.8, p41), restriction analysis (Figure 3.7 A) , and 
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Figure 3.7 Restriction Analysis of the MGza2(7.0H/E) Clone. 
(A) Shown are some of the plasmids obtained following 'shot gun' cloning of the 
HindIII/EcoRI cut AMGzal digest. Lane 1, 17HE pBSK(+)MGza2(7.0H/E); Lane 2, 
6HE pBSK(+)MGza2(7.0H/E); Lane 3, llHE contains a fragment of unknown origin; 
Lane 4, 13HE does not appear to contain any fragment; Lane 5, 12HE 
pBSK(+)MGza2(7.0H/E); and Lane 6, 16HE pBSK(+)MGza2(7.0H/E). The size marker 
used, N'HindIII is reproduced on the left. 
(B) Diagnostic Restriction Digests of the pBSK(+)MGza2(7.0H/E) Clone, l0HE & (C) 
Con-esponding Southern Analysis. An example of the restriction mapping used to further 
characterise each of the MGza2(7.0HE) genomic subclones. The N'Hindlll size markers 
are reproduced on the left. The enzymes used to restrict the clone, include: Lane 1, Kpnl; 
Lane 2, KpnI/BamHI; Lane 3, BamHI; Lane 4, Xhol; Lane 5, XhoI/BamHI ; Lane 6, 
XhoI/PstI; Lane 7, Pstl; Lane 8, XbaI/PstI; Lane 9, Xbal; Lane 10, XbaI/BamHI; Lane 11, 
Xbal/Sacl; Lane 12, Sacl; and Lane 13, Sall. DNA fragments to note in this figure include 
the : (i) 4kb Kpnl fragment in Lane 1; (ii) 2kb BamHI fragment in Lane 3; and the 1.7kb 
Sacl fragment in Lane 12. 
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prepared using the Wizard® Miniprep Purification System (Section 2.2.1, p32). These 
new clones were designated 6HE, l0HE, 12HE and 16HE respectively. 
b) Restriction Mapping the MGza2(7.0HIE) Genomic Fragment. To confirm that the 
correct MG 2 a2(7 .0H/E) fragment had been isolated, the DNA from each of the 
pBSK( + )MG2a2(7.0H/E) clones was subjected to a series of enzyme digests and the 
DNA separated using agarose (1 %) gel electrophoresis (Figure 3.7B). To further map the 
position of exon2, the DNA from these gels was then transfe1Ted to PCNM, using alkaline 
transfer and hybridised with endlabelled lBF, under conditions of high stringency (63°C; 
Figure 3.7C). It was found that lBF hybridised to a 4kb Kpnl [MG2a2(4.0K)], a 1.7kb 
Sac! [MG2 a2(2.25S)] and a 2kb BamHI [MG2 a2(2.0B)] genomic fragment. Later 
sequencing would reveal that, although both Sacl and BamHI restriction cut exon2, Kpnl 
does not (Section 2.1.1, p30; see below). 
Section 3.2.5 Confirmation of MGza within the pBSK( + )MGza2(7.0H/E) 
Genomic Fragment by DNA Sequencing. 
a) Sequencing Strategy. Once the lBF positive pBSK(+)MG2 a2(7.0H/E) clone was 
obtained it was necessary to confirm the presence of the MG 2 a exon2 and not an 
unknown homolog, before it could be confidently used to specifically disrupt the 
expression of MGza· This would be done through DNA sequencing (Part 2.6, p52) using 
primers: (i) strategically placed within the coding region of MGza exon2, lBF and 4BF; 
(ii) their 'complimentary' pairs, designated anti-IBF and anti-4BF respectively; (iii) 
m G 2 E 1 R, positioned at the start of translation, and designed to sequence the 5' 
untranslated region (UTR) of exon2; and (iv) the universal (M13) and reverse primer 
binding sites, positioned to either side of the pBSK( +) mutiple cloning site (MCS; 
Section 2.2.4, p36; Table 2.1 ). 
b) Features Identified. The sequence data from each reaction (Part 2.6, p52) was gathered 
and combined to obtain the entire sequence of a large open reading frame (ORF, 723bp) 
later found to be highly similar in sequence and predicted protein product to both RGza 
and HGza exon2 (Figure 3.8 & 3.9). This sequencing also identified some of the 
endonuclease recognition sites, first recognised through restriction mapping (e.g. BamHI 
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Figure 3.8 The MGza, RGza and HGza Coding Sequences. 
The cloning of MGza exon2 was confirmed, when the large ORF harboured by the 
putative MGza2(7.0H/E) genomic clone was shown to have a high degree of sequence 
similarity with the RGza (95.9%, R) and HGza (92.9%, H) gene coding regions (Fong et 
al., 1988; Matsuoka et al., 1988). The figure below also is the completed sequence of the 
MGza exon2 coding region, obtained by combining the sequence of the partial MGza 
cDNA clone MGzaP (P; Leck, 1993), and the sequence of the 723bp ORF within the 
pBSK( + )MGza2(7.0H/E) genomic clone (M). Note that the sequence of the putative 
MGza exon2 ends at the 'consensus' exon2/exon3 boundary (V). 
S' 
M 1 ATG GGA TGT CGG CAA AGC TCA GAG GAA AAA GAG GCA GCG p 
R 1 ATG GGA TGT CGG CAA AGC TCA GAG GAA AAA GAG GCA GCG 
H 1 ATG GGA TGT CGG CAA AGC TCA GAG GAA AAA GAA GCA GCC 
M 40 AGG CGG TCC CGG AGA ATT GAC CGC CAC CTG CGC TCC GAA p 
R 40 CGG CGG TCG AGG AGA ATT GAC CGC CAC CTG CGC TCG GAG 
H 40 CGG CGG TCC CGG AGA ATT GAC CGC CAC CTG CGC TCA GAA 
M 79 AGC CAG CGG CAG CGC CGT GAA ATC AAA CTT CTC CTG CTG p 
R 79 AGC CAG CGG CAG CGC CGT GAG ATC AAA CTT CTC CTG CTG 
H 79 AGC CAG CGG CAA CGC CGC GAA ATC AAG CTG CTC CTG CTG 
M 118 GGC ACC AGC AAC TCG GGC AAG AGC ACC ATC GTC AAG CAG p 
R 118 GGC ACC AGC AAC TCG GGC AAG AGC ACC ATC GTC AAG CAG 
H 118 GGC ACC AGC AAC TCA GGC AAG AGC ACC ATC GTC AAA CAG 
M 157 ATG AAG ATC ATC CAC AGC GGG GGC TTC AAC CTG GAC GCC p 
R 157 ATG AAA ATC ATC CAC AGC GGT GGT TTC AAC CTG GAG GCC 
H 157 ATG AAG ATC ATC CAC AGC GGC GGC TTC AAC CTG GAG GCC 
M 196 TGC AAG GAG TAC AAG CCC CTC ATC ATC TAC AAC GCC ATC p 
R 196 TGC AAG GAG TAC AAG CCC CTC ATC ATC TAC AAC GCC ATC 
H 196 TGC AAG GAG TAC AAG CCC CTC ATC ATC TAC AAT GCC ATC 
M 235 GAC TCG CTG ACC CGG ATC ATC CGG GCC CTG GCT GCC CTC p 
R 235 GAC TCG CTG ACC CGG ATC ATT CGG GCC CTG GCT GCC CTG 
H 235 GAC TCG CTG ACC CGG ATC ATC CGG GCC CTG GCC GCC CTC 
M 274 AAG ATC GAT TTC CAC AAC CCT GAC CGT GCC TAC GAC GCT p 
R 274 AAG ATT GAT TTC CAC AAC CCT GAC CGT GCC TAC GAC GCC 
H 274 AGG ATC GAC TTC CAC AAC CCC GAC CGC GCC TAC GAC GCT 
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M 313 GTG CAG CTC TTT GCT CTG ACT GGC CCA GCA GAG AGC AAG 
p 
R 313 GTG CAG CTC TTT GCC CTG ACT GGC CCG GCA GAG AGC AAG 
H 313 GTG CAG CTC TTT GCG CTG ACG GGC CCC GCT GAG AGC AAG 
4BF 
M 352 GGT GAG ATT ACA CCT GAG CTG CTG GGT GTC ATG CGA CGG 
p 1 --- --- --- --- --- --- --- --- --- --- --- CGA CGG 
R 352 GGT GAG ATC ACG CCC GAG CTG CTG GGT GTC ATG CGA CGG 
H 352 GGC GAG ATC ACA CCC GAG CTG CTG GGT GTC ATG CGA CGG 
M 391 CTC TGG GCT GAC CCA GGG GCC CAG GCC TGC TTT GGC CGC 
p 7 CTC TGG GCT GAC CCA GGG GCC CAG GCC TGC TTT GGC CGC 
R 391 CTC TGG GCT GAC CCC GGG GCC CAG GCC TGC TTC GGC CGC 
H 391 CTC TGG GCC GAC CCA GGG GCA CAG GCC TGC TTC AGC CGC 
M 430 TCT AGC GAG TAC CAC CTG GAG GAC AAT GCA GCC TAC TAC 
p 46 TCT AGC GAG TAC CAC CTG GAG GAC AAT GCA GCC TAC TAC 
R 430 TCC AGC GAG TAC CAC CTG GAG GAC AAC GCC GCT TAC TAC 
H 430 TCC AGC GAG TAC CAC CTG GAG GAC AAC GCG GCC TAC TAC 
M 469 CTG AAC GAC CTG GAG CGC ATC GCA GCG CCC GAC TAC ATC p 85 CTG AAC GAC CTG GAG CGC ATC GCA GCG CCC GAC TAC ATC 
R 469 CTG AAT GAC CTG GAG CGC ATC GCG GCG CCC GAC TAT ATC 
H 469 CTG AAC GAC CTG GAG CGC ATC GCC GCA GCT GAC TAT ATC 
M 508 CCC ACG GTG GAG GAT ATC CTA CGC TCC CGG GAC ATG ACC 
P 124 CCC ACG GTG GAG GAT ATC CTA CGC TCC CGG GAC ATG ACC 
R 508 CCC ACG GTG GAG GAC ATC CTG CGC TCT CGG GAC ATG ACC 
H 508 CCC ACT GTC GAG GAC ATC CTG CGC TCC CGG GAC ATG ACC 
M 547 ACG GGC ATT GTG GAG AAC AAG TTC ACC TTC AAG GAG CTT 
P 163 ACG GGC ATT GTG GAG AAC AAG TTC ACC TTC AAG GAG CTT 
R 547 ACG GGC ATT GTG GAA AAC AAG TTC ACC TTC AAG GAG CTT 
H 547 ACG GGC ATT GTG GAG AAC AAG TTC ACC TTC AAG GAG CTC 
M 586 ACC TTC AAG ATG GTG GAC GTG GGC GGG CAG AGG TCA GAA 
P 202 ACC TTC AAG ATG GTG GAC GTG GGC GGG CAG AGG TCA GAA 
R 586 ACC TTC AAG ATG GTG GAT GTG GGA GGG CAG AGG TCA GAG 
H 586 ACC TTC AAG ATG GTG GAC GTG GGG GGG CAG AGG TCA GAG 
M 625 CGC AAA AAG TGG ATC CAT TGC TTT GAA GGC GTC ACA GCC 
P 241 CGC AAA AAG TGG ATC CAT TGC TTT GAA GGC GTC ACA GCC 
R 625 CGC AAA AAA TGG ATC CAC TGC TTT GAG GGC GTG ACG GCC 
H 625 CGC AAA AAG TGG ATC CAC TGC TTC GAG GGC GTC ACA GCC 
M 664 ATC ATC TTC TGT GTG GAG CTC AGT GGC TAT GAC CTG AAG 
P 280 ATC ATC TTC TGT GTG GAG CTC AGT GGC TAT GAC CTG AAG 
R 664 ATC ATC TTC TGT GTG GAG CTC AGT GGC TAT GAC CTG AAG 
H 664 ATC ATC TTC TGT GTG GAG CTC AGC GGC TAC GAC CTG AAA 
V 
M 703 CTC TAT GAG GAC AAC CAG ACG 
P 319 CTC TAT GAG GAC AAC CAG ACG AGC CGG ATG GCG GAG AGC 
R 703 CTT TAT GAG GAC AAC CAG ACG AGC CGA ATG GCG GAG AGC 
H 703 CTC TAC GAG GAT AAC CAG ACA AGT CGG ATG GCA GAG AGC 
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M -
P 358 CTG CGC CTC TTT GAC TCC ATC TGC AAC AAC AAC TGG TTC 
R 742 CTG CGT CTT TTT GAC TCC ATC TGC AAC AAC AAC TGG TTC 
H 742 TTG CGC CTC TTT GAC TCC ATC TGC AAC AAC AAC TGG TTC 
M -
P 397 ATC AAC ACC TCG CTC ATC CTC TTC CTG AAC AAG AAG GAC 
R 781 ATC AAC ACC TCC CTC ATC CTC TTC CTG AAC AAG AAG GAC 
H 781 ATC AAC ACC TCA CTC ATC CTC TTC CTG AAC AAG AAG GAC 
M -
P 436 CTC CTG GCA GAG AAG ATC CGG CGT ATC CCG CTC AGC GTC 
R 820 CTC CTG TCG GAG AAG ATT CGG CGT ATC CCG CTC AGC GTC 
H 820 CTG CTG GCA GAG AAG ATC CGC CGC ATC CCG CTC ACC ATC 
M -
P 475 TGC TTC CCA GAG TAC AAG GGT CAG AAC ACG TAC GAG GAA 
R 859 TGC TTC CCC GAG TAC AAG GGT CAG AAC ACG TAC GAG GAA 
H 859 TGC TTT CCC GAG TAC AAG GGC CAG AAC ACG TAC GAG GAG 
M -
P 514 GCC GCG GTC TAC ATC CAA CGT CAG TTC GAG GAC CTC AAC 
R 898 GCC GCG GTC TAC ATC CAG CGT CAG TTC GAG GAC CTA AAC 
H 898 GCC GCT GTC TAC ATC CAG CGG CAG TTT GAA GAC CTG AAC 
M - --- --- --- --- --- --- --- --- --- --- --- --- ---
P 553 CGC AAC AAG GAG ACC AAG GAG ATC TAT TCG CAC TTC ACT 
R 937 CGA AAC AAG GAG ACC AAG GAG ATC TAC TCG CAC TTT ACC 
H 937 CGC AAC AAG GAG ACC AAG GAG ATC TAC TCC CAC TTC ACC 
M -
P 592 TGT GCC ACC GAC ACC AGT AAC ATC CAG TTT GTG TTT GAC 
R 976 TGT GCC ACC GAC ACC AGT AAC ATC CAG TTT GTC TTC GAC 
H 976 TGC GCC ACC GAC ACC AGT AAC ATC CAG TTT GTC TTC GAC 
3R 
M -
P 631 GCA GTG ACA GAT GTC ATC ATA CAG AAC AAT CTC AAG TAC 
R1015 GCA GTG ACA GAT GTC ATC ATA CAG AAC AAT CTC AAG TAC 
H1015 GCG GTG ACA GAC GTC ATC ATA CAG AAC AAT CTC AAG TAC 
3 ' 
M 
p ATT GGC 
R1059 ATT GGC CTT TGC TGA 
H1059 ATT GGC CTT TGC TGA 
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Figure 3.9 The Predicted MGza, RGza and HGza Amino Acid Sequences. 
A comparison of the completed MGza (M), RGza (R) and HGza (H) predicted peptide 
sequences shows that there is little difference between them, and none at all in the 
sequence upstream of the partial cDNA clone MGzaP (flanked by 4BF & 3R). This 
provides compelling evidence that the MGza2(7.0H/E) genomic fragment contains at least 
part of the native MGza gene. Note that the putative mouse sequence differs from the rat 
by only one amino acid , at position 275 (*; Leck, 1993). 
Ml 
Rl 
Hl 
MSl 
RSl 
HSl 
MlOl 
RlOl 
HlOl 
M151 
R151 
H151 
M201 
R201 
H201 
M251 
R251 
H251 
M301 
R301 
H301 
M351 
R351 
H351 
MGCRQSSEEK EAARRSRRIN RHLRSESQRQ RREIKLLLLG TSNSGKSTIV 
MGCRQSSEEK EAARRSRRIN RHLRSESQRQ RREIKLLLLG TSNSGKSTIV 
MGCRQSSEEK EAARRSRRIN RHLRSESQRQ RREIKLLLLG TSNSGKSTIV 
KQMKI I HSGG FNLEACKEYK PLIIYNAIDS LTRIIRALAA LRIDFHNPDR 
KQMKIIHSGG FNLEACKEYK PLIIYNAIDS LTRIIRALAA LRIDFHNPDR 
KQMKI IHSGG FNLEACKEYK PLIIYNAIDS LTRIIRALAA LRIDFHNPDR 
4BF -- -ATDAVQLFAL TGPAESKGEI PELLGVMRRL WADPGAQACF GRSSEYHLED 
ATDAVQLFAL TGPAESKGEI PELLGVMRRL WADPGAQACF GRSSEYHLED 
ATDAVQLFAL TGPAESKGEI PELLGVMRRL WADPGAQACF GRSSEYHLED 
NAAYYLNDLE RIAAPDYIPT VEDILRSRDM TTGIVENKFT FKELTFKMVD 
NAAYYLNDLE RIAAPDYIPT VEDILRSRDM TTGIVENKFT FKELTFKMVD 
NAAYYLNDLE RIAAADYIPT VEDILRSRDM TTGIVENKFT FKELTFKMVD 
VGGQRSERKK WIHCFEGVTA IIFCVELSGY DLKLYEDNQT SRMAESLRLF 
VGGQRSERKK WIHCFEGVTA IIFCVELSGY DLKLYEDNQT SRMAESLRLF 
VGGQRSERKK WIHCFEGVTA IIFCVELSAY DLKLYEDNQT SRMAESLRLF 
* 
DSICNNNWFI NTSLILFLNK KDLLAEKIRR IPLSVCFPEY KGQNTYEEAA 
DSICNNNWFI NTSLILFLNK KDLLSEKIRR IPLSVCFPEY KGQNTYEEAA 
DSICNNNWFI NTSLILFLNK KDLLAEKIRR IPLTICFPEY KGQNTYEEAA 
--3R_ VYIQRQFEDL NRNKETKEIY SHFTCATDTS NIQFVFDAVT DVIIQNNLKY 
VYIQRQFEDL NRNKETKEIY SHFTCATDTS NIQFVFDAVT DVIIQNNLKY 
VYIQRQFEDL NRNKETKEIY SHFTCATDTS NIQFVFDAVT DVIIQNNLKY 
I G- - - - -
IGLCend 
IGLCend 
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Figure 3.10 The MGza Cloning Strategy. 
(A) A restriction map of the AMG2al genomic clone, obtained through high stringency 
hybridisation with radiolabelled lBF (Figure 3.6). Note the 2kb BamHl genomic 
fragment within the larger genomic 7kb HindIII/EcoRI fragment. 
(B) Map of the MG2a2(7.0H/E) genomic subclone (Figure 3.7). Also shown in this 
figure is the position of the MG2a2( 4.0K) fragment, which encompasses both the coding 
and non-coding regions of exon2, as well as a number of the restriction sites (*) , 
confirmed through preliminary sequencing. The approximate region sequenced and the 
position of each of the primers is marked: lBF (3); anti-lBF (2); 4BF/4CF (4); anti-
4BF/anti-4CF (l); and mG2E 1R (5). Both the reverse and universal (M13) primers are 
marked. 
(C) A diagramatic representation of the pBKS(-)MG2 a2(4.0K) subclone. The BamHI 
restriction pattern will change with respect to the MCS of the cloning vector, a property 
which would later be used to identify both orientations of the cloned insert (Figure 3.11). 
Abbreviations: B, BamHI; E, EcoRI; H, HindIII; K, Kpnl; S, Sacl; Sa, Sall; X, Xbal & 
Xh, XhoI. 
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& Sacl; Figure 3.7) and a single base pair difference between the 4BF oligonucleotide 
and the corresponding mouse genomic sequence. C-366 (RGza & HGza) is substituted 
for T -366 in the MGza gene (Figure 3.8). Although this change has no affect on the 
translated protein it did, however, put into question the specificity of the 4BF primer. That 
4BF had worked so far (e.g. to create the MGzaP clone; Figure 3.5), is possibly due to the 
5' nature of the change, a region not thought critical for oligonucleotide priming. To 
compensate for this change a corrected 4BF primer, designated 4CF and an anti-4CF 
primer (Table 2.1) were designed and used in place of 4BF/anti-4BF, when necessary. 
Section 3.2.6 Cloning & Characterising the 4kb Kpnl MGza Subclone. 
a) Isolation of the pBKS(-)MGza2( 4.0K) Fragment. Because the entire coding region of 
exon2 lay within the IBP positive MGza2(4.0K) fragment, previously identified through 
restriction analysis (Figure 3.7), steps were taken to separate this fragment from the 
pBSK( + )MGza2(7.0H/E) genomic clone, so that it could be used as the basis for the 
MGza targeting construct. The plasmid pBSK(+)MGza2(7.0H/E), from clone l0HE (see 
above), and the cloning vector pBKS(-) (Appendix 2.1) were both prepared using a large 
scale purification method (Section 2.2.1, p32) and restricted (2µg) with Kpnl. The host 
vector was then dephosphorylated (Section 2.3.5, p39) and separated from uncut vector 
using agarose (1 % ) gel electrophoresis. This was repeated to isolate the MGza2( 4. OK) 
fragment, from the rest of the pBSK(+)MGza2(7.0H/E) clone and both 'DNA bands' 
were purified by freeze squeezing (Section 2.3.3, p38). Following a 2hr ligation at room 
temperature, and transformation into the chemically competent E. coli DH5a, those clones 
possessing the pBKS(-)MGza2( 4.0K) construct were identified by colony cracking and 
confirmed through the use of restriction analysis. 
b) Restriction Analysis of the pBKS(-)MGza2( 4. OK) Subclone. To determine the 
orientation of each of these putative MGza2(4.0K) subclones the DNA was prepared 
using the Wizard® Miniprep Purification System, digested (0.5µg) with either Kpnl 
and/or B amHI and separated by agarose (1 % ) gel electrophoresis (Figure 3.1 lA). 
Designated 2K, 8K and 9K, each clone was found to represent both orientations of the 
MGza2(4.0K) fragment. Clones 2K and 8K, OriII and Clone 9K, Oril (Figure 3.1GB). 
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Figure 3.11 The Characterisation of the MGza2( 4.0K) Subclones. 
(A) Diagnostic analysis of the pBSK(+)MGza2(4.0K) subclones. Lane 1, 2K plasmid 
DNA digested with Kpnl (2K/Kpnl); Lane 2, 2KJBamHI; Lane 3, 8K/Kpnl; Lane 4, 
8K/BamHI; Lane 5, 9K/Kpnl; Lane 6, 9KJBamHI; Lanes 7 & 8 contain the original 6HE 
pBSK( + )MGza2(7 .0HE) clone cut with Kpnl and BamHl respectively. The size marker 
OJHindill) is reproduced on the left. The gel clearly shows (Lanes 1, 3 & 5) that each of 
these new constructs possess a 4kb band which corresponds to the same MGza2( 4.0K) 
fragment cut from pBSK( + )MGza2(7.0H/E) (Lane 7). The smaller 2.9kb band 
represents the linearised host vector pBKS(-), whilst the 2kb BamHI band (Lanes 2, 4 & 
6), corresponds to the fragment identified through earlier restriction mapping of the 
AMGza genomic clones and the MGza2(7.0H/E) genomic subclone (Figure 3.10). 
Therefore, the BamHI restriction fragment pattern for Oril: 3.6kb, 2kb & 1.3kb (Lane 6); 
and for Orill: 4.3kb, 2kb and 0.6kb (Lanes 2 & 4). 
(B) Shown in the figure is a schematic representation of the strategy chosen to sequence 
both orientations of the MGza2( 4.0K) cloned fragment. 
(C) The figure shown is an example of the band pattern following timed deletion of the 
MGza2(4.0K) insert within clone 9K (Oril). Lane 1 contains 250ng of linear pBKS() 
MGza2(4.0K). Lanes 2-16 contains a sample of each of the timed aliquot's, following 
ExoIII degradation. On the far right is the approximate position of linear pBKS(-) vector 
(2.9kb). The arrow indicates the residual 'undigested' or 'undeleted' pBKS() 
MGza2(4.0K) construct (6.9kb). 
Abbreviations: E, EcoRI; K, Kpnl & N, Notl. 
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Section 3.2.7 The Generation of Timed Deletion MGza Clones. 
a) Sequencing the MGza2( 4. OK) Insert. A modified version of the Erase a Base® 
Protocol (Part 2.5, p48) was used to completely sequence both orientations/strands (Oril, 
sense & OriII, anti-sense) of the MG2a2(4.0K) cloned insert so that endogenous PCR 
primers could be confidently designed and later used to screen MGza targeted ES cells in 
vitro (Part 3.1, p56). Both the 9K (Oril) and 8K (OriII) pBKS(-)MG2a2( 4.0K) 
constn1cts were prepared using the large scale plasmid purification protocol and digested 
(5-l0µg) with Natl to linearise the vector (Figure 3.1 lB). The 5' overhangs were then end-
filled with a-a-phosphorothioate nucleotide's using Klenow (37°C, l0min) in the same 
buffer (lx NEBuffer 3), however, before de-protection, with EcoRI the linear and 
protected DNA was resuspended in lx EcoRI Buffer. Following EcoRI digestion the 
DNA was resuspended in lx ExoIII buffer and subjected to timed deletions (225bp/30sec; 
Figure 2.1). 2.5µL (5-25ng) of each sample was then run on a (1 % ) agarose 'checking' gel 
(Figure 3.1 lC). Once digestion had been confirmed the DNA from each sample was 
religated, transformed into chemically competent E. coli DH5a cells, and prepared using 
the small scale alkali lysis miniprep method. 'Overlapping' clones were identified by size, 
prepared (Section 2.2.1, p32) and sequenced using the Prism® TAQ Dye Primer Cycle 
Sequencing protocol (Part 2.6, p52). Each sequence was then aligned, to obtain the 
sequence of the entire MG2a2(4.0K) fragment (Figure 3.12). 
b) Sequencing the MGza2(7.0HIE) Insert. To determine whether or not the start site of 
transcription, MGza exon 1 or any promoter binding sites lay within the original 
MG 2a2(7.0H/E) insert, the Erase a Base® protocol was repeated to generate timed 
deletions of the 6HE, pBSK( + )MG2a2(7.0H/E) construct (Figure 3.10B). In this instance 
using Not! and EcoRI the 'reverse' primer was protected, however, because only one 
orientation of the MG2a2(7.0H/E) insert was available, the universal primer was also 
protected using a second pair of enzymes in order to sequence the complimentary strand: 
Sall, to generate the primer protection site, and HindIII, to expose one end to Exolll 
degradation. This sequencing helped to confirm that like the RGza and HGza genes, the 
MG 2a exonl, does not lie in close proximity to exon2 (Figure 3.5B), but may, like the 
second exon, be present on some other AM genomic clone. 
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Figure 3.12 The Complete Sequence of the MGza2(4.0K) Subclone. 
The sequence from each of the deletion clones (both strands) were combined to obtain the 
complete consensus sequence of the MGza2(4.0K) subclone (actually 3 888bp). This 
shows that the entire MGza second exon (underlined), including both the coding and non-
coding regions, has been subcloned. Points of interest to note are: (i) the putative splice 
acceptor which corresponds to the exonl/exon2 boundary (TTCTCTCTTTCCTTAG; Table 
3.2); (ii) the BsaBI (2095bp-2104bp) recognition sequence within the coding region and 
positioned close to the start site of translation; (iii) the Accl (3803-3808) restriction site at 
the 5' end of the clone; and (iv) the primer binding sites mGzE1R, mGzGp, mGzGR, 
mGzGp(NotI), lBF, 4BF, Al-1 and Al-2 (Table 2.1). The primers lBF, 4BF and GzE1R 
were used to clone the exon and provide preliminary sequence data (Figure 3.8; 3.9), 
whilst the rest would later be used later. 
5' 20 40 
* * 
60 
* CTGACAAAAGGCCGTGTGAAGACCAGGATTTACACCCTGA GAGCATCAGGTGGTGGCAAG 
80 100 120 
* * * CGTGGACTCAGGGAGAGAGG TGGCTTCAGAGATACTGTTG GAGAAGGTGGGCCCAAAGGG 
140 160 180 
* * * TTGGAGAAAACCAGAGGCCA TGGCCACTGGAGAAAGTCTG ATTTGTGGGCCCTGGGGCTT 
200 220 240 
* * * GGTTCCAAGCAAGGCCTGTA ATGGCCAGCATGGGGGATGG GCTGCCACTTCCTGAGGGTC 
260 280 300 
* * * CAAGTCAGATGTATAAAGAG TAACGTCGGTAGTTGGGTAG GCTGAGTTTCAGGTGCTGGT 
320 340 360 
* * * TACACCTAGGAGTGGAGGTG GAGAGAGGCCCTTGCCTGTG TTAGAAACTTGTCTGCCTTG 
380 400 420 
* * * GGCCTTCCATCCCAGAGCCT GGTATCAGGGAAGGGGACAT TAGATGGGTTTTAAAGTACC 
440 460 480 
* * * CGAGGCTCAATAGCCAGGCA AAGACATACCAGAGGAAAGA AAGAAGGCAAGAGATGGGCC 
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500 520 540 
* * * ATGGTGTGGGGGTGGGGCAC CCTGGGCTCCCAGGCAGAGG CAGAACTGAGCCCCCTGCTG 
560 580 600 
* * * GAGGAGACATGCCCCAGCCA CCCAGAGGGTCATGTTGAGA TCTAGGGGGTAACCTTGCCC 
620 640 660 
* * * GTGGTAGGCAACAGGTGTCA CTGGATCCAGCTGTCAATAC AGCTGTTCTCCATTAACGCT 
680 700 720 
* * * CAGGCCCACAGAGAGCCTTC GAGAAAGACTCACCCTGAGC CCTTCATAGGACCTGAGCAC 
740 760 780 
* * * AGCAACCACACCTGGACTCT GAGTCCCAGTTTTCTGAGAG CCTCCCCACCGTTTCTTGCC 
800 820 840 
* * * TCCCTAGACAGGTTATCTCG GTATTGCCCTGATTTCTCAG GCCTTGGCCATCCCCCAAGA 
860 880 900 
* * * CCATTCCTGTGCCGAGCTTT TCGTGGCGCAAGACTCCATG GTGCCCCCATCGACTGATTC 
920 940 960 
* * * CCCCTGGAAGGGACATCAGG GCCAGAGCTCTATCCTGACC CTGCTCTAAACATGCATCTG 
980 1000 1020 
* * * GCCCTAGGACGAGAGAGATG GTGGAAGTCAGGAGATACAC AGTTTTCCCTGGCCTTCTTC 
1040 1060 1080 
* * * AGGCAGGGCCACAGCCAGGA CTGTGCTGTGAAGTCAAGTG GCACTGAGCCCCCTCCCTGT 
1100 1120 1140 
* * * CCTGGGGGAGCGGACACCCA CAGCAGGGTTGTACTGTGGA GCCCCAGTCAGACAGACAGA 
1160 1180 1200 
* * * TTCAGAGGGGCAGAGTCAGC CGGGTGTAGTAGGCAGGAAG CGGTGGTAGAGGTGGACGCA 
1220 1240 1260 
* * * GCGTGGGGTCAGCGGGCCAG AGCCTTGCACAACTCAAGGT CTGCCCTGCACCTGGTCTCA 
1280 1300 1320 
* * * AGCAGATTGCAGAGTTGAAG GCATCGGCCAAGCATATTTT TTTTGCTGTGGGCTGGGCCC 
1340 1360 1380 
* * * TCACCCTGAAGCACTTAAAG GTCTGGGAGTTGCTGAACCG TAGTGCTGTTTTCTGAGGCC 
80 
1400 1420 1440 
* * * CAGTGGCTGCTCCCTTCCGT CATCCAGCCCGAGGTGGGCC TGGGAGGTAGCTCATGCTGT 
1460 1480 1500 
splice acceptor * * * 
TCTCTCTTTCCTTAGGTGAA GGGCCGGATGCAAGGCAGGG AGCCGGAGCAGCCTGAGGCA 
1520 1540 1560 
* * * GGGGGGCCTCAGGGAGCGCT GGGCCCTCCAGCCGTGCTTA GAAACATCGCCACAGCAACC 
1580 1600 1620 
* * * AGCGAGCAGACAGCAGTAGC CTGGGCAGACGCAAGCGGAC AGCTTCCTACCGTGGCAGAG 
1640 1660 1680 
* * * TACAGGGAATGACTACGGCA AATCAGGCCACACTGCTGAC AAGGGAGGTGGAGTGTCACT 
1700 1720 1740 
* * * AGAGGGGAGGGTGTGGTCTC TGCCCCACTGCACCAAGCGC CATGCCCACAGGAGAAGCGG 
1760 1780 1800 
* * * TACTGGGGCAGGGATTGCTC TGTGACACAGCCTCGCCCCA AAGCCAGTGCTGAGCACGGC 
1820 1840 1860 
* * * CGGGTCAGCTGCCTCTCTCA TCTGCCCGTCACACCAGCCC ACGTTTGAGCATCCCTCGTT 
1880 1900 1920 
* * * GTGACCATTCTGTTTGGCGA GGGGGAGAGGCGCCCACCCT GTGTTCTGCATCTGGGGGGT 
1940 1960 1980 
* * * 1-----> Translation Start Site 
NotI 5 1 mGzF(NotI) 31 
GCGGCCGCA TGGGATGTCGGCAAAGCTCA GA 
mGzF 
A TGGGATGTCGGCAAAGCTCA GA 
GGCCCGCTGCTGCCGGACCA TGGGATGTCGGCAAAGCTCA GAGGAAAAAGAGGCAGCGAG 
I I I I I I I I I I I I I I I I I I I I I I I I I 
T ACCCTACAGC CGTTTCGAGT CTCC 
31 mGzE1R 51 
2000 2020 2040 
* * * GCGGTCCCGGAGAATTGACC GCCACCTGCGCTCCGAAAGC CAGCGGCAGCGCCGTGAAAT 
2060 2080 2100 
* * * 
BsaBI 
CAAACTTCTCCTGCTGGGCA CCAGCAACTCGGGCAAGAGC ACCATCGTCAAGCAGATGAA 
81 
~ 
2120 2140 2160 
* * * 
5 1 lBF 3 1 
GCCTGCAAG GAGTACAAGCCC 
GATCATCCACAGCGGGGGCT TCAACCTGGACGCCTGCAAG GAGTACAAGCCCCTCATCAT 
I I II I I I I I I I I I I I I I I I I I I I 
TTGGACCTGCGGACGTTC CTCAT 
51 mGz<½ 31 
2180 2200 2220 
* * * CTACAACGCCATCGACTCGC TGACCCGGATCATCCGGGCC CTGGCTGCCCTCAAGATCGA 
2240 2260 2280 
* * * TTTCCACAACCCTGACCGTG CCTACGACGCTGTGCAGCTC TTTGCTCTGACTGGCCCAGC 
2300 2320 2340 
* * * 
5 1 4BF 3 1 
CCCGAGCTGCTGGGTGTC ATG 
AGAGAGCAAGGGTGAGATTA CACCTGAGCTGCTGGGTGTC ATGCGACGGCTCTGGGCTGA 
2360 2380 2400 
* * * CCCAGGGGCCCAGGCCTGCT TTGGCCGCTCTAGCGAGTAC CACCTGGAGGACAATGCAGC 
2420 2440 2460 
* * * CTACTACCTGAACGACCTGG AGCGCATCGCAGCGCCCGAC TACATCCCCACGGTGGAGGA 
2480 2500 2520 
* * * TATCCTACGCTCCCGGGACA TGACCACGGGCATTGTGGAG AACAAGTTCACCTTCAAGGA 
2540 2560 2580 
* * * 
BamHI GCTTACCTTCAAGATGGTGG ACGTGGGCGGGCAGAGGTCA GAACGCAAAA AGTGGATCCA 
2600 2620 2640 
* * * 
SacI 
TTGCTTTGAAGGCGTCACAG CCATCATCTTCTGTGTGGAG CTCAGTGGCTATGACCTGAA 
2660 2680 2700 
* * * GCTCTATGAGGACAACCAGA CGGTGAGTAGAGCCTAGGTT TCTACTGTTGGTTCCCAGGA 
2720 2740 2760 
* * * AGCAGGTGGACTTGTAGGAG CAGAGAGAGACTTTGGTCCA GGGCTGTTACTGAGCCTTGC 
2780 2800 2820 
* * * CCAGCCACGTGGACGGCGCT GTGAGTGGTTCCATAAGATG GGATGAGCACACCCCATGTT 
2840 2860 2880 
* * * TTATGTTGGGGGGTTGCAGG GGGGAATGTGGTGTGGAACA TGGTGAGTTCATGCATGACA 
82 
2900 2920 2940 
* * * CGGGACTTCAGGGGCATTCT CGTCGAGTTATGAGCCCCAG TGGACAGGGTCATGATGGTA 
2960 2980 3000 
* * * TCCCATAAGACCTCAACTTT CTACGACTCCTTCAGCCTGA GGGACATCACTTTGACCTAG 
302 0 3040 3060 
* * * ATGAACCTGCTCTGACACCT TCCAAATGGCACCACAACCC CTAGACTCCATAGGGCTCAG 
3080 3100 3120 
* * * CAGGCAAGGACCCCCCTCCT TTATCAGCTATGACGACGCC TCCCCCAACAGGTGGAACTT 
3140 3160 3180 
* * * GGGAACTTTCCTTATAGTGT TTGTTGGCTCCACTGCCCAG GTTTCCATGTCACCTTGCCC 
3200 3220 3240 
* * * TCAGTACAGTGAATACGTGA TTGTGCCTGTGCCACTTGCT GAGGAAATCCAACGTAAGGC 
3260 3280 3300 
* * * CTGGCTGGGCGTCACTGGTG GTCCATGTGGCAATGTAGCA AACCCACTAAGCTCCTACCA 
3320 3340 3360 
* * * GCACTGCAGGATATGTAGGT CCTGAGAACGGCAACCCCCG CCCAGGTCTCCTTCTTGCTC 
3380 3400 3420 
* * * TGAAGAGTCTAGCGATGATC TGGTTAAGAAGAGTAAGTCC AAGGTGCCAAGACCTGACCT 
3440 3460 3480 
* * * TGGGCTTGGTGGATAGGCTG TAGGGCCATTGTTGAGGTTC TTTGAGTCCCTTATCCTATG 
3500 3520 3540 
* * * CTTAAAACCAGTGTGTTGGA AGGGGTGTTAGGGGCATGAA ATAGGACATAGGCAACCTGA 
3560 3580 3600 
* * * AGGAGACCTAGGTCCAGTGG TTAGCTAGGAGATCTTGAGA GGGGGCTGCTGAAGAAACAG 
3620 3640 3660 
* * * TTAAGCAGAAGTAGGCCTTT TGCATGGAGAGGGTAGGCAG TATGCTCAGATCCGCCTGAG 
3680 3700 3720 
* * * GCAGAAGGCTAGACTTCCAA GCTACCTACACTCTTCCCAG GAACAGCTCTAGTAGAAGAG 
3740 3760 3780 
* * * TGGCAGTCAGACAAATGATA GTGGTCTGCTTGAGGGCTGT CTTCCGTAGTGGAGCTACTG 
83 
~ 
3800 3820 3840 
* * * 
Acer 
TGCCAGGCAGAACCACTAAA CGTAGACCTAGAGCCTCCGT TTATAGCAAATGCCCCGGGA 
11111111111111 1111111111 
GGATCTCGGAGGCA AATATCGTTT 
3 1 Al-2 5 1 
3860 3880 
* * ACTGGAAAATAAGAATCTCT GAGTAGGGTTGCGGATGCCT GGAGCTGT 
II II II II II II II II II II II II 
TTCTTAGAGA CTCATCCCAACGCC 
3 1 Al-1 5 1 
Table 3.2 The exon2/3 Boundary of the HGza and MGza Genes 
(References: Padgett et al., 1986; Matsuoka et al., 1990) 
Exon 
Human Exon2 
Mouse Exon2 
5' Boundary 3' exon2/3 Boundary 
ttcctttcccc_gg .. AGTCGG AACCAGACA V AGTCGGATG 
ttctctctttcctt_gg .. GTGAAG AACCAGACG V AGCCGGATG 
Consensus Sequence cccccccccn ... egg: G 
ttttttttt ... c_gg:G 
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Figure 3.13 A Schematic Representation of the Strategy used to Generate both the 
'Control' and 'Targeting' Constructs. 
(A) MG2a Control Construct, 9K(OriI)pBKS(-)MG2a2(4.0K):: pgkNeopla 
(B) MGza Targeting Construct, 9K(OriI)pBKS(-)MG2a2(4.0K)::pgkNeopla ::pgkTKpla 
Abbreviations: AmpR, Ampicillin Resistance Gene; A, Ace!; BB, BsaBI; K, Kpnl; N, 
Not!; NeoR, Neomycin Resistance Gene; prom, pgk, promoter; pla, polyadenylation signal; 
and TK, the Thymidine Kinase Gene. 
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Part 3.3 Targeting the MGza Gene 
Section 3.3.1 Introduction. 
The pBKS(- )MGza2( 4.0K) construct (Figure 3.1 0C; Part 3.2, p65) , was chosen as the 
starting material for both the control and targeting constructs because it contains the entire 
second exon of the MGza gene, within a large segment of the genome that is native to the 
ES cell strain to be targeted (C57BL/6), yet still, 'relatively' small and easy to manipulate, 
even after the addition of various selectable markers (Figure 3.13; Part 3.1, p56). 
Section 3.3.2 The MGza Control Construct. 
a) Introduction. To create the 'control' construct (PCR; Section 3.1.3, p58), the pgkNeopla 
gene (Appendix 2.3) was cloned into the lone BsaBl restriction site within the coding 
region of MGza exon2 (Figure 3.12; 3.14). The endogenous primer pair, designated Al-
1/2, were also designed for use in combination with the exogenous primer pair 
(NeoP5/P6), to screening of homologous recombinants in targeted ES cells. The internal 
primers mGzGp and mGzGR (Table 2.1; Figure3.12)would be used to confirm the cloning 
of the pgkNeopla (Appendix 2.3) gene in vitro and eventually, to screen targeted mouse 
genomic DNA for the presence of the pgkNeopla gene (Figure 3.13A). 
b) Preparation of the pBKS(-)MGza2(4.0K) Subclone. A sequence insertion targeting 
strategy was chosen to disrupt MGza gene expression, because the BsaBI recognition site 
identified previously (Figure 3.12), is close to the start of translation and only cuts the 4kb 
genomic insert once. This site, however, was found to be subject to Dam methylation* 
(GAT*CNNNA TC; McClelland & Nelson, 1992; Figure 3.14A). To circumvent this 
difficulty both orientations of the pBKS(-)MG2a2( 4.0K) construct were prepared using 
the large scale purification protocol, transformed into the methylase minus, chemically 
competent E. coli strain JM 110 (Section 2.1.1, p30), and recovered using the Wizard® 
Miniprep Purification System. The clones, designated 8KB and 9KB, were then used to 
confirm (i) the presence of the unprotected BsaBI restriction site; (ii) the two endogenous 
primer binding sites Al-1/2 (Figure 3.14C); and (iii) the 3' Accl restriction site later used 
to remove the Al-1/2 primer binding sites (Figure 3.12; 3.14B). 
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Figure 3.14 Confirmation of pBKS(-)MGza2(4.0K) BsaBI Restriction Site and 
the Al-1/2 Primer Binding Sites. 
(A) The DNA from the 9K pBKS(-)MGza2( 4.0K) plasmid was digested with either 
Kpn I, BsaBI and/or BamHI, and the fragments separated using agarose (1 % ) gel 
electrophoresis. Lane 1, uncut plasmid (9K); Lane 2, linearised plasmid (9K!HindIII); 
Lane 3, DNA from the 9K clone cut with fresh BsaBI (9K!BsaBI); Lane 4, 9K!BamHI; 
Lane 5, 9K!BamHI/BsaBI; and Lane 6, 9K!Kpnl. This gel shows that 9K!BsaBI (Lane 3) 
runs at the same level as uncut plasmid (Lane 1). The BsaBI should also cut the 
characteristic MGza2(2.0B) fragment (Part 3.2, p65), however, although BamHI appears 
to cut out the predicted fragments, BsaBI does not (Figure 3.10). 
(B) The DNA from the methylase minus 8KB pBKS(-)MGza(4.0K) clone, prepared 
earlier, was digested with either Ace!, Kpnl, BsaBI and/or BamHI and the fragments 
separated using agarose (1 % ) gel electrophoresis. Lane 1, uncut 8KB (control); Lane 2, 
linearised 8KB (8KB/HindIII); Lane 3, 8KB/BsaBI; Lane 4, 8KB/BamHI; Lane 5, 
8KB!BamHI/BsaBI; Lane 6, 8KB/Kpnl; and Lane 7 8KB/Accl. Points to note include the 
BsaBI cut plasmid (Lane 3), the cleaved 2kb BamHI fragment (0.47kb+ 1.53kb; Lane 5) 
and the 4kb Ace! DNA fragment (Lane 7) which coincides with the placement of the Ace! 
restriction site. In OriII (8K) the two Ace! restriction sites (the endogenous Ace! site and 
the MCS Accl site) are at either end of the cloned 4kb insert. 
(C) PCR Analysis of the Al-1/2 primer binding sites. These primers were used to amplify 
that region of the cloned MGza2(4.0K) insert between themselves and the 4BF primer 
using PCR (1.5kb). Cycles 35x; ET 2min; T8 72°C; AT 5sec; TA 63°C. The product from 
each reaction was then run on a 1 % agarose gel. The example shown is that of the Al-1 
and 4BF applied to both orientations. Lanes 1 & 9, A/HindIII (0.5µg); Lanes 2 & 8, 
ddH2O (control); Lane 3, 250pg of clone 9K; Lane 4, 9K (25pg); Lane 5, 250pg of clone 
8K; Lane 6, 8K (25pg); and Lane 7, 2500pg of C57BL/6 mouse genomic DNA. The 
product amplified from each clone also corresponds to the band amplified from the 'tail' 
DNA, indicating that both sets of primers are also native to the C57BL/6 mouse genome. 
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c) Construction of the MGza Control Construct. To make the MGza control construct the 
pgkNeopla ( 1.8kb) gene was restricted from pBSK( + )pgkNeopla vector (Appendix 2.3) 
using the both HindIIT and Eco RI, separated from the host vector using agarose (1 % ) gel 
electrophoresis and purified with the Gene Clean® Protocol (Section 2.3.3, p38). The over 
hanging 5' ends, of the pgkNeopla fragment, were then blunt ended (Section 2.3.4, p39) , 
and the pBKS(-)MGza2( 4.0K) construct digested with BsaBI (Section 2.1.2, p30). The 
blunt ends of the recipient vector were then dephosphorylated (Section 2.3 .5, p39) , and 
added to a ligation mix (Section 2.3.6, p40) containing the prepared pgkNeopla fragment. 
Following incubation the DNA was then transformed into chemically competent E. coli 
DH5a and prepared using the Wizard® Miniprep Purification System. The putative 
control constructs, pBKS() MGza2(4.0K)::pgkNeopla, representing both orientations of 
the cloned pgkNeopla fragement, were designated 26b, 29b and 30b respectively. 
d) Characterisation of the Putative Control Constructs. To confirm the presence of the 
pgkNeopla fragment and to identify its orientation, each putative control constructs was 
prepared using the large scale plasmid purification protocol, restricted (0.5µg) with either 
BamHI and/or Eco RI and separated using agarose (1 % ) gel electrophoresis (Figure 
3.15A). In this way it was found that clones 29b and 30b (Figure 3.16A), contain a copy 
of the pgkNeopla gene with its promoter in the same direction as the MGza gene, 
designated the forward orientation (F), pBKS(-)MGza2( 4.0K): :pgkNeopla(F), whilst 
clone 26b (Figure 3.16B) contains a copy of the cloned pgkNeopla insert in the reverse 
orientation (R), pBKS(-)MGza2(4.0K)::pgkNeopla(R). 
e) Confirmation of Orientation and Primer Binding Sites. PCR analysis with the Al-I 
endogenous primer was used to determine whether the 'control' exogenous primer binding 
sites (prom 1/2, NeoP5/P6; Figure 3.16), situated at either end of the pgkNeopla fragment 
(Figure 3.13), had survived blunt end cloning. This demonstrated that clones: la, 5b & 
29b possess pgkNeopla(F); 21a, 26b & 51b possess pgkNeopla(R), whilst 31b does not 
contain the pgkNeopla fragment. Furthermore although 30b was previously thought to 
contain pgkNeopla(F) no band was amplified (Section 2.3.10, p42; Figure 3.15B), 
suggesting damage to the end of the pgkNeopla insert in this instance. 
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Figure 3.15 Characterisation of the Putative MGza Control Constructs. 
(A) Diagnostic Restriction Analysis of the Putative Control Constructs. Lane 1, 
26b/BamHI; Lane 2, 26b/EcoRI; Lane 3, 29b/BamHI; Lane 4, 29b/EcoRI; Lane 5, 
30b/BamHI; Lane 6, 30b/EcoRI; Lane 7, 9KH/BamHI; and Lane 8, 9KH/EcoRI. Note that 
the size of each linearised clone (8.7kb; Lanes 2, 4 & 6), and the small BamHI fragment 
( 1.3kb; Lanes 1, 3, 5 & 7), remain the same, no matter what the orientation of the 
pgkNeopla insert, whilst the MGza2(2.0B) genomic fragment, characteristic of the 
MG 2a2(4.0K) cloned insert is lost. In the forward orientation the two new BamHI 
fragments will be 2.8kb and 1.1kb in size. In the reverse orientation the BamHI restriction 
site, within the pgkNeopla gene, will have moved to the opposite end of the insert, so the 
predicted fragments will then be 1.8 and 1.9kb in size (the 'doublet'; Lane 3; Figure 3.16). 
(B) The PCR protocol was conducted using 250ng of template DNA and the primer pairs 
pgkproml/Al-1 (R; Lanes 2 to 14) and NeoP5/Al-1 (F; Lanes 16 to 28). Cycles 35x; ET 
2min; Ts 72°C; AT 5sec; TA 63°C. The PCR product (1.8kb) was then run on a 1 % 
agarose gel. Lanes 1 & 15, A/HindIII (0.5µg); Lanes 2 & 16, ddH20; Lanes 3 & 17, clone 
9KH (negative control I); Lanes 4 & 18, la; Lanes 5 & 19, 21a; Lanes 6 & 20, 5b; Lanes 
7 & 21, 26b; Lanes 8 & 22, 29b; Lanes 9 & 23, 30b; Lanes 10 & 24, 31b; Lanes 11 & 25, 
51 b; Lanes 12 & 26, mouse genomic C57BL/6 DNA; Lane 13, 26b (R, positive control); 
Lane 27, 29b (F, positive control); and Lanes 14 & 28, ddH20. 
(C) An example of 'nested' PCR optimised using the control construct 29b. The first 
round of amplification uses the outside primers, Al-1/NeoP5 [Cycles, 20x; Extension 
Time (ET), 2min; Extension Temperature (Ts), 72°C; Annealing Time (AT), 5 sec & 
Annealing Temperature (TA), 67°CJ, and the second the two inside primers, Al-2/NeoP6 
(Cycles, 35x; ET, 2min; Ts, 72°C; AT, 5sec & TA, 65°C). The final PCR product (1.8kb) 
was then run on an agarose (1 % ) gel. Lane 1, 1/Hindill; Lane 2, 1 0fg; Lane 3, 1 00fg; Lane 
4, 1 pg; Lane 5, 1 0pg; and Lane 6, 1 00pg. The size marker, A/HindIII is reproduced on the 
left. To minimise cross contamination the template was added to each reaction mix at an 
increasing concentration. Gel courtesy of Dr Klaus Matthaei. 
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Figure 3.16 Schematic Representations of Both Orientations of the Cloned 
pgkNeopla Gene, and 'Nested' PCR. 
(not to scale) 
(A) Schematic representation of the control construct, with the pgk:Neopla gene in the 
fo1ward orientation (F), showing restriction, and primer binding sites for the two sets of 
fo1ward orientation primer sets; NeoP5/P6 and Al-1/2. 
(B) Schematic representation of the control construct, with the pgk:Neopla gene in the 
reverse orientation (R), showing restriction, and primer binding sites for the two sets of 
reverse orientation primers prom 1/2 and Al-1/2. 
(C) Schematic representation of the nested PCR strategy developd to identify 
homologous recombination in ES cells in vitro. 
Abbreviations: A, Ace!; B, BamHI; N, Natl; S, Sac!; K, Kpnl 
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f) Optiniising the 'Nested PCR' Strategy. A 'nested PCR' protocol (Nitschke et al., 1993; 
Figure 3.16C) using the control primer binding sites was used by this laboratory to screen 
for homologous recombination in vitro. A similar technique was employed, and optimised 
using dilutions of the 29b, pBKS(-)MG2a2( 4.0K): :pgkNeo(F) clone, designated the 
control construct. The sequence of the forward primer sets (Al-1/2 & NeoP5/P6) , 
however, were first checked against the MG2a2( 4.0K) insert (Figure 3.12), and other 
sequences within the Genbank and EMBL (European Molecular Biological Laboratories) 
data bases to determine the specificity of these p1imers and to ensure that any other known 
genomic sequence will not corrupt the screening of targeted C57BL/6 ES genomic DNA 
for the pgkNeopla gene (Part 3.1, p56). The control template DNA was prepared using the 
Wizard® Miniprep Purification System Protocol and diluted in l00pg/µL of mouse 
genomic DNA, which acts as a carrier, to prevent the small amount of target from 'sticking' 
to the sides of the reaction tubes (Figure 3.15C). 
Section 3.3.3 The MGza Targeting Construct. 
a) Introduction. To create the MG2a targeting construct the l00bp Ace! restriction 
fragment, encompassing the Al-1/2 primer binding sites (Figure 3.13), within the control 
construct was replaced with the pgkTKpla gene. The forward orientation control construct 
(29b) was chosen because, the transcriptional machinary used to express the MG2a gene 
should not hinder the expression of the Neor gene following its specific integration into 
the targeted ES cell genome (Capecchi, 1989). 
b) Construction of the MGza Targeting Construct. The control construct was prepared 
using the large scale purification protocol, digested (2µg) with Ace! (Section 2.1.2, p30) 
and separated from the Al-1/2 primer binding sites through agarose (1 % ) gel 
electrophoresis. The DNA band containing the rest of the vector was then purified by 
freeze squeezing, blunt ended (Section 2.3.4, p39) and dephosphorylated (Section 2.3.5, 
p39). At the same time pBSK( + )pgkTKpla (Appendix 2.4) was digested (2µg), first with 
HindITI/ Eco RI, and then with Pvul (Section 2.1.2, p30), to cut the pBSK( +) (2.9kb) host 
vector, into smaller fragments, so that it could be more easily separated from the pgkTKpla 
gene (2.7kb) using agarose (1 %) gel electrophoresis (Figure 3.17A). The pgkTKpla 
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Figure 3.17 Cloning the pgkTKpla gene. 
(A) Purification of the pgkTKpla gene fragment. Lane 1, The top band contains the 
pgkTKpla gene, whilst the lower bands represent the remainder of the pBSK( +) cloning 
vector following digestion with Pvul. The molecular weight standard, A./Accl (Lane 2). 
(B) Restriction mapping the putative targeting constructs. Lane 1, Clone 12a digested with 
HindIII (12/HindIII); Lane 2, 57a/HindIII; Lane 3, 80a/HindIII; Lane 4, 
pBSK(+)pgkTKpla/HindIII; Lane 5, 29b/HindIII; Lane 6, 12a/EcoRV; Lane 7, 
57a/EcoRV; Lane 8, 80a/EcoRV; Lane 9, pBSK(+)pgkTKpla/EcoRV; Lane 10, 
29b/EcoRV; Lane 11, 12a/BamHI; Lane 12, 57a/BamHI; Lane 13, 80a/BamHI; Lane 14, 
pBSK( + )pgkTKpla/BamHI; Lane 15, 29b/BamHI; Lane 16, A./Accl (0.5µg); and Lane 17, 
A!HindIII (0.5µg). Note the size change of the 1.3kb BamHI fragment present in the 
control construct (Lane 15), and encompassing the 1 00bp Ace! fragment to 4kb in the 
targeting construct (Lanes 11, 12 & 13), due to the addition of the 2.7kb pgkTKpla 
fragment. The 1.6kb (Lane 6) and 2.1kb (Lanes 7 & 8) EcoRV fragments are indicative of 
the pgkTKpla(R) and pgkTKpla(F) orientations respectively (Figure 3.18). 
(C) PCR analysis of clone 57, pBKS(-)MGza2(4.0K)::pgkNeopla(F):: pgkNeopla(F), 
using the primers NeoP5 (pgkNeopla) and proml (pgkTKpla). Cycles, 35x; ET, 2min; 
TE, 72°C; AT, 5sec & TA, 65°C. Following the reaction PCR product (1.9kb) was run on 
a agarose (1 %) gel. Lane 1, A/HindIII (0.5µg); Lane 2, ddH20 ; Lane 3, 2.5pg; Lane 4, 
25pg; Lane 5, 250pg; and Lane 6, 2500pg. Note that to minimise cross contamination the 
template was added from the lowest to the highest dilution. 
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Figure 3.18 The Putative Targeting Constructs. 
Schematic representation of both orientations of the cloned pgkTKpla gene, present within 
the targeting constructs. Predicted EcoRV fragment sizes for pgkTKpla(F): 6.50kb; 
2.10kb; 1.50kb; 0.60kb; 0.17kb; & 0.26kb and for pgkTKpla(R) : 6.50kb; 1.60kb; 
0.62kb; 0.17kb; 1.50kb & 0.26kb (Figure 3.17B ). Also shown are the sequencing 
primers used to verify each targeting construct. They include, anti-1BF(2), anti-4BF(3) ; 
mGzGp(l), mGzGR(4) used to sequence into the pgkNeopla fragment, and the universal 
primer to obtain sequence from the end of the pgkTKpla gene. 
Abbreviations: B, BamHI; EV, EcoRV K, Kpnl; N, Not!; NeoR, the neomycin resistance 
gene; and TK, the thymidine kinase gene. 
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fragment was then blunt ended, added to a ligation mix containing the prepared control 
construct (see above), incubated and the DNA transformed into chemically competent E. 
coli XLl-Blue cells (Section 2.1.1, p30). The presence of the cloned fragment was first 
identified using colony cracking, and later confirmed through the use of restriction 
analysis. The putative targeting construct pBKS()MGza2(4.0K)::pgkNeo(F)::pgkTKpla 
containing clones were designated 12a, 57a and 80a respectively. 
c) Characterisation of the MGza Targeting Construct. To identify the orientation of the 
cloned pgkTKpla gene, each of the putative targeting constructs were prepared using the 
Wizard® Miniprep Purification System, and digested (250ng) with either HindIII, EcoRV 
and/or BamHl, respectively (Figure 3.17B). In this way it was found that clones 57a and 
80a (Figure 3.18B), contain a copy of the pgkTKpla gene with its promoter in the forward 
orientation (F), pBKS(-)MGza2(4.0K)::pgkNeopla(F)::pgkTKpla(F), whilst clone 12a 
(Figure 3.18A) contains a copy of the cloned pgkTKpla insert in the reverse orientation 
(R), pBKS(-)MGza2( 4.0K): :pgkNeopla(F): :pgkTKpla(R). 
Figure 3.19 Verification of Primer Binding Sites. Sequence confirming the survival 
of the NeoP5 primer binding site, critical for the nested PCR screening protocol, using 
the anti- !BF endogenous primer binding site. 
3' lBF 5' 
CCCGAACATGAGGAACGTCCG 
I I I I I I I I I I I I I I I I I I I I I 
GGGCTTGTACTCCTTGCAGGC GTCCAGGTTG AAGCCCCCGC TGTGGATGAT 
5' anti-lBF 3' 
1----> pgkNeopla 
CTAGCTTCTG ATGGAATTAG AACTTGGGAA AAACAATACT GAGAATGAAG 
3' NeoPS 5' 
CCGACGACTAGAGCAAGAAGTCCG 
I I I I I I I I I I I I I I I I I I I I I I I I 
TGTATGTGGA ACAGAGGCTGCTGATCTCGTTCTTCAGGC 
d) Verification of the Targeting Construct. As a final measure of quality and to ensure that 
no damage had been done to the ends of either the pgkTKpla or pgkNeopla selection 
marker during blunt end cloning, the DNA from each putative targeting construct was 
sequenced (Figure 3.19), and subjected to PCR analysis (Figure 3.17C; 3.18). 
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Section 3.3.4 /n Vivo Targeting the MGza Gene. 
a) Preparation and Electroporation of the MGza Targeting Construct. Clone 57a 
pBKS(-) MGza2(4.0K)::pgkNeopla(F)::pgkTKpla(F) was chosen as the targeting 
construct, primarily because the direction of the pgkTKpla promoter does not oppose the 
expression of either the MGza gene or the pgkNeopla genes (Section 3.3.3, p9 l). Prior to 
electroporation into ES cells this construct was first prepared using the Qiagen Midiprep® 
Purification System and cut with Notl to linearise the clone, allowing it to effectively 
integrate into the genome. The DNA was then electroporated into C57B1/7 ES cells. 
b) Isolation of an ES cell line which is Heterozygous for MGza• The transformed cells 
were grown on media containing both neomycin and gancyclovir (Part 3.1, p56) , and the 
surviving clones (up to 300) screened using the nested PCR protocol developed 
previously. Putative homologous recombinants were then grown in culture and subjected 
to Southern analysis for final confirmation that these clones did possess a specifically 
integrated copy of the pgkNeopla gene (Figure 3.20): The genomic DNA from seven of 
these ES cell clones was prepared, digested (5µg) with Kpnl, and HindIII/EcoRI. The 
DNA fragments from each sample were then separated by agarose (1 %) gel 
electrophoresis, transferred to PCNM using alkaline transfer and subjected to high 
stringency hybridisation with an exon2 specific radiolabelled probe, representing the 
region between the mGzGp and mGzGR primer binding sites (Figure 3.12; 3.13 ; 3.20). 
The confirmed homologous recombinants were grown in culture, directly injected into 
BALB/c mouse blastocysts and implanted into pseudopregnant female foster mothers. 
This has resulted in the growth of a number of chim~ras (Figure 3.21) , which are 
currently being bred to determine germline transmission of the targeted allele. 
Special Acknowledgments. PCR and Southern screening of the large numbers of 
homologous recombinants, blastocyst injection and the supervision of mouse breeding 
was conduct by and would not have been possible without the extensive technical expertise 
possessed by the Gene Targeting Group at the John Curtin School of Medical Research, 
the Australian National University. In particular Dr Klaus Matthaei and Ginny Sargent for 
their patience. 
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Figure 3.20 Southern Analysis of Putative ES Cell Recombinants. 
PCR probe analysis of the genomic DNA prepared from the putative ES homologous 
recombinants (one to seven). Lane 1, Clone l/Kpnl; Lane 2, Clonel/HindIII/EcoRI; Lane 
3, Clone 2/Kpnl; Lane 4, Clone 2/Hindlll/EcoRl; Lane 5, Clone 3/Kpnl; Lane 6, Clone 
3/HindIII/EcoRI; Lane 7, Clone 4/ Kpnl; Lane 8, Clone 4/HindlII/EcoRI; Lane 9, Clone 
5/Kpnl; Lane 10, Clone 5/Hindlll/EcoRl; Lane 11, Clone 6/Kpnl, Lane 12, Clone 
6/Hindlll/EcoRl; Lane 13, Clone 7/Kpnl; and Lane 14, Clone 7/Hindlll/EcoRl. The 
MGza2( 4.0K) genomic fragment, isolated to create the targeting and control constructs is 
endogenous to the ES cell genome, therefore, if specific integration has occurred in at least 
one allele of the gene, then this fragment will increase in size, to 5.8kb because of the 
presence of the pgkNeopla selection marker in that allele (1.8kb; Lanes 3, 5, 7, 9 & 11). 
Furthermore there is also a change in size of the original MGza2(7 .0H/E) from 7kb to 
8.8kb in size (Lanes 2, 4, 6, 8 & 10) for the same reason. Note also the 4kb and 7kb 
fragments present in each of these lanes represents the other, non targeted allele of the 
gene region. Both gene alleles in Clone 1 appear to have escaped targeting (Lanes 1 & 2), 
whilst Clone 7 appears to have suffered multiple insertions of the targeting construct 
(Lanes 13 & 14). 
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Figure 3.21 The MGza Knockout Chimrera 
Shown is a photograph taken of one of the chimceric animals which have recently been 
produced by the Gene Targeting Facility. Note the black/white coat colouration, derived 
from the endogenous white BALB/c ES cells and the introduced black C57BL/6 ES cell 
line. Also present are litter mates and mother. 
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Chapter 4 Attempts to Clone and Characterise a Full-
length MGza cDNA Clone. 
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Part 4.1 Introduction. 
The major challenge posed by gene targeting is to prove that the phenotype of the 
knockout animal is directly due to the disruption of the gene targeted. This is especially 
difficult if there is no obvious phenotype, or if the expressed phenotype is due to a 
secondary interaction with some other protein (Chapter 5, p109). A common approach, 
although not the only one, is to generate a full length cDNA clone of the functional gene 
to see if this will rescue the phenotype of the knockout animal. A full length cDNA, in 
association with an in vitro expression system, can also be used to produce large amounts 
of the gene product. This chapter details the steps taken to generate a cDNA copy of the 
MGza mRNA. Time constraints and the lack of appropriate material meant that the 
construction and screening of a C57BL/6 (mouse brain) cDNA library was not initially 
considered, instead a reverse transcriptase-polymerase chain reaction (RT-PCR) strategy 
similar to that which was used to obtain the partial MG2 a cDNA clone was attempted 
(Leck, 1993; Figure 4.1). 
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Figure 4.1 The Cloning of a Partial MGza cDNA Fragment. 
Both the translated (exon2, red; exon3, blue) and untranslated regions of each exon are 
shown (top). Note that the position and size of exon3 is assumed from the orthologous rat 
and human Gza gene regions. The first strand synthesis is primed from the 3' 
oligonucleotide (3R) and amplified using both the 3R and 4BF in a single reaction mix 
(from Leck, 1993; see also Figure 3.5B). 
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Part 4.2 Further Characterisation of MGzcx• 
Section 4.2.1 Introduction. 
The previously cloned and sequenced partial MGza cDNA clone (Part 3.2, p65; Figure 
3.5) was obtained using RGza and HGza consensus primers (4BF & 3R; Leck, 1993). 
These primers were designed to recognise highly conserved translated regions of the gene 
based on information gained from both the rat and human orthologous sequences. To 
amplify the complete open reading frame it would be necessary to design a primer to bind 
both the 5' and 3' untranslated region (UTR). Unfortunately, the same degree of 
conservation does not exist between the RGza HGza and MGza genes in either the 5' 
and/or 3' UTR's. It was, therefore, decided to isolate and characterise mouse genomic 
clones encompassing exon3 (~300bp) as well as any 3' UTR downstream of the 3R 
binding site. Once gained this sequence information would be combined with the known 
sequence of the 5' UTR (Part 3.2, p65) to design the primers needed to generate a the full 
length cDNA using an RT-PCR strategy (Sellner et al., 1992; Section 2.3.10, p42). 
Section 4.2.2 Attempts to Isolate MGza exon3. 
a) Screening the Remaining AMGza Genomic Clones with 3R. The MGzaP probe initially 
used to screen the C57BL/6 mouse genomic library spans both exon2 and exon3. Thus it 
was assumed that any AM clone isolated using this fragment would contain either one of 
the two translated exons. Thus the AMGza clones obtained earlier (Part 3.2, p65) were 
revived through plate lysis (Section 2.2.2, p34). Each phage sample was then diluted and 
the DNA transferred to PCNM in concentrated 'dots' (Section 2.4.3, p45). The membrane-
bound DNA was then subjected to high stringency hybridisation (63°C; Section 2.4.3, 
p45) with endlabelled 3R (Section 2.4.1, p44 ). It was hoped that this approach would 
allow us to rapidly identify those clones which encompassed exon3 without the need to 
rescreen the entire C57BL/6 AM genomic library. Unfortunately, 3R did not hybridise to 
any of the AMGza genomic clones or the sample of mouse genomic DNA run as an 
independent 'control'. This was despite the fact that each of the other 3R containing 
controls clearly bound the radiolabelled primer (Figure 4.2A). This result was not, 
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however entirely unexpected because of the potential difference between rat, human and 
mouse copies of the 3R primer binding site (compare with 4BF; Section 3.2.5, p70). A 
subtle difference may affect the stability of the primer during hybridisation without 
affecting the RT-PCR strategy initially used to generate the MGzaP probe. This is 
because the primer itself only needs to bind specifically once to generate the first strand. 
However, when the hybridisation was repeated under low stringency conditions (55°C) all 
of the AMGza clones bound the labelled primer, including those which were previously 
found not to bind 3R (Section 3.2.3, p65). Later it would be shown that none of the 
AMGza clones possessed copies of exon3. At this stage, however, several questions 
remained unanswered. Was the phage titre sufficient to produce a strong enough signal 
and if interspecies differences did exist between the 3R primer and the putative 3R mouse 
primer binding site how did they affect its binding? To answer these questions it was 
necessary to sequence a subclone of the mouse genome containing exon3 using a method 
which was independent of 3R. Therefore, the decision was made to clone the exon3 
specific portion of the MGzaP(mimic) which could be used to verify the presence of 
exon3 (Figure 4.3). 
b) Cloning MGza exon3 and exon2 Specific Fragments. The MGzaP(mimic) clone 
(Figure 4.3) was prepared, digested (2µg) with Sacl and the exon3 specific fragment 
separated from the rest of the vector using agarose (1 %) gel electrophoresis. The DNA 
band was then gel purified, digested with Hinfl which cuts downstream of the putative 
exon2/3 boundary and blunt ended. The resulting fragments were then ligated into Smal 
cut pBSK( + ), confirmed through restriction analysis and sequenced using the universal 
forward and/or reverse primers (Figure 4.3; Part 2.6, p52). Note that the remainder of the 
vector possessing part of exon2 was also recovered, religated and sequenced. 
c) Screening AMGza Genomic Clones with Exon Specific Probes. Both exon2 and exon3 
specific fragments were gel purified, radiolabelled (Section 2.4.1, p44) and hybridised 
(65°C; Section 2.4.3, p45) with the, AMGza dot blot. However, whilst each of the AMGza 
clones bound the exon2 specific probe (Figure 4.2B), none of the 20 or so genomic 
clones isolated with the exon2/3 MGzaP clone (Leck, 1993) bound the cloned portion of 
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Figure 4.2 Autoradiograph Analysis of AMGza Genomic Clones. 
(A) Autoradiograph of AMGza genomic blot, following hybridisation with 3R. The 
positive controls for 3R, include: (I) a copy of the full length human cDNA; (II) 
pBSK(+)HGzacDNA(F) (Matsuoka etal., 1990); (III) the MGzaP clone (Leck, 1993); 
pBSK( + )MGzaP(696bp, 4BF/3R) and (IV) the MGzaP(mimic) , a construct made by 
removing a 1 00bp fragment from the pBSK( + )MGzaP( 696bp, 4BF/3R), and used as a 
control for RT-PCR (see also Figure 4.4; Leck, 1993). Positions (V) to (XVI) represent 
the AMGza genomic clones isolated previously (AMGzal to AMGzal 1 respectively; see 
Part 3.2, p65). 
(B) Autoradiograph of AMGza dot blot, following hybridisation with the exon2 specific 
cloned portion of MGzaP(mimic). Genomic clones shown include: (1) AMGzal; (2) 
AMGzal; (3) AMGza3; (4) AMGza4; (5) AMGza5; (6) AMG za6; (7) AMGza7; (8) 
AMGza8; (9) AMGza9; and (10) AMGzal0. 
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Figure 4.3 The MGzaP Clone, Mimic & Exon Specific Subclones. 
(A) Schematic representation of the full length partial MGzaP cDNA clone (Leck, 1993). 
(B) Schematic representation of the MGzaP(mimic), used to produce mRNA as a control 
in RT-PCR (Leck, 1993; Figure 4.4). Also shown are cloning and primer binding sites. 
(C) Schematic representation of the MGza exon3 specific subclone. 
(D) Schematic representation of the MGza exon2 specific subclone. 
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exon3, suggesting that they contain only MGza exon2. This may mean that the exon3 
containing clones are under-represented (or that the exon2 containing clones are over-
represented) in the mouse C57BL/6 genomic library. There was, however, insufficient time 
available to complete the next logical step, which was to rescreen the entire genomic library 
specifically with the exon3 specific fragment. 
Special Acknowledgments. The partial MGza cDNA clone and mimic DNA were 
constructed by Kwong Joo Leck (Leck, 1993). 
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Part 4.3 Other Work. 
Section 4.3.1 The use of RT-PCR to Obtain a MGza cDNA Clone. 
a) Introduction. As none of the original AMGza genomic clones possessed copies of 
exon3 (Part 4.2, pl0l) a different strategy was employed in an attempt to obtained a full 
length MGza cDNA. The two examples given below use oligonucleotide dT or modified 
oligonucleotide dT primers to synthesis the first strand and amplify putative MGza 
cDNA's. 
b) Froni Total Mouse Cerebellum RNA. Mouse cerebellum RNA was prepared (Section 
2.2.3, p35) and screened for the presence of MGza mRNA using the RT-PCR protocol 
developed to synthesise the partial cDNA clone (Leck, 1993; Figure 4.4A) . In this 
instance an oligonucleotide dT (18mer) primer was used to prime the reverse transcriptase 
(RT) reaction. The 5' primer mGzGF was then used in conjunction with the 
oligonucleotide dT primer to amplify putative MGza cDNA fragments. However, due to 
the low annealing temperature of the oligonucleotide dT primer this procedure resulted in 
multiple bands (smears), which although they were cloned and sequenced did not contain 
MGza sequence. 
c) Froni Mouse Cerebellum mRNA. The system next applied was adapted from the 
Promega RiboClone® System and uses a modified oligonucleotide dT primer 
[NOTI(Primer Adapter)PA; Table 2.1; Promega Catalogue] to prime the synthesis of the 
first strand, and a related primer (NOTPCR; Table 2.1) for subsequent PCR amplification. 
In this way the annealing temperature (TA) during the PCR step can be raised, increasing 
the specificity of the 5' primer binding. The presence of the Natl recognition sequence at 
the end of the primer also assists in cloning PCR products. For the first strand synthesis, 
purified (Section 2.2.3, p35) mouse cerebellum mRNA (l.25µg) was added to a reaction 
mix containing AMV RT and the NOTIPA primer (Section 2.3.10, p42). The products of 
the first strand synthesis were then subjected to amplification by PCR using the mGzGF 
and/or mG2Gp (NotI) 5' primers against the 3' NOTPCR primer. In this way a DNA band, 
corresponding in size to a predicted full length MGza cDNA clone ( ~ 1.5kb), was 
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Figure 4.4 The Products of the Two RT-PCR Protocols. 
(A) Each RNA preparation was diluted in DEPC treated ddH2O and added to an RT-
PCR mix containing both AMV RT and 'Super' TAQ DNA polymerase. The cycling 
conditions used were as follows: The first strand synthesis was conducted at 42°C for 
59min. This was followed by a denaturing step (95°C, 5min) and the MGza specific 
cDNA (637bp) amplified using PCR: Cycles, 35x; ET, 30sec; TE, 72°C; AT, 5sec; TA, 
63°C. This was followed by a final extension period of 5min at 72°C, after which the PCR 
product was heated (65°C, 15min) and separated by agarose (1 %) gel electrophoresis: 
Lane 1, I Ong MGzaP(mimic); Lane 2, ddH2O (control); Lane 3, 1 000ng RNA; Lane 4, 
I00ng RNA; Lane 5, I Ong RNA; Lane 6, Ing RNA; Lane 7, l00pg RNA; Lane 8, l0pg 
RNA. Approximately 1 0pg of MGzaP(mimic) RNA ( ~500bp; Leck, 1993) is also present 
in each of the lanes as an RT control. In Lanes 7 and 8 it appears below the 696bp 
MGzaP cDNA clone. The small band (*) present in each lane is a non-specific product 
which is routinely amplified under these conditions. 
(B) The product of first strand synthesis (RT reaction; Section 2.3.10, p42), using the 
Riboclone System NOTIP A was diluted in (1/20) within ddH2O and subjected to PCR 
amplification (Section 2.3.9, p42). Cycles, 35x; ET, 2min; TE, 72°C; AT, 30sec & TA, 
59°C. The product of each of the reactions was then run on an agarose (1 %) gel: Lane 1, 
straight mix (RT) using mGzGp(Notl) and NOTPCR primer [mGzGp(Notl)/NOTPCR]; 
Lane 2, 1/20 RT mGzGp(Notl)/NOTPCR; Lane 3, RT mGzGp/NOTPCR; Lane 4, 1/20 
RT mGzGF /NOTPCR; Lane 5, RT mGzGp/3R; Lane 6, 1/20 RT mGzGp/3R; and Lane 7 
ddH2O (control). Note the putative MGza cDNA 'fragment' ( ~ 1.5kb; Lanes 1 to 4). 
(C) Restriction Analysis of the Putative MGza cDNA Clone. Once gel purified the 
putative MGza cDNA clone (250ng) was cut with one of a number of restriction enymes 
and run on an agarose (1 % ) gel: Lane 1, uncut product; Lane 2, BamHl; and Lane 3, Sacl. 
Note that both BamHl and Sacl failed to digest the 1.5kb fragment (Lanes 2 & 3). 
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amplified. Because this result was reproduced at the higher more stringent annealing 
temperature (61°C) the band was gel purified and subjected to restriction analysis. Both 
Sacl and BamHI recognition sequences present within the cDNA clone, however, this 
purified fragment proved to be resistant to digestion by either enzyme (Figure 4.4C). 
Furthermore, no band was amplified from the initial RT mix using the mGzGp/3R primer 
set, even though 3R has been consistently used to amplify the MGzaP cDNA fragment 
from total RNA using the on-step RT-PCR reaction (Section 2.3.11, p43; Leck, 1993). 
Section 4.3.2 Northern Analysis. 
Many of the questions regarding a possible phenotype for a MGza knockout surround its 
tissue distribution which in tum may have bearing on how widespread and important its 
biological function might be. As mentioned previously there are several studies, including 
those using RT-PCR analysis, which suggest that Gza may be present in a number of 
non-neuronal organs (e.g. the lungs, kidneys etc), however the specificity of these 
approaches is open to question because of the high degree of sequence similarity between 
the different members of this family (Section 1.2.2, p3). This proposition is supported by 
the amplification of an unknown product using specific MGza primers from mRNA 
isolated from a tissue known to be especially abundant in MGza (Section 4.3.1 , p106). In 
an attempt to answer these questions both the exon2 and exon3 specific fragments were 
used in northern analysis. Whole cell RNA was prepared from both cerebral hemispheres, 
mid brain, cerebellum, kidneys, lungs, liver, sciatic, heart, hind brain, spleen and the yield 
determined. IOµg of each sample was then run on an agarose (1 %) gel (Section 2.4.4, 
p47). The RNA was then blotted onto PCNM (Northern Transfer) and hybridised (55°C) 
with both MGza exon2 and MGza exon3 specific probes (Part 4.2, plOl). Unfortunately, 
both radiolabelled fragments failed to bind a band within the expected size range in either 
the neuronal and/or non-neuronal tissue samples. This result is difficult to accept because 
of the abundance of MG 2a message within neuronal tissues (Hinton et al., 1990), 
however, time constraints meant that this experiment could not be repeated. 
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CHAPTER S General Discussion. 
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Part 5.1 Introduction. 
The work presented in this thesis outlines the approach taken to target Gza in ES cells in 
vitro, however, the implications of disrupting this gene in the whole animal remain 
uru·esol ved. Previous studies have shown that gene dosage effects, cross talk and 
functional redundancy have the potential to contribute to the overall phenotype of a 
knockout and in so doing may mask the true biological significance of the targeted gene 
product (Erickson, 1993; Shastry, 1994). Such studies have also demonstrated that the 
data gathered from gene knockouts is interpreted best if accompanied by corroborating 
and independent evidence. In this chapter I will discuss the rationale for gene targeting as 
an approach for further understanding the biological function(s) of Gza, including the 
potential problems and possible outcomes. 
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Part 5.2 Targeting Gene Expression: Past Outcomes. 
Section 5.2.1 Introduction. 
Previous studies have revealed that mice which possess a disrupted gene product can 
express a number of different phenotypes. In many instances knockout mouse are either 
phenotypically normal (Hooper et al., 1987; Kuehn et al., 1987; Bueler et al., 1992; 
Clarke et al., 1992; Collins & Wilson, 1992; Snouwaert et al., 1992), produce a minimal 
phenotype (Zijlstra et al., 1990; Joyner et al., 1991; Donehower et al. , 1992), or express a 
phenotype in unexpected tissues (Shastry, 1994). When the observed response to the 
absence of a particular gene product is specific, obvious, non-lethal and if it con-elates with 
known activity and tissue distribution then a biological function can easily be assigned to 
the protein. However, if the disrupted gene is required for survival of the foetus or if no 
obvious phenotype is expressed following the removal of the protein then very little can be 
deduced about its biological function (see below). 
Section 5.2.2 Lethal Outcomes. 
In laboratory reared mice the naturally occurring rate of prenatal death is about 20-25% 
(Wilmut et al., 1986). This can be greatly increased through the introduction of lethal 
genetic mutations and is dependent upon whether or not the protein that has been 'knocked 
out' plays an indispensable role in the survival of the foetus during development (Gridley 
et al., 1987; Green, 1989; Copp, 1995). Although gene lethal outcomes make it difficult to 
assign a biological function to the targeted protein, its role at a particular stage of foetal 
development can still be determined (Copp, 1995). Furthermore, to avoid the potentially 
lethal outcome of suppressing the ubiquitously expressed Gi2a in utero, the in vivo, tissue 
specific, post natal expression of antisense Gia RNA has been used to disrupt the 
translation of Gi2a mRNA (Simonds et al., 1989; Lyons et al., 1990; McKenzie & 
Milligan, 1990; Moxham et al., 1993). In contrast, the localisation of G2 a seems to 
suggest that it has a restricted function which is not linked to the survival of the foetus. 
This is further supported by the observation that the CNS appears to have little or no 
survival value in utero (Copp, 1995). 
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Section 5.2.3 Functional Redundancy. 
If a gene product has even a small functional advantage then it will be retained during 
evolution. It is not surprising, therefore, that many knockout mice do not differ greatly 
from the wild-type. It is not, however, correct to assume that a minimal or non-existent 
phenotypic change is due to the removal of a biologically insignificant protein. This is 
because in some instances there may be a facility in vivo to compensate for the loss of a 
functionally important protein by substituting another in its place (Brookfield, 1992; 
Tautz, 1992). The best example of this sort of functional redundancy is seen in the 
retanoic receptor a 1 (RARa 1) knockout mouse. RARa 1 is the most abundant and 
conserved of the retanoic receptor isoforms, which could be interpreted as evidence for an 
important biological function. Furthermore, the specific ligand for RARal , retanoic acid 
has been strongly implicated in embryonic development (Lammer et al., 1985; Moris Kay, 
1993). Despite such observations, however, RARal knockout mice develop normally (Li 
En et al., 1993). It has been proposed that the lack of a severe phenotypic change in these 
mice may be due to the recruitment of other retanoid receptors which could act to 
compensate for the loss of functional RARal (Li En et al., 1993). It is also possible that 
RARa 1 may not be required for development at all, but may fulfil some other biological 
role. Further examples of minimal phenotypic changes arising as a consequence of the 
disruption of apparently 'indispensable' genes include, p53 (Gammon & Lane, 1987; 
Marshall, 1991; Donehower et al., 1992), PKCy (Abeliovich et al., 1993), the homeobox 
(Hox) genes, hox-3.1 (LeMouellic et al., 1992), hox-1.5, hox-1.6 (Chisaka & Capecchi, 
1991; Lufkin et al., 1991; Chisaka et al., 1992) and c-abl (Tybulewicz et al., 1991; 
Schwartzberg et al., 1991). In these instances several related genes may need to be 
disrupted in the same animal to circumvent what may be, functional redundancy in these 
knockouts. Whilst it is not yet possible to predict whether functional redundancy will play 
a role in the phenotype expressed by a Gza knockout mouse, the relatively restricted tissue 
distribution of Gza suggests that its biological role is likely to be both unique and one 
which is not easily fulfilled by a functionally similar gene product (e.g. another G-protein; 
note that tissue distribution is not always the best guide to the in vivo function of a protein; 
Section 5.2.4, p 113). 
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Section 5.2.4 Unexpected Phenotypes. 
Whilst it may appear that knocking out Gza, which is abundant within the nervous system, 
may lead to developmental defects within these tissues, there are many examples in which 
knocking out a gene produces unexpected phenotypic changes. These include disruptions 
to the genes encoding myf-5 (Braun et al., 1992; Rudnicki et al., 1992), transforming 
growth factor a (TGFa, Luetteke et al., 1993; Mann et al. 1993), transforming growth 
factor Pl (TGFPl, Shull et al., 1992), c-Src (Soriano et al., 1991) and NGF (Lee et al. , 
1992). In each instance it was expected that the absence of these proteins would result in 
serious developmental abnormalities, corresponding with the critical role that each gene 
product is thought to play in several restricted tissue types: Myf-5, myogenesis and 
skeletal muscle differentiation; TGFa: angiogenesis, induction of cell migration and 
control of cell proliferation; TGFP, cell proliferation, differentiation, extracellular matrix 
protein production, cell adhesion and angiogenesis (Bernard et al., 1990); c-Src, found in 
platelets and the brain, is implicated in cell division and signal transduction; and NGF 
(Part 1.3, p13). However, when each of these genes are knocked out in vivo, the mutant 
differs only slightly from that of the respective wild-type, with phenotypic changes 
appearing in unexpected tissues of the body: Myf-5 knockout mice have abnormal rib 
development; TGFa knockout mice are susceptible to corneal inflammation and have 
'curly' hair; TGFP knockout mice have no obvious developmental defects except for 
multifocal inflammatory disease; and although c-Src deficient mice develop serious 
osteoporosis (suggesting that this protein may have some function in osteoclast integrity; 
Nowak, 1991; Horn et al., 1992) they have normal brain and blood. It is difficult to accept 
that in all of these cases functional redundancy (Section 5.2.3, pl 12) is the sole reason for 
a lack of more serious developmental abnormalities. It has been proposed, and what these 
observations suggest, is that some proteins serve important functions in tissues, other than 
those in which they are abundantly expressed (Shastry, 1994; Appendix 3.1). This also 
means that assigning a biological role, to any protein, based solely on its localisation can 
be misleading. It will, therefore, be interesting to see if any of the functions assigned to 
Gza, based on its tissue distribution, prove to be correct following examination of the Gza 
knockout (Part 1.4, p23 ). 
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Part 5.3 Cross Talk and Other Considerations. 
For phenotypic changes to occur, in tissues that are seemingly unrelated to the targeted 
gene product, a form of cross talk may be occurring which affects the regulation of other 
genes in the body during development (Erickson, 1993; Shastry, 1994; Gerlai, 1996). This 
theory is supported by the observation that in man a single mutation can give rise to a 
large variety of abnormalities (Davies, 1993). Observed phenotypic changes may also be 
due to: (i) the effect that the insert has on the transcription of adjacent genes (e.g. polar 
effects); and/or (ii) the genetic background of the knockout animal (Shastry, 1994; Gerlai, 
1996; Figure 5.1). Therefore, to account for each of these effects, and in so doing produce 
adequate control animals, it may be necessary to either: (i) rescue the mutation by 
introducing a transgene that expresses the functional protein (Chapter 4, p98) and/or (ii) 
generate a 'knockin' mouse (control) by introducing a small DNA marker, flanking the 
gene of interest, without disrupting its expression. If, however, the background of the 
targeted ES cells and the mouse strain to which the chimrera is mated are not identical 
(Figure 5.2; Gerlai, 1996), then using one, or other, of the parent strains as a control for 
this 'hybrid' knockout animal may not be adequate. This consideration would seem to be 
particularly important when targeting genes thought to be involved in the more subtle 
aspects of biological function, such as learning and memory (Gerlai, 1996; Appendix 5.1). 
Several examples include: PKCy (Abeliovich et al., 1993; Chen et al., 1995); the NMDA 
receptor (£1; Sakimura et al., 1995); and the dopamine receptor (d2; Balk et al., 1995). 
The MGza chimrera (Figure 3.21) are currently being bred with C57BL/6 mice, as the 
targeted ES cells were derived from a C57BL/6 mouse strain. However, if the knockout 
had been made using 129 ES cells, then it would be necessary to backcross the resulting 
hybrid animal several times to increase the proportion of one of the inherited population of 
genes (e.g. 9-10 backcrosses will reduce the proportion of one of the inherited set of 
sequences to approximately 1 % of the mouse genome; Festing, 1992). Lastly, it is of 
course possible that a failure to observe an obvious phenotypic change, or one which 
supports previous information, may simply be due to the lack of a correct in vitro fin vivo 
experimental challenge that would reveal/expose the deficiencies caused by removal of the 
gene product (e.g. IL-5; Kopf et al., 1996). 
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Figure 5.1 Behavioural Differences Between Mice Strains 129 & BL/6. 
(Taken from Gerlai, 1996) 
(A) Spatial Perlormance Learning in the Water Maze (Bemasconi-Guastalla et al., 1994; 
Wolfer & Lipp, 1994; Gerlai, 1996). The escape latency, or the time required to locate and 
climb onto a hidden platform submerged 5mm below water, against the days of training. 
Although both 129 (open squares; n=41) and BL/6 (black circles; n=61) mice started with 
the same level of perlormance, BL/6 mice achieve a significantly better perlormance with 
training. 
(B) Duration of floating in the water maze (see above). Shows a significant difference in 
the average duration of floating between 129 and BL/6 mice strains (Gerlai, 1996). 
(C) The locomotion score in the water maze or the exploratory activity. 129 mice exhibit a 
significant hypoactivity (or decrease locomotion score) when compared to BL/6 mice 
(Gerlai, 1996). 
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Figure 5.2 Chromosomal Constitution of Mice Generated by Gene Targeting. 
(Taken from Gerlai, 1996; see also Part 3.1, p56) 
If the targeted ES cells were derived from the mouse strain 129 and the chim&ra were 
mated to mice from a different strain (e.g. C57BL/6; Appendix 5.1). The offspring (Fl 
generation) will not only be heterozygous for the null-mutant allele, but will also have one 
set of chromosomes from the 129 strain and another from the BL/6 mouse strain. These 
heterozygous mice, when mated with their siblings will in turn produce a segregation F2 
population in which according to Mendel's Law, homozygous null mutant and wild-type 
mice will be found. This means that the genes which surround the targeted locus will be of 
the 129-type in the knockout (null mutant) mice and of the BL/6-type in the wild type 
mouse (control). 
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Part 5.4 Summary. 
This report has discussed the steps taken to knock out the G-protein, Gza in vivo. Initially 
it was decided to disrupt the expression of the gene as close as possible to the start site of 
transcription in order to eliminate the possibility of truncated or partial products surviving 
and performing a background function in the knockout (Part 3.1, p56). Thus, a region of 
the C57BL/6 mouse genome encompassing MGza exon2 was subcloned (Part 3.2, p65), 
sequenced and interrupted with a copy of the pgkNeopla gene. This control construct 
would later be used as the control for the nested PCR ES cell identification of true 
homologous recombinants, as it resembles the Gza gene region following targeted 
inactivation with the pgkNeopla marker. To create the targeting construct a portion of the 
control construct encompassing endogenous primer binding sites was replaced with the 
pgkTKpla gene. This plasmid was then used to inactivate the Gza gene in an ES cell line 
(C57BL/6) chosen to increase the identity and, therefore, the frequency of homologous 
rec om bi nation between the targeting construct and the host genome following 
electroporation (Part 3.3, p86). Heterozygous ES cell clones possessing a single deleted 
copy of the MGza gene were then directly injected into BALB/c blastocysts, implanted 
within pseudopregnant female foster mothers and allowed to develop. Using this 
technique a number of chimceras have been produced (Figure 3.21), however, as yet none 
have proven to be 'germline' chimcera. That is they have failed to produce heterozygous 
null (-/+) MGza mutants following breeding with homozygous ( +/+) positive C57BL/6 
partners, although it is too early to say that they will not. Not only do the foreign ES cells 
have to compete with those of the inner cell mass to enter the germline (see also Part 3.1, 
p56), but that only 50% of the germline cells produced (e.g. sperm) will possess the 
disrupted (or knocked out) copy/allele of the gene. Finally, steps were taken to isolate the 
third exon of MGza so that the sequence information gained by sequening this region of 
the gene could be used to create a full length MGza cDNA. An MGza exon3 specific 
probe was isolated and used to rescreen the AMGza cDNA clones isolated using the 
exon2/3 partial cDNA fragment (Leck, 1993). Although none of these genomic clones 
encompass the exon (Part 4.2, p 101), the cloned fragment containing part of exon3 can 
later be used to rescreen the entire genomic library. 
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Part 5.5 Conclusion. 
The putative biological functions for Oza, including a proposed role in cytosolic 
signalling, remain unclear primarily because only circumstantial evidence is currently 
available (e.g. tissue distribution, in vitro associations etc; Part 1.4, p23). The development 
of a Oza knockout mouse would allow such hypotheses to be directly tested and assist in 
elucidating the significance of this enigmatic 0-protein. 
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Appendix 1.1 Standard IUPAC One-Letter Amino Acid Codes. 
A Alanine 
C Cysteine 
D Aspartic Acid 
E Glutamic Acid 
F Phenylalanine 
G Glycine 
H Histidine 
I Isoleucine 
K Lysine 
L Leucine 
M Methionine 
N Asparagine 
p Proline 
Q Glutamine 
R Arginine 
s Serine 
T Threonine 
V Valine 
w Tryptophan 
y Tyrosine. 
Xmnl 2645 
Seal 2526 
Pvul 2416 
Nae! 131 
....., S, pI442 
fl (-)~ 
Appendix 2.1 
pBluescript Cloning Vectors 
Sspl 19 
pBluescript II SK(+/-) 
2961bp 
Aj7III 153 
Nae! 131 
Xmnl 2645 
Seal 2526 
Pvul 241 6 
Sad 759 
Bssl-ill192 
Nae! 131 
.._,ri S,pl442 
Sspl 19 ~ 
pBluescript II KS(+/-) 
2961bp 
Aj7III 153 
Nae! 131 
Kpnl759 
Plasmid Names: A. pBluescript II SK(+/-) & B. pBluescript II KS ( +/-) 
Plasmid Size: 2961 bp 
Comments: Taken from p326 Stratagene Technical Manual 
Kindly provided by: Dr K. Matthaei 
0 
"O 
0 
~ 
,:::: 
a) 
.....l 
cos 
Appedix 2.2 
Lambda DASH II Vector 
41 900 bp 
N 
~ 
0 
8 
bl) 
o:l 
A 
~ \0 
~\O~ NO~ ~N\O\OC--\0 ~0-\0N 
o~~ 00 -No ·o~~-o-r:-- · r:--r:-- 00 ~~r:--o~~o 
0: --st 
'ti 
d 
~ 
... 0000 .o · C--N · · · .N •r:--r:--r:--r:-- . • · · · 
r:--oo~ocio • ONO · . \O~~C'l~N ·c--iC'ic--iM"<t"<t"<t~ 
---NNNON~N"<t~NNN~~~N~~~~~~~~ 
~~~~~~~~0~~~888~0~~~~~~8888 ~ 
0... o...p cd 0 cd ccrj ..c:I UP. cd cd 00 00 OOP. U ..c:I ccrj cd zo cd P. 00 00 00 00 •~ 
~~x~z~~~~x~~o:io:io:ix~~~~ ~xo:io:io:io:i ~ 
J I o d> ~ (ninL44) • bio I ... (KH54) (ninS) 
~ ,.Cl 00 
cos 
I~ 20Kb ... 14 14Kb ... 14 9Kb .. 1 
Special Features: 
Increased number of Cloning Sites 
Spi+/P2 selection reduces non-recombinant background 
Applications: 
Allows high resolution restriction mapping and rapid chromosomal walking 
Cloning Capacity: 
Capacity of 9-23Kb 
Reference Elgin, E., et al., (1991) Strategies 4: 8-9 
Pvul 4246 
ColEI 
Sad 
BstXI 
Sael i 
Nod 
Eag l 
Xbal 
.5pel 
BamHJ 
Smal 
Psrl 
EcoRI 
Ampicillin 
pBSK(+)-PGK Neo pla 
~4788bp 
pgk-Neo-polyA 
Appendix 2.3 
pgkNeo Cloning Vectors 
Plasmid Name: pBSK( + )-PGK Neo pla 
Plasmid size: 4788bp 
Constructed by: X.-W . Wang & Dr K. Matthaei 
Construction date: 23.9.93 
Comments References: A 1.83kb EcoRI-
HindIII fragment excised from the pgkNeopla 
in plC20 constructed by Brue Mann# K257 
(originally from pGEM 7)~ fragment inserted into 
pBluescript SK(+) vector at EcoRI/HindIII 
pgk-promoter 
R 
Neo 
686bp 
pgk-polyA 
450bp 
Plasmid Name: plC20-HindIII/EcoRI 
Plasmid size: vector 2.67kbp/l.83kbp insert 
Constructed by: Bruce Mann 
Construction date: 1991 
Comments References: Murine pgkpromoter 
driving Neo and pgkpolyA cloned into plC 20R 
Pvul 4246 
ColEI 
Xmnl 4475 
Sacl 
&oa 
Saeli 
Nod 
&,gl 
Xba! 
Spel 
BamHI 
Sma! 
Pstl 
EcoRJ 
Ampicillin 
pBSK(+)pgkTK pla 
~5600bp 
pgkTK pla 
pgk-TK-polyA 
Appendix 2.4 
pgkTKpla Cloning Vectors 
Plasmid Name: pBSK( + )pgkTKpla 
Plasmid size: 5600bp 
Constructed by: X.-W. Wang & Dr K. Matthaei 
Comments References: A 2.7kb EcoRI-
HindIIl fragment excised from the pgk-TK+pgk polA 
in pUC20 obtained from Brue Mann #258~ inserted into 
pBluescript SK(+) vector at EcoRI/HindIII 
pgk-promoter 
TK 
686bp 
pgk-polyA 
450bp 
Plasmid Name: pUC19pgkTKpla 
Plasmid size: vector 2.67kbp/2.7kb insert 
Constructed by: Bruce Mann 
Construction dat.e: 1991 
Comments References: Murine pgkpromoter 
driving HSV-TK and pgkpolyA 
Appendix 3.1 Gene Knockouts 
(Reference: Shastry, 1994) 
DisruQted gene Tissue distribution 
Prp protein 
Mouse Po 
fyn 
lck 
csk 
c-fos 
TAP1/b2-m 
DNA methyl 
transferase 
MHC Class II 
associated 
variant chain 
Neurons, lymphocytes & 
other tissues. Also 
expressed in tooth 
bud & placenta during 
development 
PNS 
Widespread . Expressed 
high levels in brain, 
platelets & T cells 
Present in T & B cells 
Expressed high levels 
in NS & spleen, 
widespread 
Widespread 
Thymus 
Widespread 
B-lymphocyte 
PhenotyQe 
Normal development & 
behaviour 
Resistant to Scrapie 
Hypomyelination , 
degeneration of myelin 
& axons 
Hippocampal, T cell 
receptor signalling & 
LTP defects 
Thymocyte differ. 
is blocked 
Neural tube defects, 
embryonic lethality 
Osteropetrossis,delayed 
gametogenesis, altered 
behaviour & lymphophenia 
Defects in intracellular 
peptide loading & or 
transport. Deficient in 
mature CD4 8*T Cells 
Death at mid gestation & 
abnormal development 
Aberrant transp. of MHC 
ClassII molecules, 
deficient in producing 
CD4*T cells 
Hoxb-4(hox-2 . 6)Paraxial mesoderm/CNS Anterior homeotic 
transformation 
TNFR p55 Wide variety lymphoid 
& non-lymphoid cells 
Normal thymocyte & 
lymphocyte population. 
TNF signalling & host 
response to specific 
stimuli are altered 
Hox-1.1 
TCR 
Oct-2 
Tyrosine 
Phosphatase 
Irnmunoglobulin 
µ chain 
Wnt-1 (int-1) 
GATA-1 
Neural tube, spinal 
ganglia & sclerotomes 
No abnormalities in 
growth property 
Most systemic T cells Loss of thymic medullae 
increase spleenic Bcells 
B cell No effect on edogenous 
immunoglobulin gene 
Hematopoietic cells & B lymphocyte development 
their precursors is normal but T cell 
maturation is defective 
Pre-B cells precur. B cell development 
of B lymphocytes arrested 
NS Abnormalities in 
midbrain 
Erythroid Anemia 
Insulin-like Many tissues Growth deficiency 
growth factorII choroid plexus in 
adults. 
RNA pol II 
CD28 
RB 
Myogenin 
RAR 
Zeta TCR 
All cells 
Peripheral T cells 
Liver,Brain,Spinal 
cord and retina 
Muscle 
Widespread 
T cells 
No abnormalities 
Not required 
for T cell response 
Abnormalities of 
erythropoieses but not 
the retina 
Muscle defficiency 
& Neonatal death 
Postnatal lethality, 
testis degeneration 
Influences thymocyte 
diff. but not required 
for T cell generation 
Appendix 5.1 Examples of Gene Targeting Studies of Mammalian Behaviour 
Targeted ES ES Origin Chimaeras Genotype of Behavioral 
gene Crossed to Analysed Mice Change 
En-2 D3 
En-2 D3 
5-htlB na 
fyn na 
d2(dopamineP1 
receptor) 
£1 (NMDA TT2 
receptor) 
Glu recep TT2 
82 locus 
p2 ( nACh - HMI 
receptor 
subunit) 
129 BL6,CD1,129 129-BL6,129-CD1 None 
reported 
129 129 Inbred 129 Impaired 
motor 
learning 
performance 
129 129 Inbred 129 Enhanced 
aggresive 
behavior 
12 9 129 & BL6 Inbred 129 & Impaired 
129-BL6 hyb. spatial 
learning 
129 BL6 BL6-129 hyb. Decreased 
locomotory 
activities, 
impaired 
motor co-
ordination 
BL6xCBA BL6 BL6-CBA hybrid Impaired 
Spatial 
Learning 
BL6xCBA BL6 BL6-CBA hyb. Decreased 
locomotory 
129 
activities 
Impaired 
motor co-
ordination 
BL6xDBA/2 129-BL6-DBA/2hyb Impaired 
motor 
avoidance 
learning 
1-AdenylateABl 129 BL6 129-BL6 hyb. Impaired 
spatial 
learning 
mgluI D3 129 BL6 129-BL6 hyb. Motor 
impairment, 
impaired 
eye-blink 
condition 
mglI HMl 129 
NCAM E14 129 
PKCy E14 129 
aCaMKII E14 129 
BL6 
not given 
BL6 
BALB/C 
129-Bl6 hyb. Decreased 
locomotory 
activities 
impaired 
spatial 
learning 
129-? Impaired 
spatial 
learning 
129-BL6 hybrid Impaired 
spatial & 
passive-
avoidance 
learning 
129-BALB/C hyb Impaired 
spatial 
learning 
